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 Over the past decade, work in our lab has focused on phosphate tether-
mediated desymmetrization of C2-symmetric 1,3-anti-dienediol via ring-closing 
metathesis (RCM) to afford P-stereogenic bicyclo[4.3.1]phosphates.  However, 
efforts in this direction relied solely on phosphate tether-mediated coupling of allylic 
alcohol cross partners with 1,3-anti-dienediol synthons leading to the formation of 
simple bicyclo[4.3.1]phosphates and their applications in natural product synthesis.  
The objective of this dissertation work is to advance the phosphate tether-mediated 
methods to include the construction of complex bicyclo[n.3.1]phosphates via ring-
closing metathesis (RCM).  The RCM study, discussed in detail in Chapter 2, 
highlights the synthetic potential of phosphates as a temporary tethers in facilitating 
the coupling of complex fragments to produce novel P-stereogenic bicyclic phosphate 
scaffolds.  Chapter 3 describes the development of phosphate tether-mediated one-pot 
and two-pot sequential metathesis/reduction protocols towards the stereodivergent 
synthesis of complex polyols.  The potential application of phosphate tether-mediated 
reactions en route to the synthesis of the C9–C25 fragment of spirastrellolide B is 
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The development of new atom-,1 step-,2 and redox-economical3 methods to access 
complex subunits common to a variety of bioactive natural products stands at the 
forefront of modern-day synthesis and drug discovery.  In particular, tether-mediated 
transformations that couple both simple and complex molecular fragments to access 
highly functionalized core intermediates represent some of the most facile and 
convergent pathways to accomplish this goal.4  Historically, silicon has been the most 
exploited and well-studied tether, owing to its stability, ease of synthesis and advantage 
of late-stage removal.5  These attributes of silicon tethers have served as a cornerstone for 
a number of elegant applications in total synthesis.5  In contrast, the prospect of 
phosphate tethers were largely unexplored until 2005 and were only limited to two 
literature examples.6  This is surprising due to the number of salient features of phosphate 
tethers, including: (i) tripodal coupling characteristics, (ii) serving as a protecting group 
and leaving group, (iii) acting as a functional handle for transition metal-mediated 
transformations, and (iv) having the ability to possess asymmetry at phosphorus (P-
chirality).7   
In this regard, efforts in our group since 1997 have focused on investigating 
phosphorus-based transformations, including tethers since 2000, with the ultimate aim of 
generating diverse P-heterocycles with biological and synthetic utility (Figure 1.1). 8,6b  
Towards this goal, we have utilized ring-closing metathesis (RCM) to synthesize 
phosphonamides, phosphonates and phostones (P-sugars).8 In addition, generation of  
P-stereogenic phosphonamides and phosphonates were achieved via desymmetrization of 
pseudo C2-symmetric P-template via RCM and intramolecular cyclopropanation (ICP).9 
 3 
Our investigation on the use of phosphate-based tethers was initiated in 2005 with the 
report of phosphate tether-mediated desymmetrizations of a C2-symmetric diene diol via 
RCM en route to the synthesis of P-stereogenic bicyclo[4.3.1]phosphates.10 
 
Figure 1.1. Summary of our work towards exploring phosphorous-based tether and 
template-directed synthesis of diverse P-chiral heterocycles.  
 
 Our attention was next directed towards exploring the synthetic utility of 
bicyclo[4.3.1]phosphates.  Taking advantage of the steric and stereoelectronic 
differentiation present in the bicyclic framework of bicyclo[4.3.1]phosphate,  a number of 
regio- and chemoselective reactions  were developed (Figure 1.2).11  The synthetic 
potential of phosphate tether-mediated reactions was further demonstrated towards the 
synthesis of 1,3-diol containing natural products (Figure 1.3).12  In addition current 












Two Relatively Unexplored Areas of Phosphate Chemistry
(1) Their use as Temporary Tethers
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 4 
sequential synthetic strategies, which would further expedite the total synthesis projects 
and provide opportunity for library synthesis.  
 
Figure 1.2. Synthetic utility of bicyclo[4.3.1]phosphates. 
 
Figure 1.3. 1,3-diol containing natural product synthesis starting from 
bicyclo[4.3.1]phosphates. 
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applications to complex natural product synthesis, we have initiated a thorough study of 
phosphate tether-mediated RCM reactions during the period of this dissertation work.  
The purpose of this dissertation is to advance the phosphate-tether method further 
towards the construction of complex bicyclo[n.3.1]phosphates via RCM.  Before this 
study, all of our previous reports were focused on the synthesis and utility of 
bicyclo[4.3.1]phosphates derived from phosphate tether-mediated coupling of  simple, 
unsubstituted, allylic alcohol cross partners.  However, to expand the utility of phosphate 
tether in terms of accessing more stereochemically complex fragments, we deemed it 
important to have a more thorough understanding of the behavior of phosphate tethers 
during RCM across a wide range of complex substrates.   
With respect to the literature report for tether-mediated RCM studies, it should be 
noted that the lack of literature precedence for phosphate tether-mediated RCM study 
also stands in contrast to the large volume of work devoted to study silicon tethers during 
RCM.  In this regard, two seminal work by the research groups of Evans,13 Kobayashi,14 
and many others5 have provided insight on the behavior of silicon tethers in the RCM of a 
variety of substrates and the stereochemical outcome of such studies have been 
strategically utilized in many total synthesis projects.  The aim of the current chapter is to 
provide a brief account of the literature reports on the use of other tethers including 
silicon tether in RCM processes and their applications towards natural product synthesis. 
Chapter 2 of this dissertation describes phosphate tether-mediated RCM studies 
towards the construction of novel bicyclo[n.3.1]phosphate scaffolds.15  The focus of this 
study was to explore the effect of ring-size, stereochemistry and substitutions of both of 
the coupling partners in the RCM reaction.  This study highlighted the utility of 
 6 
phosphate-tether in generating complex systems and provided insight into the factors 
governing RCM in such complex systems.  
 
Figure 1.4. Chapter 2 describes phosphate tether-mediated RCM studies towards the 
generation of novel bicyclo[n.3.1]phosphate scaffolds. 
 
 The application of phosphate tether-mediated one-, two-pot sequential processes 
towards the stereodivergent synthesis of complex polyols is discussed in chapter 3.16  A 
modular 3-component coupling strategy was developed in this regard to synthesize 
stereo-enriched polyols.  The divergent aspect of the method was introduced by simple 
switching of the olefinic partners in the subsequent CM reaction to afford five 
differentiated polyols starting from three coupling partners. 
 






n = 0, 1; R = CH2OBn









































































Figure 1.5. Chapter 3 is focused on the stereodivergent synthesis of polyols by utilizing 
phosphate tether-mediated one- and two-pot sequential protocols. 
 
 Chapter 4 describes the application of phosphate tether-mediated reactions to 
synthesize the C9–C25 fragment of spirastrellolide B.  Originally isolated in 2007,17 
spirastrellolide B and its congeners possess interesting biological activity and feature a  
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B is discussed in chapter 4. 
 
challenging framework including a 38-membered macrolactone, a bicyclic and a tricyclic 
spiroacetal subunit.  A strategy aimed at developing phosphate tether-mediated regio- and 
chemoselective reactions to facilitate the synthesis of the C9–C25 fragment in an efficient 
manner will be discussed in this chapter. 
 
1.2: Background and significance 
 
 Tether-mediated RCM strategies have been utilized towards the synthesis of a 
various natural products.  Many groups have investigated the use of tethers in RCM 
including the stereochemical outcome of such tether-mediated RCM reactions.  A brief 
account of the literature reports on the use of other tethers including silicon in RCM 
processes and their applications towards natural product synthesis is discussed below. 
 
1.2.1: Silicon tether-mediated ring-closing metathesis 
  Silicon is one of the most exploited tethers used in RCM.5  It offers several 
advantages such as ease of coupling often under mild basic condition, tolerance for a 
range of functionalities that makes it attractive choice for natural product synthesis and 
mild reaction conditions  are required for removal.  In 1992, Grubbs and Fu first reported 
temporary Si-tethered (TST) RCM to synthesize 7-membered cyclic silyl ether, which 
was next treated with nBu4NF to provide 1,4-diols (Scheme 1.1).18  In 1997, Grubbs and 
coworkers illustrated the first example of RCM of vinylsilyl dienes in the presence of the 
G-I or the [Mo]-I catalyst (Scheme 1.1).19  Various 6- to 10-membered cyclic silyl ethers 
(1.1.5a–d) were generated via the RCM of Si-tethered dienes (1.1.4) in excellent yields.  
 9 
Subsequent Tamao oxidation20 of cyclic silyl ethers produced (Z)-configured olefinic 
polyhydroxy compounds (1.1.6a–b, Scheme 1.1).  In 1997, Cossy and coworkers 
reported Si-tethered RCM to generate 6–8-membered allylsiloxanes (1.1.8a–d), which 
were subjected to modified Sakurai conditions to generate substituted tetrahydrofurans or 
tetrahydropyrans (1.1.9, Scheme 1.1). 21   Notably, the formation of 7-membered 
allylsiloxane (1.1.8c) was found to be sensitive to the presence of allylic substituents 
presumably because of unfavorable steric interactions between the C2 substituent (allylic 
methyl group) and ruthenium catalyst. 
 
Scheme 1.1. Cyclic silyl ether formation via temporary Si-tethered (TST) RCM.  
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R2 = CHCPh2, 1.1.3
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 R2 = CH3, H,  R3 = Ph
R4,R5 = Ph, Me, H
 10 
chiral 1,4-diols (1.2.3) via a temporary silicon-tethered ring-closing metathesis (TST 
RCM) strategy involving the coupling of chiral, non-racemic allylic alcohols (Scheme 
1.2.).   This method was further exploited towards the asymmetric synthesis of D-altriol 
(1.2.5, Scheme 1.2).22  
 
 
Scheme 1.2. Evan’s group TST strategy to synthesize C2-symmetric, chiral 1,4-diols. 
 
Use of silicon tether towards the construction of large ring systems is also well 
documented.  In 1999, Hoye and coworkers demonstrated that TST RCM could be 
extended further to the self- and cross coupling of various alkenol partners leading to 7-, 
9- and 11-membered cyclic silaketals (1.3.3–1.3.5) with excellent Z/E selectivity 
(Scheme 1.3).23  It was noted that slow addition of the catalyst was required for the 
effective RCM process leading to 9- and 11-membered ring systems.  For the 7-
membered silaketal ring formation, both yield and the duration of the RCM process were 
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Scheme 1.3. Si-tethered RCM towards the generation of 7-, 9- and 11-membered cyclic 
silaketals.  
 
Silicon tethers have been effectively utilized in diastereoselective RCM reactions 
and the stereochemical outcome of such reactions has been thoroughly studied.  One of 
such elegant studies reported by the Evans group in 2003 documented the use of TST 
RCM strategy for the long-range asymmetric induction leading to the diastereoselective 
synthesis of (Z)-configured, 7–11-membered siloxane rings (1.4.4, Scheme 1.4).13  
Trienes were synthesized by silylating prochiral, substituted divinyl alcohol and then 
coupling with different alcohol partners.  An exclusive cis-selectivity was observed for 7-
membered siloxane ring formation whereas moderate to excellent trans-selectivity was 
observed for 8–11-membered rings.  The observed selectivity was rationalized by the 
formation of the favored TS state 1.4.5A, in which the propenyl group occupies a 
pseudoequitorial position to avoid non-bonding interactions with the isopropyl 
substituents of silicon.  Additional studies indicated that the diastereoselectivity of both 
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1.3.7a, 24 h, 91%
Z/E >99:1
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1.3.5, 10 h, 78%
Z/E 92:8
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could be optimized. 
 
 
Scheme 1.4. Diastereoselective TST RCM of prochiral alcohols towards the synthesis of 
7–11-membered siloxane rings. 
 
In 2003, Evans and coworkers reported the first application of the Si-tethered 
RCM cross-coupling reaction towards an efficient and convergent total synthesis of 
mucocin, a potent antitumor agent (1.5.4, Scheme 1.5).24  Allylic alcohol 1.5.1 was 
silylated and coupled with tetrahydrofuran-containing allylic alcohol partner 1.5.2 to 
generate the diene intermediate, which was next subjected to TST RCM in the presence 
of a stoichiometric amount of the G-I in refluxing 1,2-DCE.  A stoichiometric amount of 
catalyst was required to avoid the inherent cis-selectivity observed for 1,4-disubstituted 
7-membered siloxane systems.13  In 2008, Harvey and coworkers utilized TST-RCM in 
the kinetic resolution of diene 1.5.5 to achieve the diastereoselective synthesis of the 
1. 6 mol% G-II
CH2Cl2, 40 ºC
2. 10% Pd/C, H2
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C12–C24 fragment 1.5.6 of peloruside A, a potent cytotoxic agent (1.5.7, Scheme 1.5).25  
Diene 1.5.5 was subjected to the RCM reaction in the presence of the G-II catalyst 
[(ImesH2)(PCy3)(Cl)2Ru=CHPh] 26  in refluxing CH2Cl2 to generate the single 
diastereoisomer 1.5.6 in 35% overall yield. 
 
 
Scheme 1.5. Application of Si-tether-mediated RCM towards the synthesis of mucocin 
and peloruside A. 
 
The synthetic utility of TST RCM strategy was further demonstrated in 2001 by 

































   CH2Cl2
    imidazole
74%









    rt, 91%
4. TsNHNH2, NaOAc
    1,2-DME/H2O, ∆
















































of cis-1,5-enediols (Scheme 1.6). 27   Starting with substituted allylic alcohol 1.6.1, 
silylation, followed by addition of homoallylic alcohol 1.6.2, generated 16-stereoisomers 
of Si-tethered dienes 1.6.4.  The RCM of stereoisomeric dienes 1.6.3 were performed in 
the presence of the G-II catalyst in toluene at 95 ºC to provide 16-stereoisomers of 1.6.4 
in excellent yields.  Interestingly, comparable yields were seen in both TST RCM 
processes leading to cis- and trans-ring substitution patterns.  
 
 
Scheme 1.6. Synthesis of stereodiversified library of cis-1,5-enediols via TST RCM. 
 
In 2010, Kobayashi and coworkers published an extensive study of Si-tether 
mediated RCM towards the formation of 8-membered dioxasilane rings with regards to 
























































































































1.7.3 were synthesized via silylation of homoallylic alcohol 1.7.1, followed by the 
coupling with substituted allylic alcohol partner 1.7.2.  Dienes 1.7.3 were subjected to the 
RCM reaction in the presence of the HG-II catalyst in refluxing xylene.  It was observed 
that the stereochemistry and substituents on both alcohol coupling partners play a pivotal 
role in determining the geometry of the newly formed C=C bond.  While the cis 
relationship of R1 and R2 substituents, and the presence of C2’-Me and anti-crotyl groups 
in diene 1.7.3 led to the formation of  (E)-configured dioxasilacyclooctene, the RCM of 
silicon tethered triene 1.7.6––prepared via the coupling of homoallylic alcohol and 
prochiral alcohol, generated (Z)-configured dioxasilacyclooctene exclusively revealing 
the inherent tendency of the system to be (Z)-configured.  This data was consistent with 





















































































































R1 = alkyl, aryl
R2 = alkyl, H
36–92%
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Scheme 1.7. Study of Si-tether-mediated RCM towards the formation of (E)-selective 8-
membered dioxasilane rings. 
 
 In 2011, Kobayashi and coworkers further demonstrated the utility of the above 
mentioned Si-tether mediated (E)-selective RCM reaction towards the total synthesis of 
(+)-TMC-151C, possessing significant cytotoxicity against a wide range of tumor cell 
lines, including HCT-116, B16, and HeLa cells (Scheme 1.8).28   
 
 
Scheme 1.8. Application of Si-tether-mediated (E)-selective RCM strategy towards the 
total synthesis of (+)-TMC-151C. 
 
 The synthesis featured a vinylogous Mukaiyama aldol29 strategy to construct the 
key advanced intermediates 1.8.1 and 1.8.2 followed by a late-stage (E)-selective RCM 
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silylation of substituted allylic alcohol partner 1.8.1 and subsequent addition of 
homoallylic alcohol partner 1.8.2.  When subjected to RCM in the presence of 20 mol% 
of the HG-II catalyst, the 8-membered dioxasilane ring (not shown in the Scheme 1.8) 
was generated with exclusive (E)-selectivity in excellent yield.  Treatment of the RCM 
product with aqueous HF•pyr produced the natural product in 54% yield. 
 
1.2.2: Ketal tether-mediated ring-closing metathesis 
The use of ketals as tether systems in RCM reaction can be divided into four 
categories (Scheme 1.9).  Type A and B represent the most common use of ketal/acetal, 
but these are mostly viewed as protecting groups for ketones and diols and have little 
consideration as tethers.  Type C and D are relatively rare and can be viewed as the best 
representation for a ketal tethered-RCM process.  In 1999, Grubbs and coworkers 
reported an example of type C ketal-tethered RCM strategy in which bridged oxabicycles 
1.9.2 were generated via the RCM of 5-membered ketals 1.9.1 (Scheme 1.9).30  The RCM 
of an equimolar mixture of syn and anti-diastereomers (~1:1 ratio) of ketal 1.9.1, was 
performed efficiently in the presence of the G-I catalyst in CH2Cl2 at room temperature 
to provide bridged oxabicycle 1.9.2 in 45% yield along with unreacted anti-cyclic ketal 
1.9.3.  Interestingly, the unreacted anti-isomer 1.9.3 did not dimerize during the RCM 
reaction (0.01M) and was conveniently converted to a mixture of syn- and anti-




Scheme 1.9. Ketal tether-mediated RCM. 
 
In 1999, Burke and coworkers reported a unique type C ketal tethered-RCM 
strategy for substrate desymmetrization en route to the synthesis of (+)-exo- and endo-
brevicomin (1.10.5 and 1.10.10, Scheme 1.10).31  The pseudo-C2-symmetric triene 1.10.3 
was synthesized from the C2 symmetric substrate (3S,4S)-3,4-dihydroxy-1,5-hexadiene 
(1.10.1) via coupling with ketone 1.10.2, followed by E2-elimination of the alkyl chloride, 
to provide the corresponding olefin.  Ring-closing metathesis of triene 1.10.3 produced 
1.10.4 in 86% yield as a single diastereomer.  Subsequent hydrogenation generated (+)-
exo-brevicomin (1.10.5) in 82% yield.  Starting with a mixture of meso and (±)-diol 
1.10.6, ketalization with ketone 1.10.7 generated a mixture of diastereoisomers.  Meso-
ketal 1.10.8 was further subjected to the RCM reaction followed by hydrogenation to 
provide racemic endo-brevicomin (1.10.10).  Later, this strategy was successfully applied 
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Scheme 1.10. Synthesis of (+)-exo- and endo-brevicomin via ketal tethered-RCM 
strategy. 
 
In 1998, van Boom and coworkers exploited a ketal tether-mediated RCM 
strategy towards the synthesis of pyranose spiroacetal derivatives (1.11.2, Scheme 1.11). 
RCM of pyranose derivatives 1.11.1 was performed in the presence of the G-I catalyst in 
toluene at 60 ºC to construct [5,4]-, [5,5]-, [5,6]- and [5,7]-spiroacetals.34  In 1999, 
Harrity and coworkers reported ketal tether-mediated, tandem metathesis reactions to 
generate spiroacetals (Scheme 1.11).35  Tetraolefinic ether 1.11.3 was subjected to 
tandem RCM reaction in the presence of the G-I catalyst in CH2Cl2 to provide [4,4]-
spiroacetal 1.11.4 in excellent yield.  Interestingly, the [4,4]-spiroacetal 1.11.4 was found 
to decompose in the presence of catalytic amount of TsOH to furan, which further 
















































Scheme 1.11. Ketal tether-mediated RCM to synthesize pyranose spiroacetal derivatives.  
 
systems over an acid catalyzed spiroketalization method.  Notably, ROM-RCM (ring-
opening-ring-closing metathesis) strategy was also employed to construct [4,4]-
spiroacetal 1.11.6 in 50% yield (Scheme 1.11).  All these reactions represent early 
examples of type D ketal-tethered RCM strategy. 
In 2004, Hsung and coworkers reported the use of ketal-tethered RCM reactions 
en route to the synthesis of various spiroketals (Scheme 1.12).36  In this method, 1,2-syn 
and anti diastereoisomers of cyclic ketals 1.12.1 were treated with the G-I/G-II catalysts 
at room temperature in CH2Cl2/PhH to yield 1,2-syn and 1,2-anti- isomer of spiroketals 
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Scheme 1.12. Ketal-tethered RCM reactions towards the synthesis of spiroketals. 
 
protected allylic alcohols (R = TBS and Ac), as well as a free hydroxyl group and 
carbonyl functionality at C-2 (1.12.3, Scheme 1.12).  For larger rings formation of 5,7-, 
6,7- and 6,8-spiroketals, RCM products were obtained under higher dilution and in the 
presence of the G-II catalyst in PhH. 
 In 2004, Hsung applied ketal tether-mediated RCM towards the synthesis of bee 
pheromone 1.13.4 to further demonstrate the utility of this powerful strategy (Scheme 
1.13).36  Lithiation of substituted tetrahydropyran 1.13.1, followed by addition of crotyl 
bromide and subsequent ketalization with allylic alcohol in the presence of PPTS, 
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cyclic ketal 1.13.2 provided 5,5-spiroacetal 1.13.3, which upon hydrogenation afforded 
bee pheromone 1.13.4 in good overall yield. 
 
  
Scheme 1.13. Ketal-tethered RCM reactions towards the synthesis of bee pheromone. 
 
Later in 2005, Hsung and coworkers employed the ketal-tethered RCM strategy 
for the synthesis of C11–C23 fragment of spirastrellolide A (1.14.4, Scheme 1.14).37  The 
C11–C16 fragment was installed via ketalization of lactol 1.14.1, derived from  
D-glucose, in the presence of 1 equivalent of the Brønsted acid, Tf2NH, to produce cyclic 
ketal 1.14.3 in 89% yield as a single diastereomer.  Ring-closing metathesis of the cyclic 
ketal in the presence of the G-I catalyst in PhH provided the C11–C23 fragment 1.14.4 of 
spirastrellolide A in 50% yield.  
 
Scheme 1.14. Application of ketal-tethered RCM approach towards the synthesis of the 
C11–C23 fragment of spirastrellolide A. 
 
 
In 2006, Hsung and coworkers expanded the scope of ketal-tethered RCM 
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1.15.2 (1,2-syn and 1,2-anti-isomers) were prepared by allylation of 1.15.1.  Subsequent 
RCM generated 1,2-syn- and 1,2-anti-isomers of spiroaminals 1.15.3 in excellent yields. 
 
 
Scheme 1.15. Ketal-tethered RCM approach to spiroaminals. 
 
In 2007, Hsung and coworkers again demonstrated the utility of a ketal-tethered 
RCM strategy en route to the total synthesis of (+)-aigialospirol (1.16.5, Scheme 1.16).39  
Addition of homoallylic alcohol 1.16.2 to lactol 1.16.1 from the equatorial face of the 
corresponding oxo-carbenium, generated in the presence of stoichiometric amount of 
Tf2NH (Brønsted acid), allowed for the formation of cyclic ketal 1.16.3 as a single 
diastereomer in 76% yield.  Subsequent RCM provided spiroketal 1.16.4 in 86% yield.  
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Scheme 1.16. Application of ketal-tethered RCM strategy towards the total synthesis of 
(+)-aigialospirol. 
 
1.2.3: Additional tether-mediated ring-closing metathesis studies 
1.2.3.1: γ-lactone tether-mediated ring-closing metathesis 
In 2004, Martin and coworkers reported the synthesis of α,β-fused γ-lactone 
carbocycles and cyclic ethers via a γ-lactone tethered-RCM strategy (1.17.3, Scheme 
1.17).40  Ring-closing metathesis reactions of γ-lactones 1.17.2, derived from chiral, 2,3-
epoxy alcohol 1.17.1, were performed in the presence of the G-II catalyst to generate 
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Scheme 1.17. Example of Lactone-tethered RCM. 
 
1.2.3.2: Carboxylate tether-mediated ring-closing metathesis 
In 2012, Schmidt and coworkers reported the stereoselective synthesis of 2Z,4E-
configured dienoic acids via a one-flask RCM/base-mediated ring-opening of carboxylate 
tethered dienes (Scheme 1.18).41  Butenoates 1.18.2, synthesized from the coupling of 
allylic alcohol 1.18.1 with vinyl acetic acid, was subjected to RCM in the presence of the 
G-II catalyst in toluene in 65 ºC.  Subsequent ring-opening, mediated by NaH, produced 
a variety of 2Z,4E-configured dienoic acids 1.18.3 in good to excellent yields.  Later, this 
method was successfully applied towards the synthesis of 1.18.6, a macrolactonization 
precursor of the fungal metabolite fusanolide A.41  Towards this end, butenoate 1.18.4 
was subjected to RCM in the presence of the G-II catalyst in toluene at 80 ºC, followed 
by NaH, to facilitate ring-opening and generate dienoic acid 1.18.5.  Subsequent 
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Scheme 1.18. Application of carboxylate tether-mediated RCM towards the synthesis of 
advanced intermediate en route to fusanolide A. 
 
1.3: Use of P-tethers in synthesis 
 
 As opposed to the large body of work published on silicon tethers, literature 
reports on the use of phosphorous-based tethers is limited.  A brief account of our 
previous work will be discussed in this section, which has served as a prelude to the work 
on complex phosphate-tether method discussed in next chapter. 
 One of the earliest examples of the use of phosphoramido tether was reported in 
1997 by Sinay and coworkers towards the synthesis of C-disaccharide and its β-anomer 
via radical cyclization (Scheme 1.19).6a The coupling of two pyranose subunits was 
mediated by phosphoramido tether.  The removal of this tether was performed by using a 
2-step procedure of cleaving P-N bond by using methanolic•HCl followed by P-O bond 



































Scheme 1.19. Use of phosphoramido tether towards the synthesis of C-disaccharide and 
its β-anomer via radical cyclization.  
 
 Our group began exploring phosphorous as a temporary tether [both P(III) and 
P(V)] in 2001 with the synthesis of C2-symmetric and unsymmetric, non-racemic 1,4-
diamines 1.20.3 and 1.20.7 (Scheme 1.20).6b  Homocoupling of α-branched secondary 
allylamine 1.20.1 was performed in the presence of PCl3.  Subsequent hydrolysis and 
RCM in the presence of the G-II catalyst generated 1,3,2-diazaphosphepine 2-oxide 
1.20.2 in excellent yield.  The C2-symmetric, 1,4-diamine 1.20.3 was then generated by 
hydrolysis in a one-pot protocol combined with RCM.  Interestingly, efforts to facilitate 
this coupling/RCM sequence by utilizing other temporary tethers, including Si-tether, 
were not successful.  The synthesis of unsymmetrical, non-racemic, 1,4-diamine 1.20.7 
started with the heterocoupling of amine 1.20.4 and 1.20.5 that generated the RCM 
precursor 1.20.6 in excellent yield with good diastereoselectivity.  Subsequent one-pot 




























Scheme 1.20. Use of temporary Phosphorous tether-mediated RCM in the synthesis of 
functinalized 1,4-diamines. 
 
The study towards the synthesis of monocyclic phosphates was reported in 2006 
in which the phosphate ester played a dual role as a tether and as a leaving group in 
subsequent cuprate displacement reaction (Scheme 1.21).42,11b  In this process, the homo-
coupling of substituted allylic alcohol 1.21.1 was mediated by a phosphate triester tether 
to obtain the pseudo-C2-symmetric monocyclic phosphate scaffold (S,S)-1.21.2 in 
excellent yield.  The C2-symmetric (Z)-configured 1,4-diol 1.21.3 was produced in 
excellent yields after reductive removal of phosphate.  In a similar fashion, the 
corresponding saturated analogue 1.21.6 was produced by adding a hydrogenation step 
before tether removal.  Finally, a key symmetry breaking operation involved a highly 
diastereoselective allylic cuprate displacement reaction to generate the phosphoric acid 
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Scheme 1.21. Synthesis of monocyclic phosphate and its synthetic utility. 
 
In 2005, the utility of phosphate tethers was further demonstrated towards the 
desymmetrization of C2-symmetric diene diol (S,S)-1.22.1 via RCM (Scheme 1.22).10  
The homotopic olefinic groups present in the C2-symmetric 1,3-anti-diol diene (S,S)-
1.22.1 were differentiated and rendered diastereotopic in the process of generating the 
pseudo-C2-symmetric phosphate triester intermediate (S,S)-1.22.2 with the installation of 
phosphate tether.  This RCM precursor (S,S)-1.22.2 contained a chirotopic, non-
stereogenic phosphorus atom, which after diastereoselective RCM between the two cis-
substituted olefins, in the presence of the G-II catalyst, enabled the formation of P-
stereogenic bicyclo[4.3.1]phosphate (S,S,SP)-1.22.3 in good yield.   The overall process 
had been previously described by Schreiber and others as terminus differentiation or 











































Scheme 1.22. Synthesis of bicyclo[4.3.1]phosphate and its synthetic utility. 
 
A series of synthetically useful transformations were further developed centered 



























1H-tetrazole,CH3CN, 2 h, rt
1.
2. then m-CPBA, 1 h

















































































TemporaryTether-mediated  One-pot Sequential Processes towards (+)-Strictifolione
* *
Temporary Tether-mediated  One-pot Sequential RCM/CM/"H2" Protocol
 31 
counterpart].10,11a,b  A sequence of selective CM reactions of the external olefinic group 
of bicyclo[4.3.1]phosphate (S,S,SP)-1.22.3, followed by reductive tether-removal using 
LiAlH4, produced polyol intermediate 1.22.4.11a  Utilizing the leaving group ability of 
phosphate, a diastereselective cuprate displacement protocol was developed after 
subsequent hydrogenation of the external olefin to generate polyketide-like intermediate 
1.22.5.10  In addition, a multi-step, one-pot, sequential RCM/CM/H2 process was 
developed starting from trienes 1.22.2 to generate complex intermediates such as 1.22.6 
and 1.22.7 in a facile manner.11c  The chemo- and regioselective hydrogenation was made 
possible by the stereoelectronic properties inherent to phosphate tethers.  Most 
importantly, this tandem RCM/CM/H2 process preserved the stereochemical integrity of 
the bicyclic phosphate, which is critical for the success of later transformations.  Later in 
2014, the utility of phosphate tether-mediated one-pot sequential protocols was further 
demonstrated towards the efficient synthesis of (+)-strictifolione (Scheme 1.22).12d  This 
modular synthetic route featured two consecutive phosphate tether-mediated one-pot 
sequential protocols followed by a final cross-metathesis reaction to yield the natural 
product in a streamlined 3-pot processes starting from triene. 
 
1.4: Conclusion  
 In general, tether mediated RCM strategies have been well-studied and utilized 
towards the construction of important building blocks en route to total synthesis of 
bioactive natural products.  Our group has aimed at efforts towards the use of 
phosphorous-based tethers in RCM and their synthetic utility.  The synthetic potential of 
phosphate tether in multivalent activation of carbinol centers, serving as a protecting 
 32 
group and as a leaving group as well as their use in desymmetrization of homotopic 
olefinic groups present in 1,3-anti-diene diol substrates warrants further investigation of 
the phosphate tether in mediating coupling of complex subunits.  In addition, RCM 
studies of complex phosphate-tethered system would facilitate our understanding of the 
underlying factors governing RCM for such complex systems, which in turn, would also 
increase the applicability of phosphate tether-mediated RCM reactions towards the 
synthesis of complex advanced fragments en route to bioactive natural products.  The 
focus of this dissertation has been exploring the use of phosphate tethers in combining 
complex subunits, investigation of RCM of such complex phosphate-tethered system and 
utilizing bicyclo[n.3.1] as building blocks to synthesize stereoenriched polyols.  In 
addition, potential application of phosphate tether-mediated reactions towards the 
synthesis of the C9–C25 fragments of spirastrellolide B will also be discussed. 
 
1.5: References cited: 
 
[1]  (a) Trost, B. M. The atom economy: a search for synthetic efficiency. Science 
1991, 254, 1471–1477; (b) Trost, B. M. Atom economy - a challenge for organic 
synthesis: homogeneous catalysis leads the way. Angew. Chem., Int. Ed. Engl. 
1995, 34, 259–281. 
[2]  Wender, P. A.; Verma, V. A.; Paxton, T. J.; Pillow, T. H. Function-Oriented 
Synthesis, Step Economy, and Drug Design. Acc. Chem. Res. 2008, 41, 40–49. 
[3]  (a) Young, I. S.; Baran, P. S. Protecting-group-free synthesis as an opportunity for 
invention. Nat. Chem. 2009, 1, 193–205; (b) Hoffmann, R. W. Protecting-group-
free synthesis. Synthesis 2006, 3531–3541. 
[4]  For a review on disposable tethers in organic synthesis see: Gauthier, D. R., Jr.; 
Zandi, K. S.; Shea, K. J. Disposable tethers in synthetic organic chemistry. 
 33 
 
Tetrahedron 1998, 54, 2289–2338. 
[5]  (a) Čusak, A. Temporary Silicon-Tethered Ring-Closing Metathesis: Recent 
Advances in Methodology Development and Natural Product Synthesis. Chem. 
Eur. J. 2012, 18, 5800–5824; (b) Bracegirdle, S.; Anderson, E. A. Recent 
advances in the use of temporary silicon tethers in metal-mediated reactions. 
Chem. Soc. Rev. 2010, 39, 4114–4129. 
[6]  (a) Rubinstenn, G.; Esnault, J.; Mallet, J.-M.; Sinay, P. Radical mediated 
synthesis of N-acetyl-D-galactosamine containing C-disaccharides via a 
temporary phosphoramidic connection. Tetrahedron Asymmetry 1997, 8, 1327–
1336; (b) Sprott, K. T.; McReynolds, M. D.; Hanson, P. R. A Temporary 
Phosphorus Tether/Ring-Closing Metathesis Strategy to Functionalized 1,4-
Diamines. Org. Lett. 2001, 3, 3939–3942. 
[7]  (a) Hoveyda, A. H.; Murphy, K. E. Enantioselective synthesis of α-alkyl-β,γ-
unsaturated esters through efficient Cu-catalyzed allylic alkylations. J Am Chem 
Soc. 2003, 125, 4690–4691; (b) Morin, M. D.; Rychnovsky, S. D. Reductive 
spiroannulation of nitriles with secondary electrophiles. Org Lett. 2005, 7, 2051–
2053; (c) Bartlett, P. A.; Jernstedt, K. K. A stereocontrolled synthesis of the 
methyl ester of (±)-nonactic acid. Tetrahedron Lett. 1980, 21, 1607–1610; (d) 
Nicolaou, K. C.; Shi, G-Q.; Gunzner, J. L.; Gärtner, P.; Yang, Z. Palladium-
Catalyzed Functionalization of Lactones via Their Cyclic Ketene Acetal 
Phosphates. Efficient New Synthetic Technology for the Construction of Medium 
and Large Cyclic Ethers. J. Am. Chem. Soc. 1997, 119, 5467–5468; (e) 
Yanagisawa, A.; Noritake, Y.; Nomura, N.; Yamamoto, H. Superiority of 
Phosphate Ester as Leaving Group for Organocopper Reactions. Highly SN2’-, 
(E)-, and Antiselective Alkylation of Allylic Alcohol Derivatives. Synlett. 1991, 
251–253.  
[8]  (a) Hanson, P. R.; Stoianova, D. S. Ring closing metathesis reactions on a 
phosphonate template. Tetrahedron Lett. 1998, 39, 3939–3942; (b) Hanson, P. R.; 
Stoianova, D. S. Ring-closing metathesis strategy to P-heterocycles. Tetrahedron 
 34 
 
Lett. 1999, 40, 3297–3300; (c) Sprott, K. T.; Hanson, P. R. The Synthesis of P-
Chiral Amino Acid-Derived Phosphonamidic Anhydrides. J. Org. Chem. 2000, 65, 
4721–4728; (d) Sprott, K. T.; Hanson, P. R. The Synthesis of Sterically 
Demanding Amino Acid-Derived Cyclic Phosphonamides. J. Org. Chem. 2000, 
65, 7913–7918; (e) Sprott, K. T.; McReynolds, M. D.; Hanson, P. R. Ring-closing 
metathesis strategies to amino acid-derived P-heterocycles. Synthesis 2001, 612–
620; (f) Stoianova, D. S.; Hanson, P. R. A Ring-Closing Metathesis Strategy to 
Phosphonosugars. Org. Lett. 2001, 3, 3285–3288.  
[9]  (a) Stoianova, D. S.; Hanson, P. R. Diastereotopic Differentiation on Phosphorus 
Templates via the Ring-Closing Metathesis Reaction. Org. Lett. 2000, 2, 1769–
1772; (b) Moore, J. D.; Hanson, P. R. Substituent effects in the double 
diastereotopic differentiation of α-diazophosphonates via intramolecular 
cyclopropanation. Tetrahedron: Asymmetry 2003, 14, 873–880.  
[10]  Whitehead, A.; McReynolds, M. D.; Moore, J. D.; Hanson, P. R. Multivalent 
Activation in Temporary Phosphate Tethers: A New Tether for Small Molecule 
Synthesis. Org. Lett. 2005, 7, 3375–3378.  
[11]  (a) Waetzig, J. D.; Hanson, P. R. Temporary Phosphate Tethers: A Metathesis 
Strategy to Differentiated Polyol Subunits. Org. Lett. 2006, 8, 1673–1676; (b) 
Thomas, C. D.; McParland, J. P.; Hanson, P. R. Divalent and Multivalent 
Activation in Phosphate Triesters: A Versatile Method for the Synthesis of 
Advanced Polyol Synthons. Eur. J. Org. Chem. 2009, 5487–5500; (c) 
Venukadasula, P. K. M.; Chegondi, R.; Suryn, G. M.; Hanson, P. R. A Phosphate 
Tether-Mediated, One-Pot, Sequential Ring-Closing Metathesis/Cross-
Metathesis/Chemoselective Hydrogenation Protocol. Org. Lett. 2012, 14, 2634–
2637; (d) For a comprehensive review on our tether work, see: Hanson, P. R.; 
Jayasinghe, S.; Maitra, S.; Markley, J. L. Phosphate tethers in natural product 
synthesis. Top Curr Chem 2015, 361, 253–271. 
[12]  (a) Venukadasula, P. K. M.; Chegondi, R.; Maitra, S.; Hanson, P. R. A Concise, 
Phosphate-Mediated Approach to the Total Synthesis of (–)-Tetrahydrolipstatin. 
 35 
 
Org. Lett. 2010, 12, 1556–1559; (b) Hanson, P. R.; Chegondi, R.; Nguyen, J.; 
Thomas, C. D.; Waetzig, J. D.; Whitehead, A. Total synthesis of dolabelide C: A 
phosphate-mediated approach. J. Org. Chem. 2011, 76, 4358–4370; (c) Chegondi, 
R.; Tan, M. M. L.; Hanson, P. R. Phosphate tether-mediated approach to the 
formal total synthesis of (–)-salicylihalamides A and B. J. Org. Chem. 2011, 76, 
3909–3916; (d) Jayasinghe, S.; Venukadasula, P. K. M.; Hanson, P. R. An 
Efficient, Modular Approach for the Synthesis of (+)-Strictifolione and a Related 
Natural Product. Org. Lett. 2014, 16, 122–125; (e) Chegondi, R.; Hanson, P. R. 
Synthetic studies to lyngbouilloside: a phosphate tether-mediated synthesis of the 
macrolactone core. Tetrahedron Lett. 2015, Ahead of Print.  
[13]  Evans, P. A.; Cui, J.; Buffone, G. P. Diastereoselective temporary silicon-tethered 
ring-closing-metathesis reactions with prochiral alcohols: A new approach to 
long-range asymmetric induction. Angew. Chem., Int. Ed. 2003, 42, 1734–1737.  
[14]  Matsui, R.; Seto, K.; Fujita, K.; Suzuki, T.; Nakazaki, A.; Kobayashi, S. Unusual 
E-selective ring-closing metathesis to form eight-membered rings. Angew. Chem., 
Int. Ed. 2010, 49, 10068–10073.  
[15]  (a) Chegondi, R.; Maitra, S.; Markley, J. L.; Hanson, P. R. Phosphate-Tether-
Mediated Ring-Closing Metathesis for the Preparation of Complex 1,3-anti-Diol-
Containing Subunits. Chem. - Eur. J. 2013, 19, 8088–8093; (b) Maitra, S.; 
Markley, J. L.; Chegondi, R.; Hanson, P. R. Phosphate Tether-Mediated Ring-
Closing Metathesis for the Generation of Medium to 
LargeBicyclo[n.3.1]phosphates Tetrahedron 2015, ASAP.  
[16]  Hanson, P. R.; Jayasinghe, S.; Maitra, S.; Ndi, C. N.; Chegondi, R. A modular 
phosphate tether-mediated divergent strategy to complex polyols. Beilstein J. Org. 
Chem. 2014, 10, 2332–2337.  
[17]  Warabi, K.; Williams, D. E.; Patrick, B. O.; Roberge, M.; Andersen, R. J. 
Spirastrellolide B Reveals the Absolute Configuration of the Spirastrellolide 
Macrolide Core. J. Am. Chem. Soc. 2007, 129, 508–509.  
[18]  Fu, G. C.; Grubbs, R. H. The application of catalytic ring-closing olefin 
 36 
 
metathesis to the synthesis of unsaturated oxygen heterocycles. J. Am. Chem. Soc. 
1992, 114, 5426–5427. 
[19]  Chang, S.; Grubbs, R. H. A simple method to polyhydroxylated olefinic 
molecules using ring-closing olefin metathesis. Tetrahedron Lett. 1997, 38, 4757–
4760. 
[20]  Tamao, K.; Ishida, N.; Ito, Y.; Kumada, M. Nucleophilic hydroxymethylation of 
carbonyl compounds: 1-(hydroxymethyl)cyclohexanol. Org. Synth. 1990, 69, 96–
105. 
[21]  Meyer, C.; Cossy, J. Synthesis of oxygenated heterocycles from cyclic 
allylsiloxanes using ring-closing olefin metathesis. Tetrahedron Lett. 1997, 38, 
7861–7864. 
[22]  Evans, P. A.; Murthy, V. S. Temporary Silicon-Tethered Ring-Closing Metathesis 
Approach to C2-Symmetrical 1,4-Diols: Asymmetric Synthesis of D-Altritol. J. 
Org. Chem. 1998, 63, 6768–6769. 
[23]  Hoye, T. R.; Promo, M. A. Silicon tethered ring-closing metathesis reactions for 
self- and cross-coupling of alkenols. Tetrahedron Lett. 1999, 40, 1429–1432. 
[24]  Evans, P. A.; Cui, J.; Gharpure, S. J.; Polosukhin, A.; Zhang, H.-R. 
Enantioselective Total Synthesis of the Potent Antitumor Agent (-)-Mucocin 
Using a Temporary Silicon-Tethered Ring-Closing Metathesis Cross-Coupling 
Reaction. J. Am. Chem. Soc. 2003, 125, 14702–14703. 
[25]  Casey, E. M.; Teesdale-Spittle, P.; Harvey, J. E. Synthesis of the C12-C24 
fragment of peloruside A by silyl-tethered diastereomer-discriminating RCM. 
Tetrahedron Lett. 2008, 49, 7021–7023. 
[26]  Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Synthesis and Activity of a New 
Generation of Ruthenium-Based Olefin Metathesis Catalysts Coordinated with 
1,3-Dimesityl-4,5-dihydroimidazol-2-ylidene Ligands. Org. Lett. 1999, 1, 953–
956. 
[27]  Harrison, B. A.; Verdine, G. L. The Synthesis of an Exhaustively 
 37 
 
Stereodiversified Library of cis-1,5 Enediols by Silyl-Tethered Ring-Closing 
Metathesis. Org. Lett. 2001, 3, 2157–2159. 
[28]  Matsui, R.; Seto, K.; Sato, Y.; Suzuki, T.; Nakazaki, A.; Kobayashi, S. 
Convergent Total Synthesis of (+)-TMC-151C by a Vinylogous Mukaiyama 
Aldol Reaction and Ring-Closing Metathesis. Angew. Chem., Int. Ed. 2011, 50, 
680–683. 
[29]  (a) Shirokawa, S.; Kamiyama, M.; Nakamura, T.; Okada, M.; Nakazaki, A.; 
Hosokawa, S.; Kobayashi, S. Remote Asymmetric Induction with Vinylketene 
Silyl N,O-Acetal. J. Am. Chem. Soc. 2004, 126, 13604–13605; (b) Shinoyama, 
M.; Shirokawa, S.-i.; Nakazaki, A.; Kobayashi, S. A Switch of Facial Selectivities 
Using α-Heteroatom-Substituted Aldehydes in the Vinylogous Mukaiyama Aldol 
Reaction. Org. Lett. 2009, 11, 1277–1280; (c) Yamaoka, M.; Nakazaki, A.; 
Kobayashi, S. Rate enhancement by water in a TiCl4-mediated stereoselective 
vinylogous Mukaiyama aldol reaction. Tetrahedron Lett. 2010, 51, 287–289. 
[30]  Scholl, M.; Grubbs, R. H. Total synthesis of (–)- and (±)-frontalin via ring-closing 
metathesis. Tetrahedron Lett. 1999, 40, 1425–1428. 
[31]  Burke, S. D.; Mueller, N.; Beaudry, C. M. Desymmetrization by Ring-Closing 
Metathesis Leading to 6,8-Dioxabicyclo[3.2.1]octanes: A New Route for the 
Synthesis of (+)-exo- and endo-Brevicomin. Org. Lett. 1999, 1, 1827–1829. 
[32]  Burke, S. D.; Voight, E. A. Formal Synthesis of (+)-3-Deoxy-D-glycero-D-
galacto-2-nonulosonic Acid (KDN) via Desymmetrization by Ring-Closing 
Metathesis. Org. Lett. 2001, 3, 237–240. 
[33]  Voight, E. A.; Rein, C.; Burke, S. D. Synthesis of Sialic Acids via 
Desymmetrization by Ring-Closing Metathesis. J. Org. Chem. 2002, 67, 8489–
8499. 
[34]  Van Hooft, P. A. V.; Leeuwenburgh, M. A.; Overkleeft, H. S.; Van Der Marel, G. 
A.; Van Boeckel, C. A. A.; Van Boom, J. H. A novel and flexible synthesis of 
pyranose spiroacetal derivatives. Tetrahedron Lett. 1998, 39, 6061–6064. 
 38 
 
[35]  Bassindale, M. J.; Hamley, P.; Leitner, A.; Harrity, J. P. A. Spirocycle assembly 
through selective tandem ring closing metathesis reactions. Tetrahedron Lett. 
1999, 40, 3247–3250. 
[36]  Ghosh, S. K.; Hsung, R. P.; Wang, J. Ketal-tethered ring-closing metathesis. An 
unconventional approach to constructing spiroketals and total synthesis of an 
insect pheromone. Tetrahedron Lett. 2004, 45, 5505–5510. 
[37]  Liu, J.; Hsung, R. P. Synthesis of the C11–C23 Fragment of Spirastrellolide A. A 
Ketal-Tethered RCM Approach to the Construction of Spiroketals. Org. Lett. 
2005, 7, 2273–2276. 
[38]  Ghosh, S. K.; Ko, C.; Liu, J.; Wang, J.; Hsung, R. P. A ketal-tethered RCM 
strategy toward the synthesis of spiroketal related natural products. Tetrahedron 
2006, 62, 10485–10496. 
[39]  Figueroa, R.; Hsung, R. P.; Guevarra, C. C. An Enantioselective Total Synthesis 
of (+)-Aigialospirol. Org. Lett. 2007, 9, 4857–4859. 
[40]  Rodriguez, C. M.; Ravelo, J. L.; Martin, V. S. γ-Lactone-Tethered Ring-Closing 
Metathesis. A Route to Enantiomerically Enriched γ-Lactones α,β-Fused to 
Medium-Sized Rings. Org. Lett. 2004, 6, 4787–4789. 
[41]  Schmidt, B.; Kunz, O. One-flask tethered ring closing metathesis-electrocyclic 
ring opening for the highly stereoselective synthesis of conjugated Z/E-dienes. 
Eur. J. Org. Chem. 2012, 2012, 1008–1018. 
[42]  Whitehead, A.; McParland, J. P.; Hanson, P. R. Divalent Activation in Temporary 
Phosphate Tethers: Highly Selective Cuprate Displacement Reactions. Org. Lett. 
2006, 8, 5025–5028. 
[43]  (a) Poss, C. S.; Schreiber, S. L. Two-directional chain synthesis and terminus 
differentiation. Acc. Chem. Res. 1994, 27, 9–17; (b) For a review of both 
diastereotopic and enantiotopic differentiation, see: Magnuson, S. R. Two-











































The development of new convergent strategies that allow for the stereoselective 
formation of C–C double bonds are fundamentally important in the field of organic 
synthesis.  In this regard, olefin metathesis is one of the most powerful and important 
carbon-carbon bond forming reactions in modern synthetic organic chemistry.1  In 
particular, ring-closing metathesis (RCM) has continued to be a broadly utilized 
metathesis reaction in terms of the synthesis of small molecule and bioactive natural 
products.2,3,4  The emergence of tether-mediated  RCM strategies towards the goal of 
developing atom,5 redox6 and step7 economical synthetic routes for complex fragments is 
discussed in detail in the previous chapter.  In this respect, the most commonly used 
tethers such as silicon,8,9,10 ketal11 and carboxylate,12 etc. have provided an elegant 
solution to the coupling of complex tether-partners, under mild reaction conditions, to 
provide small, medium, and large rings.  This chapter will provide a detailed 
investigation of our phosphate tether-mediated RCM studies leading to the formation of 
complex P-stereogenic bicyclo[n.3.1]phosphates.  
2.2: Results and discussion 
In 2005, we reported phosphate tether-mediated desymmetrization of C2-
symmetric diene diol via RCM en route to the diastereoselective synthesis of 
bicyclo[4.3.1]phosphates (this process is mentioned in detail in chapter 1, Scheme 
1.22).13  Various chemo- and regioselective reactions were developed by utilizing the 
stereoelectronic properties inherent to bicyclo[4.3.1]phosphate.14  The synthetic utility of 
phosphate tethers was further established towards the synthesis of 1,3-diol containing 
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bioactive natural products.15  During the course of this study, our ongoing efforts towards 
the synthesis of 1,3-anti-diol containing natural products by using phosphate tether-
mediated selective reactions, led to its application for dictyostatin (2.1A), a marine 
macrolide with promising antitumor and anticancer activities (Figure 2.1). 16  
Retrosynthetic analysis of fragment 2.1B revealed that 2.1B could, in theory, be 
constructed through a phosphate-tether-mediated tripodal coupling of POCl3, C2-




Figure 2.1. Proposed retrosynthesis of dictyostatin involving phosphate tether-mediated 
RCM strategy. 
 
Initial studies focused on the synthesis of the C1–C8 fragment of dictyostatin 
through formation of the (Z)-configured bicyclo[5.3.1]phosphate 2.1.5 from triene 2.1.3 
(Scheme 2.1).  The triene 2.1.3 was conveniently synthesized via the coupling of 
monochlorophosphate (S,S)-2.1.2 with homoallylic alcohol cross partner 2.1.1,17 derived 
from (S)-Roche ester (Scheme 2.1).  However, the desired product, 2.1.5, was not 






















































upon RCM provided bicyclic phosphate trans,anti-2.1.6 (dictyostatin diastereomeric 
subunit) in 65% yield.  The trans,anti- descriptors used in compound trans,anti-2.1.6 
referred to the relative stereochemistry between the substituents at C3 and C4 in the 
bicyclo[5.3.1]phosphates  This result demonstrated that unforeseen factors were operative 
for the 8-membered ring formation leading to bicyclo[5.3.1]phosphate 2.1.5, thus 
prompting efforts to carry out a detailed investigation with an analogous alcohol partner.  
 
 
Scheme 2.1. Synthesis of bicyclo[5.3.1]phosphate en route to the key fragment of 
dictyostatin. 
 
The surprising outcome of the RCM reaction en route to dictyostatin and the lack 
of any literature precedence for phosphate tether-mediated RCM study have served as a 
motivation to initiate the current RCM study discussed in this chapter.  Before this study, 
all our efforts were focused on generating simple bicyclic phosphate scaffolds by 



































































gain insight into the mechanistic detail of phosphate tether-mediated RCM study across 
the wide range of substrates, which in turn would also expand the utility of phosphate 
tether to access, more stereochemically complex fragments.  It should be noted that the 
lack of literature precedence for phosphate tether-mediated RCM study stands in contrast 
to seminal work by many research groups8,9,10 on the behavior of silicon tethers in the 
RCM of a variety of substrates and is mentioned briefly in the previous chapter.  The 
objective of the current study was to probe the effect of various parameters including 
ring-size and substitutions of both of the coupling partners in the RCM reaction. 
2.2.1: Substrate design 
To facilitate our understanding of phosphate-tether-mediated RCM reaction, we 
designed substrate trienes by incorporating different olefin types and varying the 
stereochemistry of the alcohol cross partner (Figure 2.2).  The requisite trienes 2.2D–E 
were generated via the tripodal coupling of   phosphorous oxy-chloride with C2-
symmetric 1,3-anti-diols 2.2A and substituted allylic, homoallylic and higher 





Figure 2.2. Substrate design for the RCM study. 
 
2.2.2: Synthesis of P-stereogenic bicyclo[4.3.1]phosphates 
The RCM study was initiated with the synthesis of 7-membered ring starting from 
trienes 2.2.2 and 2.2.3 (Scheme 2.2).  Both of the trienes were prepared from the coupling 
of enantiomeric pseudo-C2-symmetric monocyclic phosphoryl chlorides (S,S)-2.1.2 and 
(R,R)-2.1.2 with allylic alcohol (S)-2.2.1.  When subjected to the G-II catalyst19 in 
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generated from triene 2.2.2 and 2.2.3 in 54% and 72% yield respectively (Scheme 2.2).  
The cis-/trans- descriptors in cis-2.2.5 and trans-2.2.4 refer to the relative 
stereochemistry between the substituents at C3 and C6 in the bicyclo[4.3.1]phosphates.  
It should be noted here that the elegant studies by Evans and coworkers indicated that 7-
membered rings formation of Si-tethered systems was highly diastereoselective where 
only cis-substituted 7-membered-ring products were observed.10  In contrast to the their 
observations, RCM of phosphate trienes 2.2.2 and 2.2.3 yielded both 7-membered-ring 
products trans-2.2.4 and cis-2.2.5, albeit with different reaction rates and catalyst 
loadings of the G-II catalyst (Scheme 2.2).  In addition, it was observed that the cis-
diastereomer reacted at a much faster rate (within 30 minutes as compared to the trans 
isomer that took 6 hours for completion) and with better yields. 
 
 
Scheme 2.2. Synthesis of bicyclo[4.3.1]phosphates. 
 








































































energy intermediates leading to the formation of cis-2.2.5 and trans-2.2.4 (Figure 2.3).  
Presumably, a detrimental 1,2-steric interaction between the CH2OBn group and the 
metallocyclobutane in intermediate trans-2.2.4A, outlined in Figure 2.3, is operative, thus 
slowing RCM for trans-2.2.4.  
 
 




Scheme 2.3. Double diastereotopic differentiation towards the formation of 
bicyclo[4.3.1]phosphate cis-2.3.3. 
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a double diastereotopic differentiation investigation of triene 2.3.2 was initiated (Scheme 
2.3).  RCM of triene 2.3.2, which was derived from the coupling of 
monochlorophosphate (S,S)-2.1.2 with 2,4-dimethylpenta-1,4-dien-3-ol (2.3.1), 
exclusively produced the kinetically favored cis-substituted bicyclo[4.3.1]phosphate 2.3.3.  
This outcome presumably resulted via an intermediate analogous to cis-2.2.5A, which 
lacks an unfavorable 1,2-interaction.  X-ray crystallographic data confirmed the structure 
of cis-2.3.3. 
 
2.2.3.1: Synthesis of P-stereogenic bicyclo[5.3.1]phosphates 
 
Studies were next directed to the 8-membered-ring-forming RCM reactions of 
trienes 2.4.2 and 2.4.3, which were derived from the coupling of alcohol (R)-2.4.1 with 
monochlorophosphates (S,S)-2.1.2 and (R,R)-2.1.2 respectively.  Gratifyingly, both 8-
membered bicyclo[5.3.1]phosphates, trans-2.4.4 and cis-2.4.5, were formed with good 
yields (Scheme 2.4).  The cis-/trans- descriptors in cis-2.4.5 and trans-2.4.4 refer to the 
relative stereochemistry between the substituents at C3 and C7 in the 
bicyclo[5.3.1]phosphates.  In the case of trans-2.4.4 formation, the difference in yield 
(60% as compared to the cis-diastereomer 2.4.5, which was formed in 72% yield) could 
be rationalized based on the unfavorable 1,3-interaction present in the high energy 
intermediate trans-2.4.4A between the metallocyclobutane formed on the exo face and 
the C3 substituents of homoallylic alcohol (R)-2.4.1.  
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Scheme 2.4. Synthesis of bicyclo[5.3.1]phosphates. 
 
2.2.3.2: Synthesis of bicyclo[5.3.1]phosphates with C5-methyl substitution  
To probe the effect of the unfavorable 1,3-interaction observed during the 
formation of trans-2.4.4A, next we introduced a methyl substituent at the C5 position of 
the homoallylic alcohol cross partner (R)-2.5.1 (Scheme 2.5).  The desired trienes 2.5.2 
and 2.5.3 were synthesized from the coupling of methyl-substituted alcohol (R)-2.5.1 
with monochlorophosphates (S,S)-2.1.2 and (R,R)-2.1.2, respectively.  Subjection to the 
RCM reaction, only lead to trans-2.5.4, albeit in a modest 32% yield, while cis-2.5.5 was 
not observed and this outcome further consolidated our previous assumption about 
unfavorable 1,3-interactions.  Based on these results, we have concluded that the 
unfavorable 1,3-interaction between the vinylic methyl and CH2OBn groups in cis-2.5.5A, 













































































Scheme 2.5. Effect of the substitution at C5 of homoallyl alcohol towards the synthesis of 
bicyclo[5.3.1]-phosphates.  
 
In 2011, Sorensen and coworkers reported similar observations en route to the 
synthesis of pleuromutilin, a prototype class of antibiotics, which inhibit bacterial protein 
synthesis (Scheme 2.6).20  Towards the aim of developing a streamlined and convenient 
synthesis of pleuromutilin, both diastereomeric RCM precursors 2.6.3 and 2.6.5 were 
generated.  When 2.6.3 and 2.6.5 were separately subjected to RCM in the presence of 
the HG-II catalyst21 in refluxing CH2Cl2, only one of the diastereomers (2.6.3) yielded 
the RCM product.  The product formation was rationalized based on the high-energy 
metallocyclobutane intermediate 2.6.3A in which the steric hindrance between the 
hydroxyl-derived group at C14 and methyl group at C12 prevented the formation of the 
RCM product.  However no such steric interactions were present for the diasteremeric 
RCM product 2.6.6.  This fact was further confirmed by the observed rate enhancement 












































































Scheme 2.6. Proposed conformational bias during RCM en route to the synthesis of 
pleuromutilin. 
 
2.2.3.3: Synthesis of bicyclo[5.3.1]phosphates with homoallylic alcohol partners 
containing allylic methyl substituents   
As mentioned previously, the current RCM study was initiated due to our inability 
to access the key fragment cis,anti-2.1.5 via phosphate tether-mediated RCM en route to 
the synthesis of dictyostatin (Scheme 2.1).  Structural comparison of trienes 2.4.2 and 
2.4.3, lacking the allylic methyl substituents, which readily underwent RCM (Scheme 
2.4), to trienes 2.1.3 and 2.1.4 (Scheme 2.1) allowed us to conclude that the 
stereochemistry at the allylic position determines whether the RCM is successful. 
To investigate the effect of the allylic methyl group further we synthesized trienes 
that are structurally similar to trienes 2.1.3 and 2.1.4 containing allylic methyl 
substituents.  The allylic methyl group in the triene was introduced via syn- and anti-







































































(1R,2S)-2-methyl-1-(4-nitrophenyl)but-3-en-1-ol (2.7.1) and (1R,2R)-2-methyl-1-(4-
nitrophenyl)but-3-en-1-ol (2.8.1).  Next the requisite trienes 2.7.2 and 2.7.3 were 
synthesized from the coupling of homoallylic alcohol (R)-syn-2.7.1 with 
monochlorophosphates (S,S)-2.1.2 and (R,R)-2.1.2 respectively.  When subjected to RCM, 
product was only observed with cis,syn-stereochemistry leading to the cis,syn-2.7.4 in 
65% yield.  The cis,syn- descriptors used in compound cis,syn-2.7.4 referred to the 
relative stereochemistry between the substituents at C3 and C4 (syn) and at C3 and C7 
(cis) in the bicyclo[5.3.1]phosphates. 
 
Scheme 2.7. Effect of substitution at C2 of homoallyl alcohol towards the synthesis of 
bicyclo[5.3.1]phosphates. 
 
Additional studies were conducted for the RCM reactions of trienes derived from 
monochlorophosphates (R,R)-2.1.2 and (S,S)-2.1.2 and substituted homoallyl alcohol (R)-















































































results are consistent with the previously mentioned preliminary results for dictyostatin. 
 
Scheme 2.8. Effect of substitution at C2 of homoallyl alcohol towards the synthesis of 
bicyclo[5.3.1]-phosphates. 
 
A plausible model was developed to provide insight into the observed 
stereochemical outcomes for the bicyclo[5.3.1]phosphate cases, in which the 
stereochemistry of the allylic position is the critical factor (Figure 2.4).  When 
considering the metallocyclobutane intermediates, the previous assumption that 
metallocyclobutane formation occurs on the exocyclic face eliminates the involvement of 
intermediates, endo,endo-2.4A and endo,exo-2.4B.  Inspection of the remaining two 
intermediates, exo,exo-2.4Cand exo,endo-2.4D, reveals an unfavorable steric interaction 
between the exo Me group and the required exo metallocyclobutane for the case of 
exo,exo-2.4C, an interaction that impedes the formation of the resultant bicyclic 











































































metallocyclobutane is exo is the intermediate energetically accessible such that the 
reaction can proceed to completion. This analysis, therefore, accounts for the selectivity. 
 
 
Figure 2.4. Proposed metallocyclobutane intermediate towards the formation of 
bicyclo[5.3.1]phosphates. 
 
For experimental confirmation of the proposed intermediates in Figure 2.4, we 
synthesized triene 2.9.2 from (±)-2-methylbut-3-en-1-ol (2.9.1) and the 
monochlorophosphate (S,S)-2.1.2 to perform a double diastereotopic differentiation 
experiment (Scheme 2.9).  Subsequent RCM reaction exclusively generated 
bicyclo[5.3.1]phosphate diastereomer 2.9.4, which was confirmed by X-ray 
crystallography, along with unreacted diastereomeric triene 2.9.3.  Similar diastereotopic 
differentiation studies were performed by Harvey and corworkers en route to the 
synthesis of C12–C24 fragment of peloruside A (discussed in chapter 1).22  X-ray 



















































































bicyclic phosphate 2.9.4, thus supporting our proposed favored intermediate exo,endo-
2.4D, as shown in Figure 2.4.  
 
 
Scheme 2.9. Double diastereotopic differentiation towards the formation of 
bicyclo[5.3.1]phosphate 2.9.4. 
 
2.2.3.4: Synthesis of bicyclo[5.3.1]phosphates derived from homologated diene diol 
 
Next, we extended our study of 8-membered-ring-forming RCM reactions to 
include coupling of each of the homologated monochlorophosphates, (R,R)-2.10.2 and 
(S,S)-2.10.2  with allylic alcohol (R)-2.10.1 (Scheme 2.10).  Trienes 2.10.3 and 2.10.4 
participated in the RCM reaction, although the yield of trans-substituted 
bicyclo[5.3.1]phosphate 2.10.5 was notably less than that of cis-substituted 
bicyclo[5.3.1]phosphate 2.10.6.  The lower yield of trans-2.10.5 was presumably due to 
























































Scheme 2.10. Synthesis of bicyclo[5.3.1]phosphates derived from homologated diene 
diol. 
 
In the cases of methyl-substituted homologated trienes 2.11.3 and 2.11.4, which 
were synthesized by the coupling of the methyl-substituted homologated 
monochlorophosphates, (R,R)-2.11.2 and (S,S)-2.11.2, with allylic alcohol (R)-2.11.1, no 
cis RCM product 2.11.6 was observed owing to a highly unfavorable 1,3-interaction (syn-
pentane) between the CH3 and CH2OBn groups in intermediate cis-2.11.6A (Scheme 
2.11).  In the case of the trans product formation, no such unfavorable 1,3-interaction was 
present although the lower yield observed might be rationalized based on the existing 1,2-
steric interaction between the metallocyclobutane and CH2OBn.  Notably, this 
observation was consistent with our previous observations towards the formation of 
trans-substituted bicyclo[4.3.1]phosphate 2.4.4 (Scheme 2.4) where the detrimental 1,2-



































































Scheme 2.11. Synthesis of bicyclo[5.3.1]phosphates derived from methyl-substituted 
homologated diene diol. 
 
2.2.4: Synthesis of P-stereogenic bicyclo[6.3.1]phosphates 
 Investigations towards the medium size ring formations commenced with the 
study of RCM reactions involved in the formation of bicyclo[6.3.1]phosphates, which 
requires the generation of a 9-membered ring (Scheme 2.12).  Trienes 2.12.2 and 2.12.3 
were derived from the coupling of alcohol (S)-2.12.1 with monochlorophosphates (S,S)-
2.1.2 and (R,R)-2.1.2, respectively.  Upon treatment with the G-II catalyst in refluxing 
dichloromethane, both 9-membered bicyclo[6.3.1]phosphates cis-2.12.4 and trans-2.12.5 
were formed in good yields (Scheme 2.12).  These examples suggest that like in the 
formation of bicyclo[5.3.1]phosphates (8-membered ring formation) stereochemistry at 



















































































mediated RCM reaction to bicyclo[6.3.1]phosphates. 
Scheme 2.12. Synthesis of bicyclo[6.3.1]phosphates. 
 
 To further probe substrate scope of the 9-membered ring formation, we 
extended the method to include tether-partners with greater stereochemical complexity.  
Thus, methyl-substituted homologated monochlorophosphate (S,S)-2.11.2 was coupled 
with homoallyl alcohol (R)-2.4.1 to generate triene 2.13.1 (Scheme 2.13).  Upon 
treatment with the G-II catalyst (3 mol %, single addition), successful RCM provided 
bicyclo[6.3.1]phosphate cis-2.13.2 in modest yield with exclusive Z-selectivity.  In 
addition, the effect of the allylic methyl substituent in the corresponding alcohol tether-
partner on the success of RCM was studied.  For this purpose, methyl-substituted 
homologated monochlorophosphate (S,S)-2.11.2 was coupled with anti- and syn-
crotylated alcohols 2.8.1 and 2.7.1 to generate trienes 2.13.3 and 2.13.4, respectively 





































































Scheme 2.13. Synthesis of bicyclo[6.3.1]phosphates starting from methyl-substituted 
homologated diene diol. 
 
 When subjected to the G-II catalyst (3 mol % in one portion), triene 2.13.3 
underwent RCM to provide the corresponding product cis,anti-2.13.5 in 62% yield. 
However, the bicyclo[6.3.1]phosphate cis,syn-2.13.6, resulting from the RCM of triene 
2.13.4 was not observed.  It should be noted that this reactivity was unexpected, as the 
RCM reactions of homologous systems (with identical crotylated alcohol tether partners) 
to form bicyclo[5.3.1]phosphates provided selective cis,syn-product formation (2.7.4 in 
Scheme 2.7); the corresponding cis,anti-product (2.8.4 in Scheme 2.8) was not observed. 









































































































high-energy Ru-metallocyclobutane intermediates based upon X-ray crystallographic 
analysis of the observed products cis-2.13.2 and cis,anti-2.13.5 (Figures 2.5).23  As 
shown in the second depiction of the X-ray structures in Figure 2.5, the conformation of 
bicyclo[6.3.1]phosphates cis-2.13.2 and cis,anti-2.13.5 is such that the Ru-
metallocyclobutane would presumably form on the more sterically accessible endo-face 
of the forming olefin. While unfavorable 1,3-steric interactions are present in both 
proposed intermediates (cis-2.13.2 and cis,anti-2.13.5), the successful formation of 
products implies that this interaction is not insurmountable, though longer reaction times 
were required to generate product.  
 Figure 2.5. X-ray crystal structures of bicyclo[6.3.1]phosphates and plausible  
Ru-metallocyclobutane intermediates in the formation of cis-2.4 and cis,anti-2.13.5. 
 
 Taken collectively, these results—in combination with observations gathered 
from the studies involving the formation of bicyclo[5.3.1]phosphates have led to the 

















































bicyclo[5.3.1]phosphate formation, the concave nature of the bicyclic phosphate would 
suggest that Ru-metallocyclobutane formation is only energetically feasible when the Ru-
metallocycle forms on the exo-face of the bicyclic phosphate (e.g. successful formation of 
cis,syn-2.7.4 via high energy intermediate cis,syn-2.4G, Figure 2.6)  Based upon this 
assumption, bicyclic phosphate formation is impeded in cis,anti-2.8.4 where an 
unfavorable 1,2-steric interaction is present (e.g. cis,anti-2.4E), as well as in cis-2.5.5 
where an unfavorable 1,3-steric interaction is present (e.g. cis-2.5.5A) between the exo-
intermediate Ru-metallocyclobutane and substituents on the olefinic tether-partner.  
Likewise, in the case of cis,syn-2.7.4, an unfavorable 1,2-steric interaction is present (e.g. 
cis,syn-2.4G) between the endo-Ru-metallocyclobutane and the C4-methyl substituent of 
the olefinic tether-partner preventing the formation of product.  However, subtle 
differences in the ring dynamics of the 9-membered ring (i.e. bicyclo[6.3.1]phosphate) 
versus the 8-membered ring (i.e. bicyclo[5.3.1]phosphate) may be responsible for the 
successful formation of cis,anti-2.13.5 (via cis,anti-2.13.5A), even in the presence of an 
unfavorable 1,3-steric interaction between the exo-methyl substituent on the Ru-
metallocyclobutane and the C4-methyl substituent of the alcohol tether-partner.  
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Figure 2.6. Comparison and Plausible mechanistic rationale for the formation of 
bicyclo[5.3.1]- and bicyclo[6.3.1]phosphates. 
 
2.2.5: Synthesis of P-stereogenic bicyclo[7.3.1]phosphates 
 
Studies towards the formation of 10-memberd rings via RCM started with our 
interest in synthesizing dictyostatin via alternative approach of targeting a larger ring size 
as compared to the 8-membered ring as discussed before.  Our retrosynthetic analysis 
revealed that the C1–C9 fragment 2.1A of dictyostatin could be obtained via phosphate 
tether-mediated RCM.  Interestingly, this target fragment 2.7A contained an internal (Z)-
olefin.  As such, it was unclear what selectivity would be observed in the context of 
bicyclo[7.3.1]phosphate generation prior to experimental confirmation.  In this respect, to 
check the feasibility of our proposal, we decided to synthesize a simplified analogue of 
the 10-membered ring required to synthesize dictyostatin.  Studies were therefore focused 
on the preparation of the (Z)-configured, 10-membered ring-containing subunit 2.7B 
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tether partners (Figure 2.7).  
Figure 2.7. Proposed retrosynthetic strategy en route to dictyostatin via phosphate 
tether-mediated RCM to obtain (Z)-selective 10-membered key fragment 2.7A. 
 
For this study, trienes 2.14.2a–b and 2.14.3, possessing various substitutions at 
the C3 carbinol (P1=H, TBS, and PMB), were synthesized to investigate if differently 
protected homoallylic hydroxyl group at C4 would have any effect on the selectivity of 
the resulting internal olefin (Scheme 2.14).  Subsequent RCM of 2.14.2a–b afforded 
excellent yields of (E)-configured 62icycle[7.3.1]phosphates 2.14.4a–b.  In addition, the 
diastereomeric triene 2.14.3, which was derived from (R,R)-2.1.2, also produced the 
RCM product 2.14.5 in good yield and with exclusive (E)-selectivity.  Although this 
result was not encouraging in terms of the synthesis of dictyostatin, we believe that use of 
(Z)-selective catalyst as reported by Grubbs and coworkers24 and/or introduction of silyl 
substituents on the double bond of the coupling partner as reported by Schreiber and 
coworkers 25  might provide the required (Z)-selectivity.  More studies on the 10-





















































Scheme 2.14. Formation of bicyclo[7.3.1]phosphates bearing requisite “dictyostatin-like” 
substituents. 
 
2.2.6: Synthesis of P-stereogenic bicyclo[8.3.1]phosphates 
 
 Studies were then extended to include RCM of 11-membered rings to generate 
bicyclo[8.3.1]phosphates (Scheme 2.15).  In a similar fashion, diastereomeric trienes 
2.15.2 and 2.15.3 were formed via the coupling of alcohol (S)-2.15.1 with 
monochlorophosphates (S,S)-2.1.2 and (R,R)-2.1.2.  While RCM of triene 2.15.2 
proceeded smoothly in the presence of the G-II catalyst to provide 
bicyclo[8.3.1]phosphate cis-2.15.4 in 69% yield, the corresponding RCM of 2.15.3 did 
not provide the desired product. Though the source of this observed reactivity is still 






























































context of the bicyclic phosphate framework may be responsible for stark differences in 
reactivity with respect to stereochemistry at the C3-position of the alcohol tether-partner. 
 
Scheme 2.15. Synthesis of bicyclo[8.3.1]phosphates. 
 
2.3: Conclusion 
In conclusion, we have investigated the phosphate-tether mediated diastereotopic 
differentiation of C2-symmetric dienediol subunits via RCM for complex substrates.  This 
transformation was dependent on parameters such as the concave nature of the bicyclic 
phosphate, the stereochemistry within each coupling partner, and the ring size.  Plausible 
metallocyclobutane-containing intermediates for RCM reactions that give P-stereogenic 
bicyclo[4.3.1]phosphates, bicyclo[5.3.1]phosphates and bicyclo[6.3.1]phosphates were 
proposed to rationalize observed experimental outcomes.  The notable outcome of these 
studies were: (i) the trans product formation in the bicyclo[4.3.1]phosphate series; (ii) 
exclusive (E)-selectivity observed in the bicyclo[7.3.1]phosphate series; (iii) the crucial 
role of the allylic methyl group in the coupling partner in determining the observed 



































































selectivity in the bicyclo[5.3.1]phosphate series  and (iv) the different reactivity pattern 
observed in the case of bicyclo[6.3.1]phosphate series as opposed to the 
bicyclo[5.3.1]phosphate series.  Further applications in the synthesis of polyketide natural 
products, along with studies on RCM reactions that give other bicyclo[n.3.1] phosphates 
are currently being pursued in our lab. 
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A Modular phosphate tether-mediated  


















 The central components of several polyketides that exhibit a wealth of 
medicinally important activities, including antibiotic, anticancer, antifungal, antiparasitic 
and immunosuppressive properties are 1,3-anti-diol subunits (Figure 3.1).1  The structural 
diversity and biological importance of 1,3-anti-diol containing natural products has led to 
the development of various synthetic methods for their construction. 2   Some 




Figure 3.1. Some representative examples of polyol-containing bioactive natural 
products. 
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 Divergent strategies to access functionalized core scaffolds of these bioactive 
small molecules are ideal for analog generation, which in turn enhance the quality of 
screening decks in early phase drug discovery.3  In this regard, one-pot, sequential 
processes,4 which form multiple bonds and stereocenters, while invoking step,5 atom,6 
green,7 and pot economy,8 are well suited to address the challenge of generating diverse 
compounds in an efficient manner.  This chapter provides a brief description of phosphate 
tether-mediated, one-pot, sequential RCM/CM/reduction processes towards the synthesis 
of diverse polyol-containing subunits.  Other divergent approaches towards accessing 
small libraries of polyol-containing compounds will also be discussed.  
 
3.2: Generation of stereodiverse small molecule libraries  
 The goal of diversity-oriented synthesis (DOS) is to identify therapeutic protein 
targets and their small-molecule regulators simultaneously by generating a collection of 
compounds having structural complexity and diversity.9   One such DOS approach 
includes utilizing different building blocks to couple with a common intermediate 
producing multiple scaffolds.  The complementary DOS approach utilizes 
stereochemistry to introduce diversity among constitutionally identical, stereoisomeric 
products. 10   Unlike target-oriented synthesis (TOS), DOS strategies focus on the 
generation of diverse collections of molecules, and therefore, the incorporation of easily 
derivatizable functional group handles and the development of modular strategies to 
expedite the synthesis are crucial to the success of DOS approaches.  In this respect, 
hydroxyl-containing compounds such as polyol/polyketide fragments are abundant in 
many potent biologically active natural products and, therefore, are attractive choices to 
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be incorporated in small molecule libraries.11   In addition, from a synthetic point of view, 
incorporation of hydroxyl groups in the design of library compounds is desirable as they 
can be easily be derivatized and utilized in hydroxyl-directed reactions for further 
diversification.  Similarly, a synthetic DOS strategy should be carefully chosen to 
expedite the process of library generation; these strategies must install stereochemical 
and structural diversity while, at the same time, tolerate a number of functional groups.  
In this respect, metathesis approaches are excellent choices since metathesis reactions are 
mostly run under neutral reaction conditions and exhibit a high functional group 
tolerance.  In 2009, Schreiber and coworkers demonstrated the utility of RCM reactions 
in generating a 2070-member library of 12–14-membered macrocycles.12   The screening 
of the library compounds led to the discovery of Robotnikinin (3.2A), an inhibitor of the 
Sonic Hedgehog (Shh) signaling pathway (Figure 3.2).13 
 
Figure 3.2 Some representative members of a 2070-member library of 12–14-membered 
macrocycles by Schreiber and coworkers. 
 
 Tether-mediated metathesis approaches have also been reported for the generation 





































distinct natural product-like scaffolds such as 3.1.5, 3.1.8 and 3.1.11 via the use of 
metathesis/tether-mediated metathesis as the key reaction (Scheme 3.1). 14   In this 
example, the fluorous tag attached to the linkers 3.1.1 (X = OH, NHNs) aided in the 
purification process, as well as in the release of metathesis product.  Their strategy 
involved the use of silicon as a temporary tether for a majority of the products, and a 
range of skeletally diverse compounds were synthesized by varying the linkages between 
the building blocks. 
 
  
Scheme 3.1 Selected examples of metathesis cascade leading to skeletally diverse 

















































 THF, 0 ºC, 1 h
 2. F-SPE
1. 3.1.3, NBS, CH2Cl2
0 ºC to rt, 15 min
2. inverse addn of 
3.1.2, DMAP, Et3N
0 ºC to rt; 3. F-SPE
iPr2HSiO
O
1. G I, CH2Cl2, 45 ºC
2. Et3N, P(CH2OH)3, then silica
 then filter through Celite
 3. F-SPE; 4. HF•pyridine
3.1.9
NsNH
O(a) 3.1.9, DEAD. PPh3
 THF, 0 ºC, 1h
(b) F-SPE
1. G I, CH2Cl2, 45 ºC
2. Et3N, P(CH2OH)3, then silica
 then filter through Celite
3. F-SPE; 4. HF•pyridine
1. G I, CH2Cl2, 45 ºC
2. Et3N, P(CH2OH)3, then silica
 then filter through Celite
3. F-SPE; 4. HF•pyridine
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 In 2000, Verdine and coworkers reported a modular strategy towards the synthesis 
of 16-stereoisomers of cis-1,4-enediols (Scheme 3.2).15  The core structure of the library 
members, cis-1,4-enediols, was carefully chosen to incorporate a number of properties 
including semi-rigidity of the acyclic framework, the presence of variable substituents 
that could be easily generated over few steps and the presence of hydrogen bonding 
functionalities.  In this process, two differently substituted allylic alcohols were coupled 
in the presence of MeSiCl2 and pyridine to generate the hetero-tethered product 3.2.3 in 
good to excellent yields.  Ring-closing metathesis of the hetero-tethered product 3.2.3 in 
the presence of the G-II catalyst produced the 7-membered cyclic silyl ether 3.2.4 in 
excellent yields (Scheme 3.2).  Subsequent tether removal generated 16-stereoisomers of 
cis-1,4-enediols 3.2.5.  Further functionalization on both ends of cis-1,4-dieneol scaffold 
produced an ensemble of stereodiversified chimerae 3.2.6.  Interestingly, the 
hydrophobicities of these chimeric products were significantly different, which indicated 
that stereochemical variation is essential to optimize affinity and also to tune the 
pharmacological properties of small molecule ligands. 
  













































enediol by Verdine and coworkers. 
 
 In 2001, Verdine and coworkers reported the synthesis of 16-stereoisomers of cis-
1,5-enediol intermediates en route to discovery of stereodiversified ligands (Scheme 
3.3).16  The rational design of core scaffold cis-1,5-enediol 3.3.5 was guided by a 
structural comparison of cis-1,5-enediol 3.3.5 with isoatomic tripeptide 3.3.6 scaffold  
and previously synthesized cis-1,4-enediol scaffold 3.3.7.  The cis-1,5-enediol possesses 
more structural flexibility due to the presence of an unsubstituted allylic position in 
comparison to tripeptide 3.3.6 and cis-1,4-enediol scaffold 3.3.7, which was proposed to 
be advantageous to access the biologically active confirmation not available to cis-1,4-
enediol scaffold 3.3.7.  In addition, the two hydroxyl groups present in cis-1,5-enediol 
3.3.5 are chemically differentiated, which allows for further hydroxyl-directed 
derivatization.  For the synthesis of the library compounds, substituted allylic alcohols 
3.3.1 and homoallylic alcohol fragments 3.3.2 were initially coupled in the presence of 
MeSiCl2 and pyridine to produce hetero-tethered product 3.3.3 in good to moderate 
yields.  Ring-closing methathesis was performed in the presence of the G-II catalyst in 
toluene at 95 ºC to obtain 8-membered siloxane 3.3.4 in excellent yields.  Subsequent 
tether removal under HF/pyridine condition generated 16-stereoisomers of cis-1,5-
enediol 3.3.5.  Screening of these compounds for affinity towards the mu opioid receptor 
(MOR) identified several active stereoisomers, which in turn led to the generation of a 
secondary library containing trans-1,4-enediol compounds17  Screening of this secondary 
library compounds helped in identifying multiple potent and selective partial agonist of 
MOR.  These outcomes demonstrated the need for the synthesis of stereo-enriched small 
molecule libraries.  
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Scheme 3.3 Synthesis of stereodiversified ligand libraries of cis-1,5-enediol by Verdine 
and coworkers. 
 
3.3: Results and discussion 
 In 2005, we reported the synthesis of the bicyclo[4.3.1]phosphate by utilizing a 
phosphate tether-mediated desymmetrization of 1,3-anti-diol substrate (this method was 
discussed in detail in chapter 1 and also mentioned in chapter 2).18  Diverse bicyclic 
phosphate intermediates containing additional functional handles were generated via 
phosphate tether-mediated selective cross-metathesis reactions of the external olefinic 
group.19   In addition, efforts were directed toward developing orthogonal reaction 
patterns en route to the synthesis of 1,3-anti-diol containing natural products.20  In 2012, 
we have reported a one-pot sequential protocol involving RCM/CM/chemoselective 
hydrogenation (RCM/CM/“H2”) to produce advanced phosphate intermediates 3.4.3, 
starting from triene (R,R)-3.4.1 (Scheme 3.4).21   The selective cross-metathesis and 
chemo- and regioselective hydrogenation in this one-pot sequence were achieved by 




























































importantly, this tandem RCM/CM/H2 process preserved the chemical integrity for the 
bicyclic phosphate for further transformation.  In particular, this one-pot sequential 
RCM/CM/“H2” protocol is a powerful strategy not only in terms of streamlining the 




Scheme 3.4 Phosphate tether-mediated one-pot sequential protocol involving ring-
closing metathesis/cross metathesis/chemoselective hydrogenation.protocol. 
  
In 2013, we continued our studies of phosphate-tether mediated processes with 
the synthesis of complex bicyclo[n.3.1]phosphate intermediates of different ring sizes 
utilizing phosphate tether-mediated diastereoselective RCM reactions (figure 3.3, also 







































































Figure 3.3 Synthesis of bicyclo[4.3.1]-, bicyclo[5.3.1]- and bicyclo[7.3.1]phosphates.  
 
3.3.1: Rational design 
 To further demonstrate the utility of phosphate tethers towards the efficient 
synthesis of a small collection of compounds containing stereochemically-enriched 
polyols, we designed a divergent strategy in which changing the order of addition of 
coupling partners could produce differently substituted polyol scaffolds (Figure 3.4). 
Coupling of the pseudo-C2-symmetric phosphoryl chloride (S,S)-3.4.1, generated over 
one step from 1,3-anti-diene diol, with  two different alcohols 3.4.2 and 3.4.3 separately 
would generate two different trienes.  Upon completion of the RCM, the coupling 
partners could be switched and introduced as CM partners to obtain two different bicyclic 
phosphate intermediates.  From these two intermediates, five differently-substituted 
polyol scaffolds can be generated efficiently by further functional group modification.  
Taken collectively, we realized that this modular, divergent 3-component coupling 
strategy would produce five polyol fragments, bearing differential Z- and E- olefins, from 
a pair of olefinic-alcohol components 3.4.2 and 3.4.3 and a pseudo-C2-symmetric 
phosphoryl chloride (S,S)-3.4.1. Moreover, the method relied on simple "order of 
addition" of components for the phosphoryl coupling, RCM and CM steps of the process 
as outlined in Figure 3.4.  In addition, our previous development of the one-pot sequential 
RCM/CM/“H2” protocol would further facilitate in streamlining the synthesis of polyols.  
We also aimed to develop a new one-pot sequential protocol of RCM/CM/tether removal 
to expedite the synthesis of (E),(Z)-substituted polyols.  This synthesis would further 
highlight the utility of phosphate tether mediated desymmetrization of C2-symmetric 1,3-
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anti diene-diol subunit to generate polyol scaffolds with high diastereoselectivities, which 
would otherwise be difficult to produce via (Z)- selective and (E)- selective CM of 1,3-
anti diene-diol subunits with olefinic-alcohol components. 
 
Figure 3.4 Rational design for the synthesis of stereodiverse polyols via phosphate 
tether-mediated one-, two-pot sequential RCM/CM/reduction protocol. 
 
  
The requisite trienes 3.5.4–3.5.6 for this study were generated via our previously 
reported coupling of the pseudo-C2-symmetric phosphoryl chloride (S,S)-3.4.1 with the 
olefinic alcohol components 3.5.1–3.5.3 (Scheme 3.5).18  The alcohol substrates were 
carefully chosen to incorporate exo-allylic methyl groups since previous RCM studies22 
(discussed in chapter 1) showed that the productive RCM for 8-membered ring formation 
was observed only for the (S,S)-configured trienes in the presence of an exo-methyl group 
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One-, Two pot Sequential Processes 
Generating diverse polyol scaffolds
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Scheme 3.5 Synthesis of trienes. 
 
3.3.2: Synthesis of the first set of 5 polyols  
Initial attempts were focused on generating the first set of five polyols from 
trienes 3.5.4 and 3.5.5 in a two-pot operation (Scheme 3.6).  The first operation entailed a 
one-pot, sequential RCM/CM/chemoselective hydrogenation protocol,21 yielding two 
bicyclo[n.3.1] phosphate intermediates 3.6.1 and 3.6.3, and a second pot LiAlH4 
reduction to provide the (Z)-configured tetraol subunits 3.6.2 and 3.6.4.  Trienes 3.5.4 and 
3.5.5 were generated via coupling with alcohol partners 3.5.1 and 3.5.2, respectively, and 
the divergent aspect of the method was introduced by simple switching of the olefinic 
partners in the subsequent CM reaction to afford five differentiated polyols starting from 
three coupling partners. 
In this regard, triene 3.5.4 was first subjected to RCM in the presence of the 
Hoveyda-Grubbs II (HG-II) catalyst 23  in refluxing CH2Cl2, followed by solvent 
concentration and CM with allylic alcohol 3.5.2 in refluxing CH2Cl2 for two hours.  It 
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to avoid the formation of isomerized ketone by-products.  Subsequent chemoselective 
diimide reduction with o-nitrobenzenesulfonyl hydrazine (o-NBSH)24 in CH2Cl2 at room 
temperature afforded bicyclo[5.3.1]phosphate 3.6.1 in 33% overall yield, representing а 
70% average yield/reaction in the one-pot, sequential protocol (Scheme 3.6).  Subsequent 
treatment of 3.6.1 with LiAlH4 furnished the tetraol 3.6.2 in 24% overall yield over the 
course of four reactions carried out in two pots, representing a 70% average yield per 
reaction.   
 
Scheme 3.6 Phosphate tether-mediated two-pot protocol consisting of RCM/CM/H2 and 
subsequent LAH reduction: Reaction Conditions: RCM - HG-II (3 mol%), 1,2-
DCE/CH2Cl2, 2 h; CM - HG-II (3 mol%), CH2Cl2; CM partner (3–5 equiv.); H2 - o-
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(71% avg/rxn)
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Similarly, starting with the triene 3.5.5, a one-pot RCM/CM/chemoselective H2 
was performed to obtain the bicyclo[4.3.1]phosphate 3.6.3 in 40% yield over 3 reactions 
in a one-pot operation (72% avg/rxn).  In this example, the RCM reaction was performed 
in dicholoroethane (DCE) at 70ºC for 2 h, since lower reactivity was observed in CH2Cl2.  
Subsequently, phosphate 3.6.3 was treated with LiAlH4 to generate tetraol 3.6.4 in 26% 
overall yield in the four reactions carried out in two pots, representing a 71% average 
yield per reaction (Scheme 3.6). 
Next, a one-pot RCM/CM/LAH protocol was established to obtain two additional 
tetraol subunits possessing both (E)- and (Z)-olefinic geometries.  Triene 3.5.4 was 
subjected to an RCM reaction, followed by a CM reaction with allylic alcohol 3.5.2.  
After removing solvent, the CM product was treated with LiAlH4 in THF at 0 ºC for 2 
hours to produce tetraol 3.7.1 in 38% yield over three reactions in the one-pot, sequential 
process (73% avg/rxn) (Scheme 3.7).  
 
Scheme 3.7 Phosphate tether-mediated one-pot RCM/CM/LAH protocol towards polyols 
containing (E)- and (Z)-substituted internal olefins.  
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Similarly, triene 3.5.5 was subjected to an RCM reaction, followed by CM with 
homoallylic alcohol 3.5.1, and subsequent treatment with LiAlH4 to afford tetraol 3.7.2 in 
35% yield over the three reactions, representing a 70% avg/rxn in the one-pot, sequential 
method (Scheme 3.7).  
The previously described one-pot sequential RCM/CM/LAH procedure was 
further merged with global hydrogenation to generated saturated polyol scaffold.  The 
resulting tetraols 3.7.1 and 3.7.2, obtained after one-pot, sequential RCM/CM/LAH 
protocol, were separately treated with o-NBSH to obtain tetraol 3.8.1 in 26% yield over 




Scheme 3.8 Phosphate tether-mediated two-pot RCM/CM/LAH and global reduction 
protocol towards the generation of saturated polyol. 
 
Utilizing this two-pot sequential protocol, the same tetraol 3.8.1 was obtained 
starting from two different trienes (3.5.4 and 3.5.5) and reacting with two different CM 
partners (Scheme 3.8).  It should be noted, that after phosphate tether removal, treatment 
of tetraol with o-NBSH (10 eq) resulted in the global reduction of both (E)- and (Z)-
3.8.1
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configured olefins in very good yields; in contrast, diimide reduction in the presence of 
phosphate intermediates did not hydrogenate the endo-cyclic olefin even when large 
excesses of diimide reagent were employed (30 eq).  This empirical result further 
substantiates the protecting group ability of the phosphate tether for the endocyclic (Z) 
olefin.  
 Overall, 5 diverse polyol scaffolds were generated starting from three coupling 
partners by simply altering the order of addition for the coupling and in the cross-
metathesis reaction (Scheme 3.9). The development of phosphate tether-mediated one- 
and two-pot sequential reactions facilitated the synthesis of these polyols. 
  
 
Scheme 3.9 Synthesis of 5-diverse polyols via phosphate tether-mediated one-pot, two-
























































































3.3.3: Synthesis of the second set of 5 polyols  
 
Next, our attempts were focused on generating the second set of five polyols 
starting from trienes 3.5.6 and 3.5.5.  Utilizing the aforementioned strategy detailed in 
Scheme 3.6, triene 3.5.6 was subjected to the one-pot, sequential RCM/CM/ 
chemoselective H2 procedure and subsequent LAH reduction to generate tetraol 3.10.2 in 
24% yield over 4 reactions in a two-pot operation (70% avg/rxn, Scheme 3.10).  Further, 
starting with same triene 3.5.5, which was previously used in Scheme 3.6, but utilizing a 
different cross-metathesis partner (homoallylic alcohol 3.5.3), a different tetraol 3.10.4 
was generated in 23% yield over the four reactions in a two-pot operation (69% avg/rxn) 




Scheme 3.10 Phosphate tether-mediated two-pot protocol consisting of RCM/CM/H2 and 
subsequent LAH reduction: Reaction Conditions: RCM - HG-II (3 mol%), 1,2-
DCE/CH2Cl2, 2 h; CM - HG-II (3 mol%), CH2Cl2; CM partner (3–5 equiv.); H2 - o-
NBSH (12 equiv.), CH2Cl2, Et3N, overnight.  
 
In a similar manner as described above in Scheme 3.7, starting with triene 3.5.6, 
RCM and subsequent CM with allylic alcohol 3.5.2 were performed, followed by tether 
removal with LiAlH4, to obtain tetraol 3.11.1 in 42% yield over three reactions in the 
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subjected to RCM, followed by CM with homoallylic alcohol 3.5.3 and LiAlH4 
reduction, to furnish tetraol 3.11.2 in an overall 40% yield over three reactions in a one-
pot operation (72% avg/rxn).   
 
  
Scheme 3.11 Phosphate tether-mediated one-pot RCM/CM/LAH protocol towards 
polyols containing (E)- and (Z)-substituted internal olefins.  
 
 
Tetraols 3.11.1 and 3.11.2 obtained from trienes 3.5.6 and 3.5.5 respectively, were 
separately subjected to a global hydrogenation using o-NBSH to afford tetraol 3.12.1 
(Scheme 3.12) in 34% yield over four reactions in a two-pot operation starting from 
triene 3.5.5 (77% avg/rxn).  
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Scheme 3.12 Phosphate tether-mediated two-pot RCM/CM/LAH and global reduction 
protocol towards the generation of saturated polyol.  
 
Overall, 5 polyol diverse scaffolds were generated starting from three coupling 
partners by simple alteration of the order of addition for the coupling and in the cross-
metathesis reactions (Scheme 3.13).  
 
 
Scheme 3.13 Synthesis of 5-diverse polyols via phosphate tether-mediated one-pot, two-
pot sequential protocols. 
 
3.12.1
34% over 4 rxns in two pots
(77% avg/rxn)
1i. 3 mol% HG-II 
1,2-DCE/CH2Cl2
ii. 3 mol% HG-II 
3.5.2 or 3.5.3
 (3–5 equiv)
iii. LiAlH4, THF, 0 ºC
2. o-NBSH (20 equiv)





























 over 3 rxns in one pot
3.12.1
77% avg/rxn
 over 4 rxns in two pots
3.10.4
69% avg/rxn






































































3.4: Conclusion  
 In conclusion, diverse polyol scaffolds, bearing a central 1,3-anti-diol subunit 
with differential olefinic geometries at the periphery, were generated efficiently via a 
phosphate tether mediated 3-component coupling and subsequent one-pot, two-pot 
sequential metathesis/reduction reactions.  The polyols were synthesized by utilizing the 
following properties of phosphate triester including (i) the ability to serve as a temporary 
tether, (ii) protecting group properties, (iii) the ability to mediate tripodal coupling and 
facilitate sequential metathesis/reduction protocols.  The divergent nature of this strategy 
was developed by altering the “order of addition” of a pair of olefinic-alcohol 
components to a pseudo-C2-symmetric phosphoryl chloride.  Future directions will focus 
on further diversification of the scaffolds by utilizing hydroxyl-directed transformations. 
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Marine invertebrates are excellent sources of antimitotic secondary metabolites 
that contain a range of structural diversity such as found in polyketides, cycle peptides, 
terpenoids and cyclic ketones.  Some representative examples of such antimitotic 
secondary metabolites are discodermolide, dolastatin-10, laulimalide, eleutherobin, 
halichondrin B, peloruside, vitilevuamide, spongistatin, and hemiasterlin.1,2  The use of 
antimitotic drugs that are based on natural products, such as the taxane (paclitaxel and 
docetaxel) and Vinca alkaloid (vincristine, vinblastine, vinorelbine) families in cancer 
treatment, has inspired the search for additional natural products that show similar 
antimitotic activities.  The spirastrellolides are a class of such secondary metabolites that 
show potent activity in a cell-based antimitotic assay.3  Interest in the development of 
methods towards polyketide natural products has inspired efforts towards this goal.  This 
chapter provides our initial efforts towards the synthesis of the C9–C25 fragment of 
spirastrellolide B.  
  
4.1.1: Overview of the spirastrellolides family 
 
Spirastrellolide A is the first member of the family and was isolated in 2003 by 
Anderson and coworkers from the extracts of the Caribbean marine sponge Spirastrella 
coccinea (Figure 4.1).4  The key structural features of the macrolide include a 47-carbon 
linear polyketide backbone, a highly functionalized 38-membered lactone that contains a 
tetrahydropyran, and two spiro-bispyran substructures embedded in the macrocycle, as 
well as a side chain-containing carboxylic acid.  In terms of biological activity, 
spirastrellolide A methyl ester 4.1.1A exhibited potent activity (IC50 100 ng/mL) in a 
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cell-based (human carcinoma MCF-7 cells) antimitotic assay.3  Typically, antimitotic 
macrolides act by preventing tubulin polymerization (formation of microtubules), a 
necessary element for cell division.5   However, the antimitotic activity of spirastrellolide 
A is not caused by interference with tubulin polymerization, but rather has been found to 
be a potent inhibitor of protein phosphatase 2A (IC50 = 1nM). 6   In addition, 
spirastrellolide A has been shown to accelerate the premature entry of cells into mitosis.6  
In 2007, Anderson and coworkers isolated spirastrellolide B from the same extract, 
and confirmed the absolute configuration of the macrocyclic core of the spirastrellolides 
using X-ray crystallographic data of the degradation product of spirastrellolide B.7 
Additional family members, methylspirastrellolides C–G, were isolated from a S. 
coccinea extract in 2007, and among them, methylspirastrellolide C–E were tested in a 
cell-based assay for premature mitosis.8  The IC50 values were found to be 0.4, 0.7, and 
0.7 µM, respectively, which are comparable to that of methylspirastrellolide A (IC50 = 0.4 
µM).8  In addition, the absolute stereochemistry of C46 was unambiguously determined 
based on chiral GC analysis of methylspirastrellolide D. 8 
 
 






























R=R1=X=Z=H; Y=Cl, !15,16; Spirastrellolide A
R=R1=X=Y=Z=H; Spirastrellolide B
R=R1=X=Y=H; Z= OH; Spirastrellolide C
R=R1=Z= H, X=Y=Cl; !15,16 Spirastrellolide D
R=R1=X=Y=Z= H !15,16; Spirastrellolide E
R=R1=X=Z= H, Y = Cl; Spirastrellolide F




4.1.2: Spirastrellolides and other PP2A inhibitors 
 
 The reversible phosphorylation of proteins containing hydroxyl group bearing 
amino acids such as serine, threonine and tyrosine represents one of the fundamental 
mechanisms by which crucial cellular processes are regulated.9  The mechanism can 
involve changes in protein conformation, protein-protein interaction, protein-ligand 
interaction, membrane permeability and solute gradients among others.9  The 
phosphorylation process is catalyzed by protein kinases (PKs), and the reverse process of 
dephosphorylation is catalyzed by protein phosphatases (PPs) (Figure 4.2).  There are 
different classes/types of phosphatases known to be present on eukaryotic cells, based on 
the substrate specificity, metal-ion dependency, and biochemical assay categorizations.10 
Irregularities in protein phosphorylation is known to contribute to many human diseases 
such as cancer and diabetes.11  Therefore it is imperative to identify inhibitors of 
phosphatases in order to understand their role in such biological problems and aid in 























In 2001, Wipf and coworkers designed a library of protein Serine/Threonine 
phosphatase (PSTPase) inhibitors based on the structure-activity-relationship studies for 
the natural-product inhibitors and a pharmacophore model was proposed to summarize 
the important features of such inhibitors (Figure 4.3).12  According to this model, the 
presence of a carboxylate or a phosphate group, a hydrophobic backbone, and H-bond 




Figure 4.3. Phamacophore model developed by Wipf and coworkers for PP1 and PP2A 




























































































0.2 nM (PP2A); 20 nM  (PP1)
100 (PP1/PP2A)
Calyculin A 
0.1–1 nM (PP2A); 0.5–2 nM (PP1)
5 (PP1/PP2A)
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 There are many selective small molecule natural product inhibitors reported in the 
literature that are promising targets because of their ability to mimic and/or complement 
small areas of the protein-protein interaction while avoiding problems faced by common 
peptide inhibitors (high molecular weight, poor permeability, hydrolytic instability and 
isolation issues).  Some representative examples of small molecule inhibitors of PP1 or 
PP2A, are the Fostriecin, Spirastrellolide A, Calyculin A and Okadaic classes of 
inhibitors, as shown in Figure 4.3.  Structually, all of naturals products shown in the 
Figure 4.3 belong to polyketide-class of phosphatase inhibitor— except for Cantharidin, 
which is a terpenoid class of natural product inhibitors.13   
 
 
Figure 4.4. Active site of PP1•OA complex. 
 
 Okadaic acid (OA), isolated from marine sponges Halichondria okadai and 
Halichondria melanodocia, was one of the first small molecules to be isolated among the 
protein phosphatase inhibitors and studied extensively.14  In 2001, Holmes and coworkers 





















































crystal structure revealed that the acidic group present in OA resided in a hydrophobic 
groove adjacent to the active site of the protein and interacts with the basic residues 
within the active site.  In addition, it was also observed that OA existed as pseudo-cyclic 
shape in which the C24 hydroxyl group has hydrogen bonding with the C1 carboxylic 
acid group.  For spirastrellolide A, no correlation of structure and biological activity 
(PP2A inhibition activity) has been reported yet.  But a crude comparison of 
spirastrellolide A with okadaic acid (OA)16 reveals the presence of similar functionalities 
in both molecules (Figure 4.5).  It should be noted that the structural comparison alone, 
might be an oversimplification in terms of identifying the pharmacophore present in 
spirastrellolide A.  However, synthetic studies towards the spirastrellolide family,  in 
which subtle manipulation of functionalities could be incorporated to provide SAR, 




Figure 4.5. Spirastrellolide A. 
  


































38-membered macrolactone and a bicyclic and a tricyclic spiroacetal unit.17  In 2012, 
both of the family members, spirastrellolides A and B, were reisolated as free acids from 
a marine sponge Epipolasis sp. and tested against HeLa cancer cell lines.  The IC50 values 
of the free acids of spirastrellolides A and B were found to be 20 and 40 nM respectively, 
comparable to the corresponding methyl ester of spirastrellolide A and B which exhibited 
IC50 values of 30 nM and 70 nM, respectively.18  
 
4.2: Synthetic efforts towards spirastrellolides  
 
 The interesting biological activity and novel structural features of spirastrellolides 
has inspired many synthetic efforts towards spirastrellolides A, B, E and F.19  The total 
synthesis of spirastrellolide A was accomplished by both the Fürstner and the Paterson 
groups.20,21,22  For the purpose of this chapter, only the key features of the synthetic 
studies towards the southern hemisphere fragments will be discussed. 
 
4.2.1: Paterson group’s synthesis of the C1–C25 fragment of spirastrellolide A 
 Due to the lack of X-ray crystal data, the stereocenters at C3, C7, C9–C24, C27–
C38 and C-46 of methylspirastrellolide A were not unambiguously assigned until the 
isolation of spirastrellolide B in 2007.7  Therefore, synthetic studies before 2007 were 
focused on generating all possible stereoisomers.   The Paterson group demonstrated a 
monumental effort towards this challenge by producing diastereomers of the southern 
fragments through the development efficient and convergent synthetic strategies (Figure 
4.6).20a,b,c  All of the syntheses from the Paterson group included elegant boron-mediated 
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Figure 4.6. Diastereomeric fragments of the southern hemisphere of 
methylspirastrellolide A synthesized by Paterson and coworkers. 
 
asymmetric aldol and allylation strategies to construct key fragments.  Since similar 
strategies have been utilized for the fragments, as well as the total synthesis, only one of 
the full reports on the synthesis of the southern hemisphere by the Paterson group is 
described herein. 
 In 2005, Paterson and coworkers reported the synthesis of two diastereomeric  
C1–C25 fragments of spirastrellolide A (Scheme 4.1–4.2).20b  A late stage union of two 
key fragments, the C1–C16 alkyne fragment and  the C17–C25 aldehyde fragment, was 
established to access the open chain precursor prior to spirocyclization.  Both of the 
fragments were efficiently synthesized utilizing boron-mediated asymmetric allylation 
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Scheme 4.1. Paterson’s synthesis of the C1–C16 fragment of spirastrellolide A. 
 
 A boron-mediated aldol reaction of ethyl ketone 4.1.3 separately with aldehyde 
4.1.1 or 4.1.2 was employed to generate β-hydroxy keto products 4.1.4 and 4.1.5 in 
excellent yields and diastereoselectivities (Scheme 4.1).23  The aldol products 4.1.4 and 
4.1.5 were later converted to diastereomeric alkyne fragments 4.1.6 and 4.1.7 over a few 
steps. 
 The synthesis of the C17–C25 fragment commenced with Brown allylation24 of 
aldehyde 4.2.1, followed by methylation, desilylation and oxidation to obtain aldehyde 
4.2.2 (Scheme 4.2).  Subsequent boron-mediated aldol reaction23 provided keto 
compound 4.24, which was further functionalized to generate the C17–C25 fragment 4.25 
in 14 linear steps overall.  The late stage coupling of two key intermediates, the C1–C16 
alkyne fragment and the C17–C25 aldehyde fragment was achieved via lithiation of 
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Scheme 4.2. Paterson’s synthesis of the two diastrereomeric C1–C25 fragments of 
spirastrellolide A. 
 
product in a 1:1 diastereomeric mixture at C17.  Subsequent oxidation and Lindlar 
hydrogenation furnished (Z)-enones 4.26 and 4.27 in 77% and 66% yields, respectively, 
over 3 steps.  The open-chain precursors 4.26 and 4.27 were then treated with HF•MeCN, 
which led to acetonide deprotection and desilylation, followed by spirocyclization, to 
provide a single diastereomer of spiroacetal 4.28 and 4.29. 
 
4.2.2: The Fürstner group synthesis of the C1–C24 fragments of spirastrellolide F 
and spirastrellolide A 
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reported in 2006.25  As in the original approaches published by Paterson (vide supra), 
initial efforts by the Fürstner group were also focused on generating diastereomer of the 
southern fragments due to the ambiguity in assigning the absolute stereochemistry of the 
natural product.  In 2006, Fürstner and coworkers reported the synthesis of two possible 
diastereomers of the C1–C25 fragment of spirastrellolide A (Figure 4.7). 25 
 
 
Figure 4.7. Fürstner’s synthesis of two diastereomeric C1–C25 fragments of 
methylspirastrellolide A. 
 
However, their first attempt at the total synthesis of spirastrellolide A was 
unsuccessful, and included the union of the southern fragment and the northern fragment 
via ring-closing metathesis (RCM).26  The synthetic route was therefore revised, which 
required significant changes in the strategy for the construction of the southern fragment 
en route to the synthesis of southern hemisphere of spirastrellolide F, as described below 
in Scheme 4.3–4.4. 27 
 The construction of the C1–C16 started with the modified Mukaiyama aldol 
reaction28 of C11–C16 fragment 4.3.1 with silyl enol ether intermediate of the C1–C10 












R,R = C(CH3)2; 24 LLS, 32 TSC
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diastereomer.  Further manipulations included 1,3-anti reduction following the Evans-
Tischenko protocol, 29  the reduction of the ester (at C1), C-Si bond cleavage and 
persilylation to deliver the C1–C16 fragment 4.3.4 over 13 longest linear steps and 
overall 22 steps (Scheme 4.3).  
 The 2,3-anti-3,4-syn stereocenters of C17–C24 fragment 4.3.9 was established via 
a highly diastereoselctive glycolate aldol reaction30 of aldehyde 4.3.5 with silyl ketene 
acetal 4.3.6 (Scheme 4.3).31   Subsequent desilylation, protection of vicinal alcohols and 
 
Scheme 4.3. Fürstner synthesis of C1–C16 and C17–C24 fragments of spirastrellolide F. 
 
conversion of the alkyne terminus to the carbonyl group, produced C17–C24 fragment 
4.3.9 efficiently over 11 longest linear steps and 12 total steps overall (Scheme 4.3). 
The endgame towards the completion of the C1–C24 fragment included the 
lithiation of alkyne 4.3.4 and subsequent addition to aldehyde 4.3.9 to provide the key 
intermediate 4.4.1 in excellent yield (Scheme 4.4).  Oxidation of the resultant alcohol in 
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internal alkyne, PMB deprotection and subsequent spirocyclization were achieved in one 
single step by using Pd(OH)2 in EtOAc.  It should be noted that Pd(OH)2 in EtOAc was 
found to be the only catalyst effective for this whole transformation in which the solvent 




Scheme 4.4. Endgame towards the synthesis of the C1–C24 fragment of spirastrellolide 
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In 2013, Fürstner and coworkers reported the total synthesis of 
spirastrellolide A methyl ester which encompassed a similar synthetic strategy to 
access the southern hemisphere, namely the C1–C24 fragment (Scheme 4.5).32  
The synthesis started with the union of methyl ketone 4.3.2, the C1–C10 fragment 
and the aldehyde 4.5.1, the C11–C16 fragment, via modified Mukaiyama aldol 
reaction.28  This key bond formation was quite similar to the synthetic route for 
spirastrellolide F (described above); however, the aldehyde 4.5.1, utilized in this 
strategy, contained a dithiane functional group, which served the dual purpose of 
being a functional handle to couple advanced fragments and also as a masked 
carbonyl that was revealed at a later stage of the synthesis to form the double 
bond in between C15 and C16.  The southern fragment was further elaborated via 
the addition of dithiane 4.5.2 to the aldehyde 4.5.3, the C17–C24 fragment, in the 
presence of a mixed metallic reagent to obtain the extended C1–C24 fragment 
4.5.4 in excellent yield.  Subsequent oxidation and PMB deprotection yielded the 
spirocyclic precursor, which upon the treatment with PPTS produced the 
spirocyclic intermediate albeit in modest yield mainly due to primary TBS 
deprotection (at C1).  After reprotecting the primary alcohol at C1 in the presence 
of TBSOTf, the secondary alcohol at C24 was converted to enol triflate present in 
4.5.6.  The endgame included deprotection of dithiane to reveal the carbonyl at 
C16 and subsequent oxidation of the primary alcohol (at C1) to carboxylic acid in 
a 2-step DMP/Pinnick oxidation protocol33 to provide the C1–C24 fragment 4.5.7 
over 26 linear steps. 
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Scheme 4.5. Fürstner’s  group synthesis of the C1–C24 fragment of 
methylspirastrellolide A. 
 
4.2.3: The Phillips group synthesis of the C1–C23 fragment of spirastrellolide B 
In 2008, Phillips and coworkers reported the synthesis of the C1–C23 fragment of 
spirastrellolide B utilizing Kulinkovich-cyclopropanol ring-opening strategy34 twice for 
the key bond forming reactions (Scheme 4.6–4.7). 35   The desired cyclopropanol 
intermediate was generated from TBS-protected alcohol 4.6.1 by treating with 
cyclohexylmagnesium bromide in the presence of Ti(OiPr)4 (Scheme 4.6).  The first 
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the presence of Fe(NO3)2 and DBU to produce the corresponding enone, which was 
cyclized to pyran 4.6.2 over five steps.  Mukaiyama aldol reaction between pyran 4.6.2 
and aldehyde 4.6.3, synthesized over six steps, yielded a β-hydroxyketo intermediate, 
which was diastereoselectively reduced in the presence of Li(tBuO)3AlH.  Subsequent 
TBS protection of the resulting alcohol generated the C1–C16 fragment 4.6.5.   
 
 
Scheme 4.6. Philip’s synthesis of the C1–C16 and C17–C24 fragments of spirastrellolide 
B. 
 
The synthesis of the C17–C23 fragment 4.6.9 started with the reduction and 
protection of propargylic alcohol 4.6.6 to generate the protected (E)-substituted allylic 
alcohol 4.6.7 in 74% yield (Scheme 4.6).  Subsequent Sharpless asymmetric 
dihyroxylation, silylation and hydrogenolysis of the benzyl group generated the primary 
alcohol intermediate 4.6.8.  Further oxidation and methylation produced the desired 
methyl ester substrate 4.6.9, the C17–C23 fragment over 11 longest linear steps. 
 The two key fragments were next united by utilizing a second Kulinkovich-
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subjected to Ti(iOPr)4 and cyclohexylmagnesium bromide to generate the advanced 
cyclopropanol intermediate 4.7.1 in 90% yield (Scheme 4.7).  Subsequent ring-opening in 
the presence of Fe(NO3)2 and Bu3SnH to produce ketone 4.7.2 in 71% yield.  
Desilylation, along with spirocyclization in the presence of HF in MeCN and 
reprotection, delivered the spirocyclized product 4.7.3, the C1–C23 fragment over 15 
longest linear steps. 
 
  
Scheme 4.7. Endgame for the C1–C23 fragment of spirastrellolide B by Philips et. al. 
 
4.2.4: The Smith group synthesis of the C1–C25 fragments of spirastrellolide A, B 
and the C1–C24 fragment of spirastrellolide E 
In 2007, Smith and coworkers reported the synthesis of the C1–C25 fragment of 
spirastrellolide A and later, in 2010, expanded the method to access the southern 
hemispheres of both A and B.36  Both of the syntheses featured the elegant anion relay 
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en route to the spirastrellolide family as described below in Scheme 4.8–4.9.  
 
Scheme 4.8. Synthesis of the C1–C25 fragment of spirastrellolide A by Smith and 
coworkers.  
 
The spirocycle–containing C11–C22 fragment 4.8.4 was synthesized by 
employing the ARC strategy to couple 3 synthons, epoxide 4.8.1, dithiane-containing 
subunits 4.8.2 and 4.8.3 (Scheme 4.8).   Subsequent treatment of dithiane 4.8.5 with the 
Schlosser base 38  and concomitant addition of epoxy-spirocycle intermediate 4.8.4 
revealed the C1–C22 fragment 4.8.6 in 87% yield.  This fragment was further converted 
the aldehyde 4.8.7 containing the C1–C22 framework.  Next, the 4-carbon fragment 
4.8.8, the dithiane-containing C23–C26 fragment, was installed by treating 4.8.8 with 
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the major diastereomer 4.8.9 obtained from this reaction turned out to be the C22 epimer 
of the desired alcohol.  The alcohol was then oxidized and reduced in the presence of 
DiBAL-H to produce a single diastereomer of the required alcohol via chelation 
controlled addition of hydride, and subsequent protection of the resultant alcohol 
furnished pivaloyl protected 4.8.10, which was converted to the desired C1–C25 
fragment 4.8.11 (Scheme 4.8).  The synthetic sequence consisted of 33 longest linear 
steps and 43 overall steps. 
 In 2010, Smith and coworkers exploited a similar strategy to access the C1–C25 
fragment of spirastrellolide B (Scheme 4.9).36b  The synthetic sequence, consisting of 32 
longest linear steps, involved similar bond disconnections, and heavily relied on ARC 
strategy to couple simple building blocks in an efficient manner to construct the key 
fragments.  The only structural difference of the C1–C25 fragments of spirastrellolide A 
and B is the absence of internal double bond in the B ring of spiroacetal of spirastrellolide 
B.  This factor was addressed earlier in the synthesis to investigate if the conformational 
change of the reduced spirocyclic product could be beneficial for improving the 
selectivity of desired alcohol formed by dithiane addition.  Accordingly, the spiroacetal 
4.9.1 was chemoselectively reduced in the presence of PtO2.  Subsequent introduction of 
the dithiane group 4.8.8 following Honda’s protocol39 furnished alcohol 4.9.3, though as 
separable 1:1 diastereomeric mixture.  This protocol was an improvement considering 
that the analogous unsaturated (at C15–C16) spirocyclic aldehyde 4.8.7 (Scheme 4.8), 
towards the synthesis of C1–C25 fragment of spirastrellolide A, provided the undesired 
isomer 4.8.9 in 6.5:1 ratio when subjected to the same reaction (Scheme 4.8).  
Subsequent oxidation-reduction sequence, dithiane removal, followed by chelation-
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controlled 1,2-reduction revealed the eastern half of the fragment.  Further, removal of 
benzyl groups and the use of Fraser-Reid tactic40 generated epoxide 4.9.4, which was 
then subjected to the addition of dithiane 4.9.5 to obtain fully functionalized, dithiane-
containing C1–C25 fragment 4.9.6. Removal of dithiane followed by reduction and 
subsequent protection generated the C1–C25 fragment 4.9.7 of spirostrellolide B. 
 
Scheme 4.9. Synthesis of the C1–C25 fragment of spirastrellolide B by Smith and 
coworkers. 
 
In 2015, Smith and coworkers reported the synthesis of the C1–C24 fragment of 
spirastrellolide E by utilizing ARC strategy in conjunction with directed, regioselective 
gold-catalyzed alkyne functionalization (Scheme 4.10).41   Lithiation of TBS-dithiane 
4.10.1 and subsequent addition of epoxide 4.10.2 led to the generation of the intermediate 
lithium alkoxide, which underwent solvent-mediated Brook rearrangement in the 
presence of HMPA and epoxide 4.10.3 to furnish the 3-component adduct 4.10.4 in an 
impressive 68% yield.  
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subjected to addition of alkyne 4.10.6 in the presence of LDA to produce alcohol 4.10.7 
in excellent yield (85%) as a mixture of diastereomers at C15 (Scheme 4.10).  
   
Scheme 4.10. Synthesis of the C1–C24 fragment of spirastrellolide E by Smith and 
coworkers. 
 
The diastereomers were separated and treated with DIBAL-H and DDQ to 
remove the benzoyl and PMB groups, respectively to obtain triol 4.10.9.  When 
separately treated in the presence of the cationic gold reagent 4.10.10, first developed by 
Echavarren and coworkers, 42 the anti-isomer (the stereochemistry referred to the relative 

























































































4.10.11; 19 LLS, 36 TSC







the desired C1–C24 fragment 4.10.11 of spirastrellolide E.  Interestingly, the cis-isomer 
(C15-epimer of 4.10.9) did not furnish the desired product.  Overall, this second 
generation synthesis, consisting of 19 longest linear steps, provides a scalable, 
streamlined and modular route to access the advanced C1–C24 fragment of 
spirastrellolide E. 
 Shortly after this publication, Smith and coworkers reported a similar strategy 
towards the construction of the C1–C23 fragment of spirastrellolide E, in which 
mechanistic aspect of the gold-catalyzed, spirocyclization step was studied in detail 
(Scheme 4.11).43   Following same synthetic strategy as discussed before, the addition of 
the lithiated C16–C23 fragment 4.11.1 to the aldehyde 4.10.5 generated alcohol 4.11.2 in 
89% combined yield.  Removal of benzoyl group followed by PMB deprotection 
produced the spirocyclization precursor triol 4.11.3 in excellent yield.  The anti-isomer 
4.11.3a was subjected to spirocyclization in the presence of the cationic gold reagent 
4.10.10 to generate the C1–C23 fragment 4.11.4 as reported before by Smith and 
coworkers towards the synthesis of the C1–C24 fragment of spirostrellolide E (Scheme 
4.10).41  Unlike the previous report, in which the syn-isomer did not furnish the desired 
spirocycle, the study of the crucial Au-catalyzed cyclization step, in this case facilitated 
the conversion of the syn-isomer to the desired spirocyclic product.  The spirocyclization 
of the syn-isomer 4.11.3b was achieved first by protecting both of hydroxyl group at C13 
and C15 as acetonide and then by treating with AuCl and K2CO3 to obtain the spirocycle 
present in the C1–C23 fragment in 24% yield over 2 steps. 
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Scheme 4.11. Study of gold-catalyzed spirocyclization en route to the C1–C23 fragment 
of spirastrellolide E by Smith and coworkers. 
 
4.2.5: The Hsung group synthesis of the C1–C23 fragment of spirastrellolide A 
 In 2006, Hsung and coworkers reported the synthesis of the C1–C16 fragment of 
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from 1,5-pentanediol, was subjected to directed reductive ring-opening, acetonide 
protection of the diol, debenzylation and Parikh-Doering oxidation (modified Moffat 
protocol)45 to produce aldehyde 4.12.2.  The aldehyde was next converted to pyran 4.12.3 
in excellent yield via Wittig olefination and subsequent deprotection followed by 
intramolecular O-1,4-addition. Pivaloyl protection of the primary alcohol present in pyran 
4.12.3 followed by coupling with aldehyde 4.12.4 under Mukaiyama’s condition46 
produced the C1–C16 fragments 4.12.5 and 4.12.6 in moderate yields and selectivity. 
   
Scheme 4.12. Hsung’s synthesis of the C1–C16 fragment of spirastrellolide A. 
 
In 2005, Hsung and coworkers reported the synthesis of the C22 epimer of the 
C11–C23 fragment 4.13.6 of spirastrellolide A employing a ketal-tethered RCM strategy 
to construct the spirocycle (Scheme 4.13, also mentioned briefly in chapter 1).47  Starting 
with substituted allylic alcohol 4.13.1, synthesized from D-glucose over 8 steps, a linear 
strategy was followed to construct the key RCM precursor 4.13.5.  Protection of the 
secondary alcohol followed by deprotection of both TBS groups generated the 
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alcohol.  Subsequent hydroboration-oxidation revealed diol 4.13.2 in 78% yield (over 3 
steps).  The generation of intermediate lactone (not shown in the scheme below) was 
performed by TEMPO oxidation followed by deprotection-protection of the C23 
hydroxyl group as TBDPS ether.  The later step was required, as the C23 TBS group did 
not survive the subsequent cyclic ketalization step.  Addition of vinylmagnesium bromide 
to the lactone produced lactol 4.13.3 as single diastereomer in 73% yield.  The key RCM 
precursor 4.13.5 was generated by the ketalization of lactol 4.13.3 with homoallylic 
alcohol 4.13.4 in the presence of the Bronsted acid Tf2NH as a single isomer.  When 
subjected to the G-I catalyst, 4.13.5 underwent RCM to produce the C22 epimer of the 
C11–C23 fragment 4.13.6 in 50% overall yield over two steps.  Overall, the synthetic 
route, consisting of 18 longest linear steps and 21 total steps, demonstrated the utility of 
ketal tether-mediated RCM strategy to build complex spirocyclic core such as 4.13.6 
(Scheme 4.13). 
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 In 2008, Hsung and coworkers reported the synthesis of the C1–C23 fragment 
4.14.6, which involved ketal tethered-RCM strategy to construct the spirocyclic key 
intermediate 4.14.2 and then a late-stage union of two key fragments 4.14.4 (C1–C10 
fragment) and 4.14.3 (C11–C23) via Mukaiyama aldol reaction (Scheme 4.14).48  This 
synthesis featured a streamlined and concise synthesis of the C11–C23 fragment 4.14.2 
starting from (+)-2,3-(O)-iso-propylidene-L-threitol (4.14.1) as compared to the 
previously discussed synthesis reported in 2005.47  Further deprotection of PMB group 
followed by Parikh-Doering oxidation45 of 4.14.2 produced the coupling partner aldehyde 
4.14.3 in 79% overall yield.  Subsequent Mukaiyama aldol46 reaction of aldehyde 4.14.3 
and methyl ketone 4.14.4,44 synthesized over 12 steps, in the presence of stoichiometric 
amount of BF3•Et2O generated solely C11, C13-anti-diastereomer 4.14.5 in 62% yield. 
Directed reduction of 4.14.5 revealed diol in 68% yield with 3:1 anti/syn (C9 and C11) 
ratio.  Acetonide protection of resulting diol generated the C1–C23 fragment 4.14.6 in 
overall 17 longest linear steps and 29 total steps.  
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4.2.6: The Brabander group synthesis of the C1–C22 fragment of spirastrellolide A 
 
In 2006, Brabander and coworkers reported the synthesis of two diastereomers of 
C1–C22 fragment of spirastrellolide A utilizing a late-stage, substrate-controlled, 1,3-
anti-Mukaiyama aldol reaction49 to couple two key fragments 4.15.5 and 4.15.6 (Scheme 
4.15).50   Initial efforts to construct spirocyclic intermediate 4.15.4 started with lithiation 
of alkyene 4.15.1 and subsequent addition of amide 4.15.2 to produce the coupling 
product 4.15.3 in 82% yield.  Reduction of alkyne to the (Z)-alkene intermediate and 
acid-catalyzed spirocyclization in the presence of p-TsOH generated spirocyclic 
intermediate 4.15.4.  Aldehyde 4.15.5, generated after Swern oxidation, was then 
subjected to substrate-controlled, 1,3-anti-Mukaiyama aldol reaction49 with enantiomeric 
methyl ketones 4.15.6 and ent-4.15.6, separately, in the presence of TMSOTf and 2,6-
lutidine to produce two diastereomers of β-hydroxy ketone 4.15.7.  Subsequent reduction 
to obtain 1,3-anti-diols51 and PMB deprotection delivered the diastereomers of the C1–
C22 fragment 4.15.8 of spirostrellolide A efficiently over 13-longest linear steps. 
 
Scheme 4.15. Brabander’s synthesis of the diastreomeric fragments containing C1–C22 
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4.2.7: The Chandrasekhar group synthesis of the C9–C25 fragment of 
spirastrellolide B 
 
 In 2008, Chandrasekhar and coworkers reported the synthesis of the C9–C25 
fragment by utilizing a combination of “chiron” 52 and asymmetric approaches (Scheme 
4.16).53  The C9–C16 fragment was derived from known epoxide 4.16.1 over 11 steps, 
that included a Sharpless asymmetric epoxidation54 to introduce C13 stereogenecity and 
then a diastrereoselective and regioselctive cuprate55 reaction to generate C14-Me center.  
 
   
Scheme 4.16. Chandrasekhar’s synthesis of the C9–C25 fragment of spirastrellolide B. 
 
 The other key fragment 4.16.3, the C17–C25 was synthesized from D-glucose 
following a chiron approach that involved utilizing the stereocenters of the substrate 
(usually a carbohydrate or amino acid) to access elaborated advanced fragments.52  The 
late-stage union of the key fragments 4.16.2 and 4.16.3 was established by lithiation of 


































rt, 30 min, 98%
2. Pd-CaCO3









4.16.6, 21 LLS, 33 TSC




















4.16.4 in excellent yield as a mixture of diastereomers.  The newly formed hydroxyl 
group of 4.16.4 was then oxidized and the internal triple bond was reduced using the 
Lindlar catalyst to generate the spirocyclization precursor 4.16.5.  Finally, 
spirocyclcization in the presence of .8% H2SO4 produced the C9–C25 fragment 4.16.6 of 
spirastrellolide B in a 21-longest linear step and 33 overall total steps synthetic sequence. 
 
4.2.8: Yadav group synthesis of the C1–C25 fragment of spirastrellolide B and F 
 In 2013, Yadav and coworkers reported the synthesis of the C1–C25 fragment of 
spirastrellolide B and F employing a late-stage union of two advanced fragments via 
Horner–Wadsworth–Emmons (HWE)56 coupling strategy (Scheme 4.17).57   The coupling 
partners required for the HWE coupling, namely the aldehyde 4.17.1 and  the β-keto-
phosphonate intermediate 4.17.2 were synthesized in 35 and 17 steps respectively.   
   


































































18 steps, R = C(CH3)2
4.17.1, C1–C15
35 steps
4.17.5; C1–C25 fragment of 
spirastrellolide B & F, 38 LLS, 56 TSC
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 For the final coupling, aldehyde 4.17.1 was subjected to HWE coupling with 
phosphonate 4.17.2 in the presence of Ba(OH)256 to produce the enone 4.17.3 in good 
yield.   Subsequent reduction of enone with (BDP)2CuH 58 generated ketone 4.17.4 in 
excellent yield, which was then treated with PTSA/MeOH to produce the C1–C25 
fragment 4.17.5 in excellent yield. 
 
4.3: Results and discussion 
 
 Our group has concentrated efforts aimed at developing efficient synthetic 
strategies utilizing phosphate tether-mediated desymmetrization of C2-symmetric 1,3-
diene diols en route to 1,3-anti-diol group containing bioactive natural products.59 
Aligned with this goal, we were interested in the total synthesis of spirastrellolide B, 
possessing a challenging framework of a 38-membered macrolactone, and a bicyclic and 
tricyclic spiroacetal unit buried within the framework.  Even though there are elegant 
reports from the Paterson and the Fürstner group regarding the total synthesis of 
spirastrellolide A and/or F, the total synthesis of its congener, spirastrellolide B has not 
been reported to date.  In addition, despite having striking structural similarities, 
spirastrellolide A is known to be a potent inhibitor of PP2A while spirastrellolide B has 
not been tested/or reported to be a phosphatase inhibitor.  In fact, there were no biological 
activities reported for spirastrellolide B until 2012.  In 2012, both of the family members, 
A and B were re-isolated as free acids and tested against HeLa cancer cell lines.  As 
discussed earlier in this chapter, the IC50 values of the free acids of spirastrellolide A and 
B were found to be 20 and 40 nM, respectively, comparable to the corresponding methyl 
ester of spirastrellolide A and B which exhibited IC50 values of 30 nM and 70 nM, 
respectively.  However, unlike spirastrellolide A, the cytotoxity of spirastrellolide B has 
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not been linked to a phosphatase inhibition mechanism.  Therefore, the total synthesis of 
spirastrellolide B will serve not merely as another synthetic campaign but for the 
identification of the pharmacophore of spirastrellolide A/B, which could, in turn serve, as 
an excellent biological tool to investigate protein phosphatase-mediated cellular 
regulation. 
 
4.3.1: Proposed retrosynthetic analysis of the C9–C25 fragment of spirastrellolide B 
 In a collaborative project in the Hanson lab, we are aiming for the total synthesis 
of spirastrellolide B, in which my contribution has involved the assembly of the C9–C25 
fragment 4.18.1 (Scheme 4.18).  In this regard, we designed a synthetic route which 
utilizes phosphate tether-mediated regioselective oxidation and diastereoselective cuprate 
displacement of bicyclo[4.3.1]phosphate (R,R,RP)-4.18.5 to access the western C9–C16 
subunit 4.18.4.   
  
Scheme 4.18. Our retrosynthetic strategy for C9–C25 fragment of spirastrellolide B. 
 Our proposed retrosynthetic route relies on a late-stage Achmatowicz 
























































envisioned to be derived via Suzuki-Miyaura coupling of a furan substrate 4.18.3 with the 
1,3-diol containing synthon 4.18.4.  Overall, successful implementation of this route 
would achieve the synthesis of the C9–C25 fragment of spirastrellolide B with a longest 
linear sequence (LLS) of 14 steps and a total step count (TSC) of 22.  In comparison, a 
brief summary of other elegant synthetic routes towards similar fragments of 
spirastrellolides to our proposed route towards the C9–C25 fragment of spiratsrellolide B 
is shown in Figure 4.8.   
 
Author and References (fragment targeted) 
Key Reactions 
Step count  
(LLS and TSC) 
Paterson et. al. Org Lett. 2005 (C1–C25 of spirastrellolide A) 
Boron-mediated asymmetric aldol and allylation  
20 LLS, 40 TSC 
Fürstner et. al. Angew. Chem. Int. Ed. 2009  
(C1–C24 of spirastrellolide F) 
Mukaiyama aldol and glycolate aldol strategy 
22 LLS, 43 TSC 
Fürstner et. al. Chem. Eur. J. 2013 (C1–C24 of spirastrellolide A) 
Mukaiyama aldol and strategic use of dithiane functionality 
26 LLS, 45 TSC 
Phillips et. al. Org. Lett. 2008 (C1–C23 of spirastrellolide B) 
Use of Kulinkovich-cyclopropanol ring-opening strategy twice 
15 LLS, 30 TSC 
Smith et. al.  Org. Lett. 2007 (C1–C25 of spirastrellolide A) 
Anion relay chemistry (ARC) 
32 LLS, 42 TSC 
Smith et. al. Tetrahedron 2010 (C1–C25 of spirastrellolide B) 
Anion relay chemistry (ARC) 
33 LLS, 43 TSC 
Smith et. al. Tetrahedron Lett. 2015 (C1–C24 of spirastrellolide E) 
Anion relay chemistry (ARC) and gold-catalyzed alkyne 
functionalization 
19 LLS, 36 TSC 
Smith et. al. Org. Lett. 2015 (C1–C23 of spirastrellolide E) 19 LLS, 34 TSC 
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Anion relay chemistry (ARC) and gold-catalyzed alkyne 
functionalization 
Hsung et. al. Org. Lett. 2008 (C1–C23 of spirastrellolide E) 
Ketal-tetherd RCM and Mukaiyama aldol 
17 LLS, 29 TSC 
Brabander et. al. Synlett 2006 (C1–C22 of spirastrellolide A) 
Mukaiyama aldol strategy 
13 LLS, 24 TSC 
Chandrasekhar et. al. Org. Lett. 2008 (C9–C25 of spirastrellolide B) 
chiron and asymmetric approaches 
21 LLS, 33 TSC 
Yadav et. al. Org. Biomol. Chem. 2013  
(C9–C25 of spirastrellolide B) 
HWE olefination and conjugate reduction 
38 LLS, 56 TSC 
Our proposed route (C9–C25 of spirastrellolide B) 
Achmatowicz spiroketalization, Suzuki-Miyaura coupling and 
phosphate tether-mediated stereoselective reactions 
14 LLS, 22 TSC 
Figure 4.8: A brief summary of steps counts and key reaction towards similar fragments 
targeted by different groups in comparison with our proposed route. 
 
4.3.2: Model studies towards the synthesis of the C9–C23 fragment of 
spirastrellolide B 
 
Our initial focus was to check the feasibility of the key reactions in this synthetic 
route, namely the Suzuki-Miyaura coupling and Achmatowicz cyclization.  Therefore, we 
chose to synthesize a shorter fragment, the C9–C23 containing 4.19.1 fragment, with less 
complexity but with an appropriate core scaffold consisting of the spiroacetal unit and 
other required functional groups (Scheme 4.19).  Alternatively, we were looking into the 
same bond formation between C15 and C16 via a cross-metathesis and hydrogenation 




Scheme 4.19. Retrosynthetic plans for model studies. 
 
4.3.2.1: Synthesis of the C9–C16 fragment and the C17–C23 fragment: model 
studies towards the synthesis of C9–C23 fragment of spirastrellolide B 
 
Towards the aforementioned goal, we initiated our synthesis of the C9–C16 
polyol containing fragment 4.19.5 (Scheme 4.20).  Starting with the 
bicylo[4.3.1]phosphate 4.20.1, prepared over 4 steps from 1,5-dichloropentane-2,4-dione, 
the regioselective hydroboration-oxidation in the presence of 9-BBN60 followed by a 
mild work-up protocol developed by Burke and coworkers, 61  provided phosphate 
intermediate containing a primary alcohol (not shown in the Scheme) in 78% yield.  
Subsequent PMB ether formation in the presence of p-methoxybenzyl 
trichloroacetimidate and catalytic amount of PPTS delivered PMB ether 4.20.2 in 72% 





































































and regioselective allylic cuprate displacement protocol.  For this purpose, phosphate 
4.20.2 was treated with dimethyl cuprate generated in situ by the reaction of dimethyl 
zinc and copper cyanide. After completion of the reaction, monitored by TLC, the crude 
phosphoric acid was subjected to Red-Al reduction to generate diol in 80% yield (over 2 
steps).  Selective monoprotection (as a TIPS-ether) of the less-hindered secondary 
alcohol produced the C9–C16 fragment, 4.19.5 over 8 total steps.60  
 
 
Scheme 4.20. Synthesis of the C9–C16 fragment and the model C17–C23 furan fragment. 
 The synthesis of the C17–C23 fragment 4.19.3 started with the HWE olefination 
of 5-bromo-2-furaldehyde (4.20.3) to generate ester 4.20.4 in excellent yield (Scheme 
4.20).  Subsequent Sharpless asymmetric dihyroxylation 62  followed by acetonide 
protection produced the coupling partner 4.19.3. 
 Concurrent with the effort outlined above, we also focused on a cross-metathesis 
route towards the construction of the same fragment 4.21.1 (Scheme 4.21).  For that 
purpose, we began with the synthesis of vinyl furan fragment 4.19.6.  Following 
Molander’s protocol,63 the Suzuki-Miyaura coupling of furan 4.19.3 was performed with 
potassium vinyltrifluroborate in the presence of catalytic PdCl2 and CaCO3 in refluxing 
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when the vinyl furan intermediate 4.19.6 was subjected to the CM reaction with olefin 
4.19.5 in the presence of the HG-II catalyst, the desired CM product 4.21.2 was not 
observed.  
   
Scheme 4.21. Cross-metathesis efforts towards C15–C16 bond formation. 
 
4.3.2.2: Efforts towards the synthesis of the model C9–C23 fragment via Suzuki-
Miyuara coupling 
 We therefore directed our attention towards our previously designed route of 
Suzuki-Miyuara coupling with bromofuran intermediate 4.19.3 and borate ester 4.19.4 
(Scheme 4.19).  The corresponding borate ester synthesis started with 
bicylo[4.3.1]phosphate 4.20.1, which was converted to alcohol via a hydroboration-
oxidation protocol and subsequent benzylation to produce benzylated 
bicyclo[4.3.1]phosphate 4.18.5 (Scheme 4.22).  Allylic cuprate displacement, followed 












































4.21.1, R = C(CH3)2
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Scheme 4.22. Synthesis of the C9–C16 fragment. 
 
 The synthesis of borate ester 4.23.2 commenced with the initial attempt of 
hydroboration of protected diol 4.23.1 in the presence of 9-BBN (Scheme 4.23). 
However, even with different protecting groups, we were unable to obtain the 
hydroborated product 4.23.2.  Therefore, we decided to pursue metal-catalyzed 
hydroboration route.64  Gratifyingly, we were able to isolate the alkyl pinacolboronates 
4.23.3, albeit in low yield (47%).  Our first attempt at the Suzuki-Miyaura coupling of 
alkyl pinacolboronates 4.23.3 with bromofuran derivative 4.19.3 in the presence of 
PdCl2(dppf)•CH2Cl2, Cs2CO3 and AsPh3 in refluxing toluene-water generated the Suzuki-
Miyaura product 4.23.4 only in trace amount; mostly unreacted starting materials were 
observed.  
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 To facilitate the Suzuki-Miyaura coupling reaction, we decided to prepare the 
boronic ester 4.24.1 via a cross-metathesis route.  Accordingly, olefin 4.22.1 was 
subjected to cross-metathesis reaction with vinylpinacolatoborane in the presence of the 
HG-II catalyst, in refluxing toluene, to produce the boronic ester 4.24.1 in excellent yield 
(Scheme 4.24).65  
 
 











DME-H2O (2:1), 85 ºC, 19 h
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Pd2(dba)3, K3PO4, PCy3
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DME-H2O (2:1), 85 ºC, 19 h
29
Pd2(dba)3, K3PO4, S-Phos






























 Next, we performed optimization studies for the Suzuki-Miyaura coupling 
reaction of boronic ester 4.24.1 and bromofuran 4.19.3.  Our initial attempts of Suzuki-
Miyaura coupling in the presence of Pd2(dba)3, PCy3 and K3PO4 in refluxing DMF-H2O 
resulted the formation of product in only 25% yield (entry 1, Scheme 4.24). Change in 
solvent did not improve the yield (entry 2); however, change of ligand from PCy3 to P(2-
furyl)3 improved the yield to 52% (entry 4).66  The best result (56%, entry 9) for this 
coupling reaction was achieved using the Pd-IPent-PEPSI catalyst,67 developed by Organ 
and coworkers, in the presence of 5M KOH in refluxing THF.   
 Subsequent hydrogenation under Lindlar reduction condition provided the 
saturated furan intermediate 4.25.1, with which we planned to perform a global 
deprotection followed by Achmatowicz cyclization (Scheme 4.25).  Unfortunately, we 
were unable to achieve the globally deprotected product 4.25.2, even after subjecting 
4.25.1 to various deprotection conditions.  With these unforeseen results in hand, we 
continued towards the synthesis of different intermediates en route to the synthesis of the 
C9–C25 fragment of spirastrellolide B. 
   

































HF•CH3CN, Dowex-50X, TFA/DCM, PPTS-MeOH, HCl(1N)/THF







4.3.3: Synthesis of the C17–C25 fragment 
 In light of the outcome of model studies, we revisited our synthetic route and 
decided to prepare the furan containing C17–C25 fragment 4.26.1 without protecting the 
adjacent diol.  Our initial retrosynthetic analysis of the C17–C25 fragment 4.26.1 
involved the installation of cis-dihydroxyl groups (at C21 and C22) via dihydroxylation. 
The C23–C24 bond formation of furan intermediate 4.26.2 would be achieved by  
anti-selective aldol reaction between 5-bromofuryl acrylaldehyde 4.26.3 and 
propanaldehyde (4.26.4).  However, no aldol product formation was observed after 
several trials, presumably due to the deactivation of aldehyde by the electron rich furan 
ring.  The alternative strategy towards the construction of the C17–C25 fragment 4.26.1 
included a CM protocol uniting the furan-containing fragment 4.26.6 and olefin 4.26.7 to 
achieve the C21–C22 bond formation.  For this purpose, the furan intermediate 4.26.6 
was synthesized via a Wittig olefination starting from 5-bromo-2-furaldehyde (4.20.3) in 
65% yield. 68 
   





























































 The synthesis of the olefinic CM-partner commenced with the PMB protection of 
(S)-Roche ester (4.27.1), followed by the conversion to Weinreb aminde 4.27.2 in the 
presence of (OMe)NH(Me)HCl and iPrMgCl (Scheme 4.27).69  Subsequent Grignard 
addition followed by the CBS reduction,70 generated olefinic cross-partner, substituted 
allylic alcohol 4.26.7.  Further CM reaction with furan substrate 4.26.6 in the presence of 
HG-II catalyst in refluxing CH2Cl2 produced furan substituted allylic alcohol 4.26.5 in 
72% yield.  Subsequent TBS protection of the hydroxyl group at C23 in the cross-
metathesis product and dihydroxylation35 delivered the coupling partner 4.26.1, the C17–
C25 fragment in 7 overall steps. 
 
   
Scheme 4.27. Synthesis of the C17–C25 furan fragment. 
 
4.3.4: Progress towards the C9–C23 fragment 
 Suzuki-Miyaura coupling of the boronic ester C9–C16 fragment 4.24.1 and furan 
























































product 4.28.1 in 50% yield (Scheme 4.28).  Subsequent hydrogenation using o-NBSH 
yielded the Achmatowicz precursor 4.28.2 in 84% yield.  Next, we performed the 
Achmatowicz cyclization by subjecting the hydrogenated product 4.28.2 to NBS, 
NaHCO3 and NaOAc in THF/H2O (4:1) mixture to produce α,β-unsaturated pyran 4.28.3 
in 82% yield.71   Our next goal was to protect the secondary hydroxyl group at C22 as 
acetate prior to spirocycliczation in order to prevent the possible formation of bridged 
product during spirocyclization.  However, when subjected to Ac2O and pyridine in the 
presence of DMAP, the only product isolated was the ring-opened product 4.28.5, no 
diacetate product 4.28.4 was observed. 
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4.4: Future direction 
Future directions towards the synthesis of the C9–C25 fragment involve the 
selective protection of C22 hydroxyl as TBS ether or Pivaloyl ester (Scheme 4.29). 
Alternatively, the double bond present in α,β-unsaturated pyran 4.28.3 will be reduced 
which might prevent the formation of ring-opening product.  Our next goal would be to 
subject the saturated pyran intermediate 4.29.2 to spirocyclization condition without 
protecting the hydroxyl group at C22.  Subsequent reduction of the carbonyl group would 
generate the C9–C25 fragment 4.29.3.   
In conclusion, we were able to construct the key intermediate 4.28.3 required for 
spirocyclization by utilizing a late-stage Achmatowicz cyclization.  The key 
intermediates required for the Suzuki-Miyaura coupling were generated over 7 steps (for 
the furan intermediate) and 9 steps (the boronic ester).  Studies will be next directed to 
facilitate the spirocyclization reaction with or without protecting C22 hydroxyl group.  In 
addition, ongoing efforts are aimed towards developing one-pot sequential 
RCM/hydroboration and one-pot sequential CM/Suzuki/H2 to further streamline the 
synthesis of the C9–C25 fragment.  The successful implementation of the one-pot 
RCM/hydroboration protocol would further reduce the step count of the boronic ester 
intermediate from 9 steps to 8 steps.  In addition, the development of one-pot 
CM/Suzuki/H2 protocol would facilitate the synthesis of the C9–C25 fragment of 
spirastrellolide B over 14 longest linear steps and 22 total steps.   
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General Experimental Section 
 All reactions were carried out in an oven- or flame-dried glassware under argon 
atmosphere using standard gas-tight syringes, cannulae, and septa.  Stirring was achieved 
with oven-dried magnetic stir bars. The solvents Et2O, THF and CH2Cl2 were purified by 
passage through a purification system (Solv-Tek) employing activated Al2O3  ((Pangborn, A. 
B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 
1518–1520).  Et3N was purified by passage over basic alumina and stored over KOH.  
Butyllithium was purchased from Aldrich and titrated prior to use.  All olefin metathesis 
catalysts were acquired from Materia and used without further purification.  Flash column 
chromatography was performed with Sorbent Technologies (30930M-25, Silica Gel 60A, 
40-63 mm) and thin layer chromatography was performed on silica gel 60F254 plates (EM-
5717, Merck).  Deuterated solvents were purchased from Cambridge Isotope laboratories. 
1H and 13C NMR spectra were recorded in CDCl3 (unless otherwise mentioned) on a Bruker 
DRX-500 spectrometer operating at 500 MHz, and 125 MHz, respectively and calibrated to 
the solvent peak. 31P NMR spectra was recorded on Bruker DRX-400 spectrometer 
operating at 162 MHz. High-resolution mass spectrometry (HRMS) was recorded on a LCT 
Premier Spectrometer (Micromass UK Limited) operating on ESI (MeOH).  Observed 
rotations at 589 nm, were measured using AUTOPOL IV Model automatic polarimeter.  IR 
was recorded on Shimadzu FTIR-8400S instrument. 
  
5.1: Phosphate tether-mediated ring-closing metathesis studies (Chapter 2) 
Experimental Section 
General procedure for Triene generation: To a solution of alcohol  (1.1 mmol) in THF 
(0.2 M), at -40 ºC under argon, was added nBuLi (2.5 M, 0.9 mmol), dropwise.  The mixture 
was allowed to stir for 5 minutes, at which point a solution of phosphate monochloride (1.5 
mmol) in THF (1 mL) was slowly added to the reaction vessel via cannulation. The mixture 
stirred at –40 ºC for 2 hours (monitored by TLC) and was quenched with 5 mL of aqueous 
NH4Cl (sat.).  The biphasic solution was separated, and the aqueous layer was extracted 
 155 
EtOAc (3 x 10 mL).  The combined organic layers were washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure.  Purification via flash chromatography 
(Hexanes:EtOAc eluent) provided triene-containing monocyclic phosphate triester product. 
All of the trienes reported here are synthesized following the same procedure. 
 
General procedure for RCM to provide bicyclo[4.3.1] phosphates, bicyclo[5.3.1] 
phosphates and bicyclo[6.3.1]phosphates: To a flask containing monocyclic phosphate 
triester (1 mmol) in CH2Cl2 (dry, degassed, 0.007 M), equipped with an argon inlet and 
reflux condenser, was added the G-II catalyst (portion-wise), and the reaction mixture was 
heated to reflux. Upon completion (monitored by TLC), the reaction was cooled to room 
temperature and concentrated under reduced pressure. Purification via flash chromatography 
(Hexanes:EtOAc eluent) provided the corresponding bicyclic phosphate. 
 
General procedure for RCM to provide bicyclo[5.3.1]phosphates (generated from 
homologated diene diol), bicyclo[6.3.1]phosphates (generated from homologated diene 
diol) and bicyclo[8.3.1]phosphates: To a flask containing monocyclic phosphate triester (1 
mmol) in CH2Cl2 (dry, degassed, 0.001 M), equipped with an argon inlet and reflux 
condenser, was added p-benzoquinone (10 mol %). Then, G-I or G-II catalyst [see reaction 
Schemes, vide supra] was added to the reaction [portion-wise over the allotted reaction 
time], and the reaction mixture was heated to reflux.  Upon completion (monitored by TLC), 
the reaction was cooled to room temperature and concentrated under reduced pressure. 
Purification via flash chromatography (Hexanes:EtOAc eluent) provided the corresponding 









Yield: 82% (172 mg isolated as colorless oil starting from 100 mg of 
monochlorophosphate); 
FTIR (thin film): 2952, 2949, 1615, 1547, 1252, 1234, 1009, 845, 741 cm-1; 
Optical Rotation: [α]D = +23.0 (c = 0.1, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.28 (d, J = 8.0 Hz, 2H), 6.87 (d, J = 8.1 Hz, 2H), 6.01 (ddd, 
J = 16.7, 10.8, 5.7 Hz, 1H), 5.96–5.78 (m, 2H), 5.45 (d, J = 17.1 Hz, 1H), 5.38 (d, J = 17.2 
Hz, 1H), 5.29 (d, J = 10.6 Hz, 2H), 5.10–5.02 (m, 3H), 4.97–4.90 (m, 1H), 4.60–4.55 (m, 
1H), 4.49 (d, J = 11.5 Hz, 1H), 4.36 (d, J = 11.5 Hz, 1H), 3.81 (s, 3H), 3.41 (dd, J = 9.0, 7.1 
Hz, 1H), 3.32 (dd, J = 8.9, 7.1 Hz, 1H), 2.50 (dq, J = 13.8, 6.9 Hz, 1H), 2.18–2.11 (m, 1H), 
2.06 (ddd, J = 18.5, 14.0, 6.0 Hz, 2H), 1.07 (d, J = 6.8 Hz, 3H), 0.99 (d, J = 6.8 Hz, 3H);  
13C NMR (126 MHz, CDCl3) δ 159.0, 140.0, 135.4 (d, JCP = 4.0 Hz), 135.3 (d, JCP = 7.6 
Hz), 130.7, 129.4, 117.7, 117.1, 115.6, 113.7, 85.0 (d, JCP = 7.4 Hz), 77.3 (d, JCP = 6.8 Hz), 
75.5 (d, JCP = 6.2 Hz), 72.8 (d, JCP = 6.0 Hz), 72.5, 55.3, 41.2 (d, JCP = 3.5 Hz), 36.1 (d, JCP 
= 3.9 Hz), 35.2 (d, JCP = 7.3 Hz), 17.5, 11.9;  
31P NMR (162 MHz, CDCl3) δ –7.01;  
















Yield: 75% (55 mg isolated starting from 32 mg of monochlorophosphate); 
FTIR (thin film): 2978, 2962, 1610, 1521, 1278, 1249, 1000, 836, 746 cm-1; 
Optical Rotation: [α]D = –26.2 (c = 1, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.28 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 6.00 
(dddd, J = 17.1, 10.5, 6.2, 0.8 Hz, 1H), 5.90 (dddd, J = 17.1, 10.7, 5.1, 1.7 Hz, 1H), 5.85–
5.79 (m, 1H), 5.44 (ddd, J = 17.1, 1.5, 1.2 Hz, 1H), 5.35 (ddd, J = 17.2, 1.3, 1.0 Hz, 1H), 
5.27 (dddd, J = 10.7, 4.8, 1.3, 1.0 Hz, 2H), 5.06–5.00 (m, 3H), 4.96 (ddt, J = 9.6, 7.9, 5.0 
Hz, 1H), 4.55 (dddd, J = 9.7, 6.5, 4.3 Hz, 1H), 4.51 (d, J = 11.5 Hz, 1H), 4.38 (d, J = 11.5 
Hz, 1H), 3.80 (s, 3H), 3.49 (dd, J = 9.2, 6.2 Hz, 1H), 3.35 (dd, J = 9.2, 6.6 Hz, 1H), 2.53–
2.43 (m, 1H), 2.14 (dddd, J = 14.5, 7.9, 4.8, 1.5 Hz, 1H), 2.10–2.05 (m, 1H), 2.02 (dddd, J = 
14.6, 5.6, 3.9, 1.7 Hz, 1H), 1.04 (d, J = 6.4 Hz, 3H), 1.00 (d, J = 5.8 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 159.1, 140.0, 135.4 (d, JCP = 3.9 Hz), 135.3 (d, JCP = 7.6 
Hz), 130.7, 129.4, 117.7, 117.1, 115.6, 113.7, 85.0 (d, JCP = 7.4 Hz), 77.4 (d, JCP = 6.7 Hz), 
75.5 (d, JCP = 6.2 Hz), 72.8, 72.6, 55.3, 41.2 (d, JCP = 3.5 Hz), 36.2 (d, JCP = 3.9 Hz), 35.2 
(d, JCP = 7.3 Hz), 17.5, 11.8; 
31P NMR (162 MHz, CDCl3) δ –6.64; 
















Yield: 65% (60 mg isolated as colorless oil starting from 80 mg of triene); 
FTIR (thin film): 2982, 2934, 1605, 1507, 1268, 1241, 1003, 831, 741 cm-1; 
Optical Rotation: [α]D = –7.3 (c = 0.16, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 8.5 Hz, 2H), 6.87 (d, J = 8.5 Hz, 2H), 5.87 (dddd, J 
= 17.2, 10.6, 5.4, 2.0 Hz, 1H), 5.49 (ddd, J = 11.6, 8.2, 2.8 Hz, 1H), 5.43 (ddd, J = 17.2, 1.2, 
1.2 Hz, 1H), 5.39 (d, J = 11.9 Hz, 1H), 5.27 (ddd, J = 10.6, 1.2, 1.1 Hz, 1H), 4.98 (dd, J = 
11.8, 5.4 Hz, 1H), 4.48 (s, 2H), 4.06 (ddd, J = 29.1, 11.5, 3.3 Hz, 1H), 3.80 (s, 3H), 3.71 (t, J 
= 8.9 Hz, 1H), 3.53–3.45 (m, 1H), 3.48 (dd, J = 9.1, 5.9 Hz, 2H), 2.24–2.11 (m, 2H), 1.78 
(ddd, J = 14.5, 3.9, 1.8 Hz, 1H), 1.19 (d, J = 7.2 Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H);  
13C NMR (126 MHz, CDCl3) δ 159.1, 136.0, 135.4 (d, JCP = 10.5 Hz), 130.7, 129.2, 128.1, 
117.1 (d, JCP = 1.3 Hz), 113.7, 83.6 (d, JCP = 7.4 Hz), 77.8 (d, JCP = 7.2 Hz), 76.1 (d, JCP = 
6.3 Hz), 72.9, 72.2, 55.2, 36.5 (d, JCP = 6.2 Hz), 35.1, 32.6 (d, JCP = 1.3 Hz), 17.4, 9.4;  
31P NMR (162 MHz, CDCl3) δ –10.71; 
 HRMS: cald. for C21H29O6PNa (M+Na)+ 431.1599; found 431.1575 (TOF MS ES+). 
(4S,6S)-2-((2,4-dimethylpenta-1,4-dien-3-yl)oxy)-4,6-divinyl-1,3,2- 
dioxaphosphinane 2-oxide (2.3.2): 
 
 
Yield: 35% (53 mg isolated as colorless oil starting from 111 mg of monochlorophosphate); 















Optical Rotation: [α]D  = +48.40 (c = 0.75, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 6.02 (ddd, J = 16.7, 10.7, 5.5 Hz 1H), 5.90 (dddd, J = 17.3, 
10.6, 5.1, 1.5 Hz, 1H), 5.45 (d, J = 22.0 Hz, 1H), 5.39 (d, J = 21.6 Hz, 1H), 5.33–5.27 (m, 
2H), 5.20–5.11 (m, 3H), 5.11–5.03 (m, 1H), 5.01 (s, 2H), 4.99–4.92 (m, 1H), 2.17 (dddd, J = 
12.8, 7.8, 4.8, 1.4 Hz, 1H), 2.07 (dddd, J = 14.7, 5.4, 3.7, 1.8 Hz, 1H), 1.66 (s, 6H); 
13C NMR (126 MHz, CDCl3) δ 141.3 (d, JCP = 4.3 Hz), 141.1 (d, JCP = 5.3 Hz), 135.2 (d, 
JCP = 3.2 Hz), 135.1 (d, JCP = 7.5 Hz), 117.7, 117.5, 114.4, 113.5, 84.7 (d, JCP = 5.2 Hz), 
77.6 (d, JCP = 6.8 Hz), 76.0 (d, JCP = 6.1 Hz), 35.1 (d, JCP = 7.7 Hz), 18.0, 17.4; 
31P NMR (162 MHz, CDCl3) δ –8.58; 
HRMS cald for C14H21O4PNa (M+Na)+ 307.1075; found 307.1067 (TOF MS ES+). 
(1S,3R,6S,8S)-4-methyl-3-(prop-1-en-2-yl)-8-vinyl-2,9,10-trioxa-1- 




Yield: 36% brsm (4.8 mg isolated as colorless oil starting from 20 mg of triene); 
FTIR (thin film): 2922, 1726, 1298, 1026, 966, 768 cm-1;  
Optical Rotation: [α]D  = +103.14(c = 0.17, CHCl3);  
1H NMR (500 MHz, CDCl3) δ 5.89 (dddd, J = 17.2, 10.8, 5.1, 2.1 Hz 1H), 5.59 (d, J = 5.3 
Hz, 1H), 5.45 (d, J = 17.2 Hz, 1H), 5.43–5.39 (m, 1H), 5.28 (d, J = 10.7 Hz, 1H), 5.12 (d, J 
= 21.5 Hz, 1H), 5.09–5.03 (m, 3H), 2.19 (ddd, J = 14.5, 12.1, 6.2 Hz, 1H), 1.93–1.81 (m, 
1H), 1.79 (s, 3H), 1.75 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 141.1 (d, JCP = 10.1 Hz), 138.1, 135.0 (d, JCP = 10.2 Hz), 
124.9, 117.1 (d, JCP = 1.0 Hz), 116.6, 80.6 (d, JCP = 5.7 Hz), 76.7 (d, JCP = 6.2 Hz), 76.5 (d, 
JCP = 6.2 Hz), 35.3 (d, JCP = 6.2 Hz), 22.2, 17.5; 














Yield: 69% (105 mg isolated as colorless oil starting from 84 mg of monochlorophosphate); 
FTIR (thin film): 2920, 2359,1827, 1649, 1454, 1283, 1121, 1097, 999, 929, 739 cm-1;  
Optical Rotation: [α]D  = +40.72 (c = 1.04, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 7.36–7.27 (m, 5H), 6.06 (ddd, J = 17.1, 10.6, 6.2 Hz, 1H), 
5.89 (dddd, J = 17.2, 10.6, 5.2, 1.7 Hz, 1H), 5.43 (ddd, J = 17.1, 1.3, 1.1 Hz, 1H), 5.35 (ddd, 
J = 17.2, 1.4, 1.0 Hz, 1H), 5.28 (dd, J = 11.7, 1.1 Hz, 1H), 5.23 (dd, J = 10.6, 1.1 Hz, 1H), 
5.08–4.95 (m, 2H), 4.86–4.80 (m, 2H), 4.80–4.71 (m, 1H), 4.60 (d, J = 12.0 Hz, 1H), 4.55 
(d, J = 12.0 Hz, 1H), 3.71–3.63 (m, 2H), 2.53–2.40 (m, 2H), 2.14 (dddd, J = 14.6, 8.1, 4.9, 
1.5 Hz, 1H), 2.04 (dddd, J = 14.7, 5.4, 3.8, 1.8 Hz, 1H), 1.77 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 141.2, 138.1, 135.3 (d, JCP = 3.0 Hz), 135.2 (d, JCP = 7.8 
Hz), 128.3, 127.7, 127.6 (d, JCP = 5.8 Hz), 117.9 117.2, 113.9, 78.1 (d, JCP = 6.9 Hz), 76.1 
(d, JCP = 6.3 Hz), 75.8 (d, JCP = 6.2 Hz), 73.3, 71.8 (d, JCP = 3.2 Hz), 40.9 (d, JCP = 5.8 Hz), 
35.3 (d, JCP = 7.6 Hz), 22.2; 
31P NMR (162 MHz, CDCl3) δ –8.20; 
HRMS cald for C20H27O5PNa (M+Na)+ 401.1494; found 401.1512 (TOF MS ES+). 
(1S,3R,7S,9S,Z)-3-((benzyloxy)methyl)-5-methyl-9-vinyl-2,10,11-trioxa-1-




















Yield: 32% (11.8 mg isolated as colorless oil starting from 40 mg of triene); 
FTIR (thin film): 2918, 2849, 1718, 1582, 1364, 1333, 1283, 1126, 1090, 1001, 901 cm-1;  
Optical Rotation: [α]D  = +24.51(c = 0.16, CHCl3);  
1H NMR (500 MHz, CDCl3) δ 7.41–7.27 (m, 5H), 5.84 (dddd, J = 17.2, 10.6, 5.4, 2.1 Hz, 
1H), 5.42 (ddd, J = 17.1, 5.8, 4.6 Hz, 1H), 5.34–5.16 (m, 2H), 5.24 (m, ddd, J = 10.7, 1.2, 
1.1 Hz, 1H), 5.02 (dd, J = 11.7, 5.4 Hz, 1H), 4.68 (dd, J = 11.9, 4.3 Hz, 1H), 4.60 (dd, J = 
11.9, 5.1 Hz, 1H), 4.08 (dd, J = 10.0, 6.2 Hz, 1H), 3.75 (dd, J = 10.0, 6.5 Hz, 1H), 3.38–3.26 
(m, 1H), 2.21–2.14 (m, 1H), 2.09 (dd, J = 13.9, 3.1 Hz, 1H), 1.92–1.89 (m, 1H), 1.88 (dd, J 
= 2.4, 1.4 Hz, 3H), 1.76 (ddd, J = 14.5, 3.9, 1.9 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 137.9, 135.5, 128.8, 128.4, 127.9, 127.7, 124.6, 117.2, 77.6 
(d, JCP  = 7.4 Hz), 75.3  (d, JCP  = 5.8 Hz), 73.7, 72.3, 36.7 (d, JCP  = 6.6 Hz), 34.7, 34.1, 29.7; 
31P NMR (162 MHz, CDCl3) δ (ppm) –10.34; 
HRMS cald for C18H23O5PNa (M+Na)+ 373.1181; found 373.1176 (TOF MS ES+). 
(4R,6R)-2-(((R)-1-(benzyloxy)-4-methylpent-4-en-2-yl)oxy)-4,6-divinyl-1,3,2- 
dioxaphosphinane 2-oxide (2.5.3):  
 
 
Yield: 45% (85 mg isolated as colorless oil starting from 105 mg of monochlorophosphate); 
FTIR (thin film): 2924, 1827, 1645, 1454, 1285, 1120, 1003, 926 cm-1;  
Optical Rotation: [α]D  = –53.0 (c = 2.61, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 7.35–7.28 (m, 5H), 6.08 (dddd, J = 17.2, 10.6, 6.3, 0.8 Hz, 
1H), 5.82 (dddd, J = 17.4, 10.6, 5.2, 1.7 Hz, 1H), 5.37(ddd, J = 7.4, 1.4, 1.2 Hz, 1H), 5.32 
(ddd, J = 7.2, 1.4, 1.1 Hz, 1H),), 5.27 (ddd, J = 10.5, 1.2, 1.0 Hz, 1H), 5.22 (ddd, J = 10.6, 
1.3, 1.1 Hz, 1H), 5.06–4.97 (m, 2H), 4.86–4.78 (m, 2H), 4.77–4.71 (m, 1H), 4.58 (d, J = 
11.9 Hz, 1H), 4.52 (d, J = 11.8 Hz, 1H), 3.66 (ddd, J = 10.7, 3.5, 1.7 Hz, 1H), 3.58 (dd, J = 









(dddd, J = 14.4, 8.0, 4.8, 1.6 Hz, 1H), 2.01 (dddd, J = 14.7, 5.5, 3.9, 1.8 Hz, 1H), 1.79 (s, 
3H); 
13C NMR (126 MHz, CDCl3) δ 140.9, 137.9, 135.3, 135.3 (d, JCP = 3.0 Hz), 128.3, 127.8, 
127.7 (d, JCP = 5.4 Hz), 117.8, 117.0, 114.0, 78.1 (d, JCP = 6.8 Hz), 76.1 (d, JCP = 6.1 Hz), 
75.71 (d, JCP = 6.0 Hz), 73.3, 71.6 (d, JCP = 4.3 Hz), 40.6 (d, JCP = 4.8 Hz), 35.3 (d, JCP = 
7.6 Hz), 22.6; 
31P NMR (162 MHz, CDCl3) δ –8.09; 
HRMS cald for C20H27O5PNa (M+Na)+ 401.1494; found 401.1479 (TOF MS ES+). 
(4R,6R)-2-(((1R,2S)-2-methyl-1-(4-nitrophenyl)but-3-en-1-yl)oxy)-4,6-divinyl-1,3,2-
dioxaphosphinane 2-oxide (2.7.2):  
 
Yield: 57% (95 mg isolated as colorless oil starting from 91 mg of monochlorophosphate); 
FTIR (thin film): 3080, 2969, 2913, 1617, 1525, 1339, 1281, 1102, 1019, 921, 879,  
751 cm-1; 
Optical Rotation: [α]D = –44.8 (c = 0.5, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 8.20 (d, J = 8.2 Hz, 2H), 7.47 (d, J = 8.7 Hz, 2H), 6.01 (ddd, 
J = 16.4, 10.7, 5.4 Hz, 1H), 5.72 (ddd, J = 15.9, 10.6, 5.3 Hz, 1H), 5.61 (ddd, J = 17.8, 9.0, 
5.5 Hz, 1H), 5.43–5.31 (m, 3H), 5.18 (ddd, J = 6.0, 2.7, 0.9 Hz, 2H), 5.14–5.06 (m, 1H), 
5.02 (d, J = 10.3 Hz, 1H), 4.97 (dd, J = 17.2, 1.0 Hz, 1H), 4.69–4.62 (m, 1H), 2.81–2.73 (m, 
1H), 2.17–2.10 (m, 1H), 2.01 (dddd, J = 14.8, 5.3, 3.6, 1.8 Hz, 1H), 1.14 (d, J = 6.8 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 147.6, 145.9 (d, JCP = 2.3 Hz), 137.3, 134.9 (d, JCP = 3.2 
Hz),  
134.4 (d, JCP  = 7.3 Hz), 127.9, 123.3 (d, JCP = 5.1 Hz), 118.0 (d, JCP = 14.5 Hz), 117.6, 
117.2, 82.8 (d, JCP = 6.0 Hz), 77.9 (d, JCP = 6.8 Hz), 75.9 (d, J = 6.1 Hz), 44.2 (d, JCP = 6.7 
Hz), 34.9 (d, JCP = 7.7 Hz), 15.6; 









HRMS: cald. for C18H22NO6PNa (M+Na)+ 402.1082; found 402.1069 (TOF MS ES+). 
(1R,3R,4S,7R,9R,Z)-4-methyl-3-(4-nitrophenyl)-9-vinyl-2,10,11-trioxa-1 
phosphabicyclo[5.3.1]undec-5-ene 1-oxide (cis,syn-2.7.4):  
 
 
Yield: 65% (18 mg isolated as colorless oil starting from 30 mg of triene); 
FTIR (thin film): 2982, 2923, 1613, 1545, 1324, 1295, 1012, 975, 814, 759 cm-1; 
Optical Rotation: [α]D = +70.4 (c = 1.05, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 8.21 (d, J = 8.8 Hz, 2H), 7.43 (d, J = 8.7 Hz, 2H), 5.91 
(dddd, J = 17.2, 10.7, 5.1, 2.3 Hz, 1H), 5.67 (d, J = 11.7 Hz, 1H), 5.51–5.44 (m, 2H), 5.38 
(dd, J = 25.2, 4.8 Hz, 1H), 5.32 (ddd, J = 10.7, 1.1, 1.0 Hz, 1H), 5.30–5.21 (m, 2H), 4.09–
4.01 (m, 1H), 2.31 (ddd, J = 14.7, 12.0, 6.1 Hz, 1H), 1.99 (ddd, J = 14.7, 3.7, 2.1 Hz, 1H), 
0.80 (d, J = 6.9 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 147.9, 143.4 (d, JCP = 13.6 Hz), 134.7 (d, JCP = 10.0 Hz), 
131.6, 130.7, 128.2, 123.2, 117.5 (d, JCP = 1.0 Hz), 78.4 (d, JCP = 3.7 Hz), 78.3 (d, JCP = 7.3 
Hz), 77.7 (d, JCP = 6.3 Hz), 36.2 (d, JCP = 6.6 Hz), 34.2, 16.8; 
31P NMR (162 MHz, CDCl3) δ –9.46; 
HRMS: cald. for 2(C16H18NO6P)Na (2M+Na)+ 725.1641; found 725.1623 (TOF MS ES+). 
(4S,6S)-2-(((1R,2S)-2-methyl-1-(4-nitrophenyl)but-3-en-1-yl)oxy)-4,6-divinyl-1,3,2-
dioxaphosphinane 2-oxide (2.7.3): 
 
Yield: 57% (90 mg isolated as colorless oil starting from 91 mg of monochlorophosphate); 
FTIR (thin film): 3059, 2952, 2931, 1617, 1501, 1331, 1269, 1139, 1024, 927, 739 cm-1; 
















1H NMR (500 MHz, CDCl3) δ 8.21 (d, J = 8.7 Hz, 2H), 7.48 (d, J = 8.7 Hz, 2H), 5.96–5.85 
(m, 2H), 5.66 (ddd, J = 17.5, 8.8, 5.6 Hz, 1H), 5.48 (d, J = 17.1 Hz, 1H), 5.42 (dd, J = 8.5, 
6.0 Hz, 1H), 5.33 (d, J = 10.7 Hz, 1H), 5.29 (d, J = 17.2 Hz, 1H), 5.25 (d, J = 10.6 Hz, 1H), 
5.07–4.98 (m, 4H), 2.79–2.71 (m, 1H), 2.18 (dddd, J = 14.1, 7.6, 4.7, 1.6 Hz, 1H), 2.08 
(dddd, J = 14.8, 5.6, 3.8, 1.8 Hz, 1H), 1.07 (d, J = 6.8 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 147.5, 145.9 (d, JCP = 3.1 Hz), 137.7, 134.8 (d, JCP = 3.6 
Hz), 134.7 (d, JCP = 7.1 Hz), 127.8, 123.3, 118.0, 117.7, 116.9, 82.8 (d, JCP = 6.0 Hz), 77.6 
(d, JCP = 6.8 Hz), 76.4 (d, JCP = 6.3 Hz), 44.0 (d, JCP = 6.1 Hz), 35.0 (d, JCP = 7.9 Hz), 14.8; 
31P NMR (162 MHz, CDCl3) δ –7.82; 
HRMS: cald. for C18H22NO6PNa (M+Na)+ 402.1082; found 402.1072 (TOF MS ES+).  
(4R,6R)-2-(((1R,2R)-2-methyl-1-(4-nitrophenyl)but-3-en-1-yl)oxy)-4,6-divinyl-1,3,2-
dioxaphosphinane 2-oxide (2.8.2):  
 
Yield: 55% (100 mg isolated as colorless oil starting from 100 mg of 
monochlorophosphate); 
FTIR (thin film): 2972, 2933, 1610, 1521, 1348, 1282, 1112, 1004, 927, 885, 750 cm-1; 
Optical Rotation: [α]D = –32.8 (c = 0.6, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 8.21 (d, J = 8.7 Hz, 2H), 7.47 (d, J = 8.7 Hz, 2H), 6.01 
(dddd, J = 17.0, 10.7, 5.3, 0.7 Hz, 1H), 5.81–5.70 (m, 2H), 5.43–5.38 (m, 2H), 5.36 (d, J = 
10.9 Hz, 1H), 5.21 (d, J = 17.0 Hz, 1H), 5.19 (d, J = 10.9 Hz, 1H), 5.11 (d, J = 10.3 Hz, 1H), 
5.13–5.06 (m, 1H), 5.02 (d, J = 17.1 Hz, 1H), 4.76–4.69 (m, 1H), 2.77–2.68 (m, 1H), 2.15 
(dddd, J = 9.5, 8.0, 4.5, 2.1 Hz, 1H), 2.03 (dddd, J = 14.8, 5.4, 3.6, 1.8 Hz, 1H), 1.01 (d, J = 
6.9 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 147.6, 146.1 (d, JCP = 2.5 Hz), 137.7, 135.0 (d, JCP = 3.2 
Hz), 134.5 (d, JCP = 7.2 Hz), 127.7, 123.5, 117.9, 117.7, 117.1, 82.8 (d, JCP = 6.0 Hz), 77.9 









31P NMR (162 MHz, CDCl3) δ –7.61; 
HRMS: cald. for C18H22NO6PNa (M+Na)+ 402.1082; found 402.1074 (TOF MS ES+). 
(4S,6S)-2-(((1R,2R)-2-methyl-1-(4-nitrophenyl)but-3-en-1-yl)oxy)-4,6-divinyl-1,3,2-
dioxaphosphinane 2-oxide (2.8.3):  
 
Yield: 61% (110 mg isolated as colorless oil starting from 100 mg of 
monochlorophosphate); 
FTIR (thin film): 2954, 2931, 1608, 1529, 1319, 1289, 1136, 1015, 920, 875, 751 cm-1; 
Optical Rotation: [α]D = +41.1 (c = 1.24, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 8.21 (d, J = 8.7 Hz, 2H), 7.48 (d, J = 8.7 Hz, 2H), 5.96–5.88 
(m, 2H), 5.73 (ddd, J = 17.9, 10.3, 7.8Hz, 1H), 5.48 (d, J = 17.0 Hz, 1H), 5.39 (dd, J = 8.6, 
6.2 Hz, 1H), 5.33 (d, J = 4.2 Hz, 1H), 5.30 (d, J = 11.1 Hz, 1H), 5.27 (d, J = 10.6 Hz, 1H), 
5.09 (d, J = 10.3 Hz, 1H), 5.07–4.99 (m, 3H), 2.75–2.67 (m, 1H), 2.18 (dddd, J = 14.1, 7.6, 
4.7, 1.5 Hz, 1H), 2.08 (dddd, J = 14.8, 5.6, 3.8, 1.8 Hz, 1H), 0.99 (d, J = 6.9 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 147.5, 146.1 (d, JCP = 2.9 Hz), 137.9, 134.7 (d, JCP = 3.4 
Hz), 134.7 (d, JCP = 7.2 Hz), 127.6, 123.3, 118.0, 117.7, 117.0, 82.9 (d, JCP = 5.9 Hz), 77.7 
(d, JCP = 6.8 Hz), 76.3 (d, JCP = 6.3 Hz), 44.4 (d, JCP = 6.2 Hz), 35.0 (d, JCP = 7.8 Hz), 15.8; 
31P NMR (162 MHz, CDCl3) δ –7.82; 
HRMS: cald. for C18H22NO6PNa (M+Na)+ 402.1082; found 402.1064 (TOF MS ES+). 
(1S,3R,4R,7S,9S,Z)-4-methyl-3-(4-nitrophenyl)-9-vinyl-2,10,11-trioxa-1-



















Yield: 62% (17 mg isolated starting from 30 mg of triene); 
FTIR (thin film): 2984, 2914, 1623, 1523, 1349, 1290, 1004, 970, 852, 750 cm-1; 
Optical Rotation: [α]D = +151.2 (c = 0.4, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 8.27 (d, J = 8.8 Hz, 2H), 7.74(d, J = 8.8 Hz, 2H), 5.86 (dddd, 
J = 17.1, 10.6, 5.5, 2.0 Hz, 1H), 5.66–5.58 (m, 2H), 5.40 (d, J = 17.2 Hz, 1H), 5.38 (dd, J = 
24.8, 5.6 Hz, 1H), 5.27 (d, J = 10.6 Hz, 1H), 5.04 (dd, J = 11.8, 5.5 Hz, 1H), 4.59 (dd, J = 
29.6, 11.7 Hz, 1H), 4.04–3.90 (m, 1H), 2.26 (ddd, J = 14.6, 12.0, 5.8 Hz, 1H), 1.87 (ddd, J = 
14.6, 3.8, 1.8 Hz, 1H), 0.85 (d, J = 6.6 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 148.3, 142.9, 134.9 (d, JCP = 10.3 Hz), 134.6, 130.1, 130.0, 
123.8, 117.5 (d, JCP = 1.3 Hz), 83.2 (d, JCP = 6.6 Hz), 78.2 (d, JCP = 7.3 Hz), 77.1 (d, JCP = 
6.5 Hz), 36.2 (d, JCP = 6.4 Hz), 34.5, 18.3; 
31P NMR (162 MHz, CDCl3) δ –11.71; 
HRMS: cald. for 2(C16H18NO6P)Na (2M+Na)+ 725.1641; found 725.1647 (TOF MS ES+). 
(4S,6S)-2-((2-methylbut-3-en-1-yl)oxy)-4,6-divinyl-1,3,2-dioxaphosphinane 2-oxide 
(2.9.2): (pair of diastereomers detected by 13C NMR) 
 
 
Yield: 67% (84 mg isolated as colorless oil starting from 102 mg of monochlorophosphate); 
FTIR (thin film): 2964, 2926, 1647, 1458, 1283, 1140, 1119, 1013, 926 cm-1;  
Optical Rotation: [α]D  =  +62.02(c = 1.24, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 6.03 (ddd, J = 16.6, 10.6, 6.2 Hz, 1H), 5.90 (ddddd, J = 17.7, 
10.6, 5.2, 1.7, 0.7 Hz, 1H), 5.75 (dddd, J = 17.4, 10.2, 7.0, 2.7 Hz, 1H), 5.46 (ddd, J = 17.2, 
1.1, 1.1 Hz, 1H), 5.37 (ddd, J = 17.2, 1.2, 0.9 Hz, 1H), 5.33 – 5.27 (m, 2H), 5.14–5.01 (m, 









(m, 1H), 2.17 (dddd, J = 14.6, 8.3, 4.9, 1.5 Hz, 1H), 2.10–1.98 (m, 1H), 1.06 (d, J = 6.8 Hz, 
3H); 
13C NMR (126 MHz, CDCl3) δ 139.4 (d, JCP = 5.7 Hz), 135.0 (d, JCP = 3.0 Hz), 135.0, 
118.1 (d, JCP = 1.6 Hz), 117.4, 115.4 (d, JCP = 7.1 Hz), 77.8 (d, JCP = 6.8 Hz), 76.0 (d, JCP = 
1.1 Hz), 75.9 (d, JCP = 1.0 Hz), 71.6 (d, JCP = 6.2 Hz), 38.2 (d, JCP = 7.3 Hz), 38.1 (d, JCP = 
7.1 Hz), 35.2 (d, JCP = 1.1 Hz), 35.1 (d, JCP = 1.1 Hz), 16.0 (d, JCP = 6.0 Hz); 
 31P NMR (162 MHz, CDCl3) δ –7.61; 
HRMS cald for C12H19O4PNa (M+Na)+ 281.0919; found 281.0913 (TOF MS ES+). 
(4S,6S)-2-(((S)-2-methylbut-3-en-1-yl)oxy)-4,6-divinyl-1,3,2- 
dioxaphosphinane 2-oxide (2.9.3): 
 
 
Yield: 27% (8.7 mg isolated starting from 32.7 mg of triene 2.9.2); 
FTIR (thin film): 2968, 2920, 1625, 1456, 1280, 1145, 1016, 925 cm-1;  
Optical Rotation: [α]D  =  +83.91(c = 0.44, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 6.04 (ddd, J = 17.0, 10.6, 6.0 Hz, 1H), 5.91 (dddd, J = 17.3, 
10.5, 5.1, 1.2 Hz, 1H), 5.76 (ddd, J = 14.1, 10.4, 7.0 Hz, 1H), 5.46 (d, J = 17.1 Hz, 1H), 5.38 
(d, J = 17.2 Hz, 1H), 5.31 (ddd, J = 10.6, 1.9, 1.0 Hz, 2H), 5.16–5.06 (m, 2H), 5.06–5.01 (m, 
1H), 5.01–4.95 (m, 1H), 4.03–3.95 (m, 2H), 2.57 (dt, J = 13.4, 6.7 Hz, 1H), 2.17 (dddd, J = 
14.7, 8.1, 4.7, 1.3 Hz, 1H), 2.08–2.01 (m, 1H), 1.07 (d, J = 6.8 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 139.5, 135.1 (d, JCP = 2.9 Hz), 135.0, 118.1, 117.4, 115.4, 
77.8 (d, JCP = 6.8 Hz), 76.0 (d, JCP = 6.1 Hz), 71.6 (d, JCP = 6.1 Hz), 38.2 (d, JCP = 7.0 Hz), 
35.2 (d, JCP = 7.7 Hz), 16.0; 
31P NMR (162 MHz, CDCl3) δ –7.61; 














undec-5-ene 1-oxide (2.9.4):1 
 
 
Yield: 39% (11.4 mg isolated starting from 32.7 mg of triene); 
FTIR (thin film): 2922, 1827, 1649, 1448, 1375, 1281, 1140, 1119, 1003, 928 cm-1;  
Optical Rotation: [α]D  = +122.98 (c = 0.57, CHCl3);  
                                                
[1] CCDC 905667 contains the crystallographic data for this compound.  This X-ray crystallography 
data has been published in:  Chegondi, R.; Maitra, S.; Markley, J. L.; Hanson, P. R. Phosphate-
Tether-Mediated Ring-Closing Metathesis for the Preparation of Complex 1,3-anti-Diol-Containing 























1H NMR (400 MHz, CDCl3) δ 5.85 (dddd, J = 18.0, 10.6, 5.4, 2.1 Hz, 1H), 5.48–5.45 (m, 
2H), 5.45–5.39 (m, 1H), 5.33–5.22 (m, 2H), 5.07 (dd, J = 11.7, 5.3 Hz, 1H), 4.33 (ddd, J = 
10.8, 6.2, 2.1 Hz, 1H), 3.64–3.52 (m, 1H), 3.34 (ddd, J = 30.9, 12.5, 10.8 Hz, 1H), 2.26–2.15 
(m, 1H), 1.82 (ddd, J = 14.5, 3.7, 2.0 Hz, 1H), 1.01 (d, J = 6.6 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 135.0 (d, JCP = 10.1 Hz), 134.1, 129.3, 117.3 (d, JCP = 1.1 
Hz), 77.9 (d, JCP = 7.1 Hz), 77.1 (d, JCP = 6.2 Hz), 68.2 (d, JCP = 5.0 Hz), 36.2 (d, JCP = 6.5 
Hz), 31.2, 16.6; 
31P NMR (162 MHz, CDCl3) δ –8.05; 
HRMS cald for C10H15O4PNa (M+Na)+ 253.0606; found 253.0617 (TOF MS ES+). 
(4R,6R)-4,6-diallyl-2-(((R)-1-(benzyloxy)but-3-en-2-yl)oxy)-1,3,2- 
dioxaphosphinane 2-oxide (2.10.3): 
 
Yield: 73% (139 mg isolated as colorless oil starting from 119 mg of monochlorophosphate); 
FTIR (thin film): 2924, 1643, 1431, 1366, 1286, 1095, 1011, 976, 922 cm-1;  
Optical Rotation: [α]D  = +41.66 (c = 0.71, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 7.37–7.28 (m, 5H), 5.94 (ddd, J = 17.2, 10.5, 6.7 Hz, 1H), 
5.84 – 5.77 (m, 1H), 5.77–5.70 (m, 1H), 5.44 (ddd, J = 17.2, 1.1,1.1 Hz, 1H), 5.31 (ddd, J = 
10.5, 1.1, 1.1 Hz, 1H), 5.18–5.12 (m, 3H), 5.12–5.09 (m, 1H), 5.07–5.00 (m, 1H), 4.67–4.55 
(m, 3H), 4.55–4.48 (m, 1H), 3.67 (dd, J = 10.5, 5.6 Hz, 1H), 3.63 (ddd, J = 10.5, 4.7, 1.1 Hz, 
1H), 2.66 (dt, J = 13.2, 6.5 Hz, 1H), 2.54 (ddd, J = 7.6, 6.6, 3.3 Hz, 1H), 2.44–2.33 (m, 2H), 
2.00 (dddd, J = 13.5, 8.4, 5.0, 1.2 Hz, 1H), 1.89 (dddd, J = 14.6, 5.4, 3.8, 1.8 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 137.9, 133.9 (d, JCP = 3.9 Hz), 132.6 (d, JCP = 5.7 Hz), 
132.3, 128.4 (d, JCP = 9.9 Hz), 127.8 (d, JCP = 2.7 Hz), 127.6, 118.7 (d, JCP = 2.6 Hz), 78.0 
(d, JCP = 5.6 Hz), 77.3, 75.3 (d, JCP = 6.7 Hz), 73.3 (d, JCP = 6.1 Hz), 72.2 (d, JCP = 6.0 Hz), 
40.0 (d, JCP = 7.7 Hz), 40.0 (d, JCP = 3.5 Hz), 33.0 (d, JCP = 6.8 Hz), 31.0; 








HRMS cald for C20H27O5PNa (M+Na)+ 401.1494; found 401.1493 (TOF MS ES+). 
(4S,6S)-4,6-diallyl-2-(((R)-1-(benzyloxy)but-3-en-2-yl)oxy)-1,3,2- 
dioxaphosphinane 2-oxide (2.10.4): 
 
Yield: 64% (206 mg isolated starting from 200 mg of monochlorophosphate); 
FTIR (thin film): 2922, 1641, 1364, 1286, 1095, 1119, 1007, 920 cm-1;  
Optical Rotation: [α]D  = –44.31 (c = 0.24, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 7.36–7.28 (m, 5H), 5.90 (ddd, J = 16.9, 10.6, 6.0 Hz, 1H), 
5.81–5.72 (m, 1H), 5.72–5.62 (m, 1H), 5.45 (ddd, J = 17.2, 1.2 Hz, 1H), 5.31 (ddd, J = 10.6, 
1.2 Hz, 1H), 5.15–5.10 (m, 3H), 5.10–5.07 (m, 1H), 5.02 (td, J = 11.6, 5.5 Hz, 1H), 4.63 – 
4.54 (m, 4H), 3.62 (dd, J = 5.5, 0.8 Hz, 2H), 2.70 (dt, J = 13.3, 6.7 Hz, 1H), 2.49–2.43 (m, 
1H), 2.39 (dd, J = 14.5, 7.3 Hz, 1H), 2.34–2.26 (m, 1H), 2.02–1.93 (m, 1H), 1.87–1.79 (m, 
1H); 
13C NMR (126 MHz, CDCl3) δ 137.7, 133.4 (d, JCP = 3.8 Hz), 132.8, 132.3, 128.4, 127.7 (d, 
JCP = 7.8 Hz), 118.7 (d, JCP = 8.5 Hz), 118.5, 77.7 (d, JCP = 7.1 Hz), 77.6 (d, JCP = 5.5 Hz), 
75.0 (d, JCP = 6.6 Hz), 73.2, 72.4 (d, JCP = 6.0 Hz), 40.0 (d, JCP = 8.0 Hz), 38.8 (d, JCP = 2.8 
Hz), 32.9 (d, JCP = 6.9 Hz), 30.9; 
 31P NMR (162 MHz, CDCl3) δ –7.59; 
HRMS cald for C20H27O5PNa (M+Na)+ 401.1494; found 401.1491 (TOF MS ES+). 
(1S,3R,7R,9R,Z)-9-allyl-3-((benzyloxy)methyl)-2,10,11-trioxa-1- 
phosphabicyclo[5.3.1]undec-4-ene 1-oxide (trans-2.10.5): 
 
Yield: 11% (3 mg isolated starting from 30 mg of triene); 













Optical Rotation: [α]D  = +61.6 (c = 0.38, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 7.40–7.28 (m, 5H), 5.89–5.78 (m, 3H), 5.19 (dd, J = 4.2, 2.8 
Hz, 1H), 5.15 (s, 1H), 5.03 (ddd, J = 28.5, 7.1 Hz, 1H), 4.83–4.73 (m, 1H), 4.68 (d, J = 11.8 
Hz, 1H), 4.59 (d, J = 11.8 Hz, 1H), 4.52–4.37 (m, 1H), 4.03 (dd, J = 9.8, 6.9 Hz, 1H), 3.79 
(dd, J = 9.8, 7.2 Hz, 1H), 3.17 (ddd, J = 13.6, 10.4, 6.2 Hz, 1H), 2.59 – 2.50 (m, 1H), 2.41 
(dt, J = 14.3, 6.7 Hz, 1H), 2.27 (ddd, J = 14.6, 11.9, 5.2 Hz, 1H), 2.21–2.13 (m, 1H), 1.69 
(dd, J = 14.6, 1.1 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 137.8, 132.1, 130.1, 128.4 (d, JCP = 7.3 Hz), 128.0, 127.7 (d, 
JCP = 12.6 Hz), 126.4, 119.0, 75.8 (d, JCP = 7.4 Hz), 73.6, 73.1 (d, JCP = 6.4 Hz), 71.8 (d, JCP 
= 2.1 Hz), 40.6 (d, JCP = 8.6 Hz), 33.5 (d, JCP = 6.3 Hz), 31.1 (d, JCP = 32.0 Hz), 29.7; 
31P NMR (162 MHz, CDCl3) δ –10.75; 
HRMS cald for C18H23O5PNa (M+Na)+ 373.1181; found 373.1173 (TOF MS ES+). 
(1R,3R,7S,9S,Z)-9-allyl-3-((benzyloxy)methyl)-2,10,11-trioxa-1-
phosphabicyclo[5.3.1]undec-4-ene 1-oxide (cis-2.10.6): 
 
 
Yield: 46% (20.2 mg isolated starting from 48 mg of triene); 
FTIR (thin film): 2924, 2363, 1641, 1497, 1452, 1364, 1292, 1103, 978, 928 cm-1;  
Optical Rotation: [α]D  = +43.30(c = 1.03, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 7.39–7.27 (m, 5H), 5.89–5.81 (m, 1H), 5.81–5.74 (m, 1H), 
5.68 (dd, J = 11.9, 3.0 Hz, 1H), 5.25–5.17 (m, 2H), 5.16 (d, J = 1.1 Hz, 1H), 4.79 (dddd, J = 
12.5, 6.2, 6.2, 2.7 Hz, 1H), 4.63 (d, J = 12.3 Hz, 1H), 4.59 (d, J = 12.2 Hz, 1H), 4.56–4.41 
(m, 1H), 3.70–3.61 (m, 2H), 3.31 (td, J = 13.1, 8.4 Hz, 1H), 2.53 (ddd, J = 12.9, 7.1, 1.3 Hz, 
1H), 2.47 – 2.36 (m, 1H), 2.24 (ddd, J = 14.6, 12.2, 5.2 Hz, 1H), 2.07 (ddd, J = 13.7, 8.4, 5.3 







13C NMR (126 MHz, CDCl3) δ 137.8, 132.0, 130.3, 128.3, 127.6 (d, JCP = 15.2 Hz), 126.2, 
124.2, 119.0, 77.2 (d, JCP = 5.5 Hz), 76.0 (d, JCP = 7.3 Hz), 74.3 (d, JCP = 6.4 Hz), 73.1, 71.4 
(d, JCP = 12.0 Hz), 40.4 (d, JCP = 9.2 Hz), 33.8 (d, JCP = 6.3 Hz), 30.2 (d, JCP = 10.3 Hz); 
31P NMR (162 MHz, CDCl3) δ –7.60; 
HRMS cald for C18H23O5PNa (M+Na)+ 373.1181; found 373.1174 (TOF MS ES+). 
(4R,6R)-2-(((R)-1-(benzyloxy)but-3-en-2-yl)oxy)-4,6-bis(2-methylallyl)-1,3,2-
dioxaphosphinane 2-oxide (2.11.3): 
 
Yield: 67% (83 mg isolated starting from 80 mg of monochlorophosphate); 
FTIR (thin film): 3076, 2964, 2926, 2359, 1827, 1649, 1454, 1364, 1288, 1099, 1074, 1007, 
982, 739 cm-1;  
Optical Rotation: [α]D  = +44.04 (c = 1.3, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 7.34 (d, J = 4.4 Hz, 3H), 7.32–7.28 (m, 2H), 5.95 (ddd, J = 
17.2, 10.5, 6.7 Hz, 1H), 5.44 (ddd, J = 17.2, 1.3, 1.3 Hz, 1H), 5.31 (ddd, J = 10.6, 1.1, 1.2 
Hz, 1H), 5.08–4.99 (m, 1H), 4.85 (ddd, J = 7.04, 1.6, 1.6 Hz, 2H), 4.77 (d, J = 9.8 Hz, 2H), 
4.74–4.59 (m, 3H), 4.56 (d, J = 12.0 Hz, 1H), 3.67 (dd, J = 10.5, 5.6 Hz, 1H), 3.63 (ddd, J = 
10.6, 4.9, 1.0 Hz, 1H), 2.62 (dd, J = 14.2, 6.7 Hz, 1H), 2.53 (dd, J = 14.1, 6.7 Hz, 1H), 2.37 
(dd, J = 14.1, 7.8 Hz, 1H), 2.32 (dd, J = 13.6, 6.5 Hz, 1H), 1.98 (dddd, J = 13.0, 8.0, 4.9, 1.2 
Hz, 1H), 1.89 (dddd, J = 14.6, 5.4, 3.9, 1.9 Hz, 1H), 1.75 (s, 3H), 1.73 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 140.4, 140.2, 139.8, 137.9, 134.0 (d, JCP = 4.1 Hz), 128.3, 
127.6, 118.7, 114.6 (d, JCP = 3.7 Hz), 114.2 (d, JCP = 4.8 Hz), 78.0 (d, JCP = 5.6 Hz), 76.1 (d, 
JCP = 6.9 Hz), 74.4 (d, JCP = 6.6 Hz), 73.2, 72.2 (d, JCP = 5.8 Hz), 43.8 (d, JCP = 7.5 Hz), 
42.8 (d, JCP = 3.4 Hz), 33.2 (d, JCP = 6.8 Hz), 22.6, 22.3; 















Yield: 60% (110 mg isolated starting from 120 mg of monochlorophosphate); 
FTIR (thin film): 2918, 1827, 1649, 1448, 1290, 1092, 1074, 1007, 976 cm-1;  
Optical Rotation: [α]D  = –40.69 (c = 1.4, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 7.38–7.28 (m, 5H), 5.90 (ddd, J = 16.9, 10.6, 6.1 Hz, 1H), 
5.44 (d, J = 17.2 Hz, 1H), 5.30 (d, J = 10.6 Hz, 1H), 5.01 (dq, J = 12.4, 6.1 Hz, 1H), 4.85 
(ddd, J = 10.6, 1.4, 1.4 Hz, 2H), 4.79–4.68 (m, 4H), 4.61 (d, J = 12.1 Hz, 1H), 4.57 (d, J = 
12.0 Hz, 1H), 3.66–3.57 (m, 2H), 2.65 (dd, J = 14.1, 6.9 Hz, 1H), 2.49 (dd, J = 14.1, 6.4 Hz, 
1H), 2.39 (dd, J = 14.2, 7.7 Hz, 1H), 2.29 (dd, J = 14.1, 7.3 Hz, 1H), 1.97 (dddd, J = 14.7, 
8.2, 5.1,1.3 Hz, 1H), 1.87 (dddd, J = 14.6, 5.3, 3.7,1.9 Hz, 1H), 1.74 (s, 3H), 1.69 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ140.5, 140.3, 137.7, 133.5 (d, JCP = 3.8 Hz), 128.4 (d, JCP = 
2.7 Hz), 128.4, 127.8 (d, JCP = 5.0 Hz), 127.7 (d, JCP = 9.0 Hz), 118.5, 114.1 (d, JCP = 2.9 
Hz), 77.7 (d, JCP = 5.5 Hz), 76.3 (d, JCP = 7.0 Hz), 74.3 (d, JCP = 6.7 Hz), 73.2, 72.3 (d, JCP = 
6.1 Hz), 43.8 (d, JCP = 7.7 Hz), 42.7 (d, JCP = 3.0 Hz), 33.1 (d, JCP = 7.1 Hz), 22.6, 22.3; 
31P NMR (162 MHz, CDCl3) δ –7.58; 
HRMS cald for C22H31O5PNa (M+Na)+ 429.1807; found 429.1794 (TOF MS ES+). 
(1S,3R,7R,9R,Z)-3-((benzyloxy)methyl)-5-methyl-9-(2-methylallyl)-2,10,11-trioxa-1-



















Yield: 49% (76% brsm, 14 mg isolated starting from 30 mg of triene); 
FTIR (thin film): 2924, 2853, 1718, 1649, 1452, 1246, 1175, 1095, 1013, 899, 818, 748 cm-1;  
Optical Rotation: [α]D  = +50.10 (c = 1.3, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 7.39–7.28 (m, 5H), 5.57 (s, 1H), 4.98 (dd, J = 25.2, 1.7 Hz, 
1H), 4.93–4.84 (m, 2H), 4.82 (s, 1H), 4.67 (d, J = 11.9 Hz, 1H), 4.58 (d, J = 11.9 Hz, 1H), 
4.56–4.45 (m, 1H), 3.94 (dd, J = 9.9, 7.0 Hz, 1H), 3.72 (dd, J = 9.9, 6.6 Hz, 1H), 3.29 (t, J = 
12.8 Hz, 1H), 2.57 (dd, J = 14.0, 6.6 Hz, 1H), 2.33 (ddd, J = 14.0, 6.8, 1.4 Hz, 1H), 2.24 
(ddd, J = 14.6, 11.7, 5.3 Hz, 1H), 1.97 (dd, J = 13.1, 5.2 Hz, 1H), 1.86 (t, J = 1.6 Hz, 3H), 
1.78 (s, 3H), 1.73 (d, J = 14.6 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 140.1, 137.8, 137.1, 128.4, 127.8 (d, JCP = 26.9 Hz), 123.6, 
114.4, 76.1 (d, JCP = 7.7 Hz), 75.2 (d, JCP = 7.4 Hz), 73.6, 72.3 (d, JCP = 6.4 Hz), 72.1 (d, JCP 
= 3.7 Hz), 44.7 (d, JCP = 7.7 Hz), 36.5, 33.7 (d, JCP = 6.6 Hz), 29.7, 24.3, 22.8; 
31P NMR (162 MHz, CDCl3) δ –4.06; 





Yield: 60% (97 mg isolated starting from 89 mg of monochlorophosphate); 
FTIR (thin film): 2917, 2359, 1641, 1454, 1281, 1119, 991, 926, 750, 698, 667 cm-1; 
Optical Rotation: [α]D = +48.94 (c = 0.66, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.31–7.21 (m, 5H, aromatic), 6.01 (dddd, J = 17.0, 10.7, 6.2, 
0.8 Hz, 1H, H2C=CHCHO(P)CH2), 5.82–5.70 (m, 2H, H2C=CHCHO(P)CH2, 
H2C=CHCH2CH2), 5.33–5.30 (m, 1H, H2C=CHCHO(P)CH2), 5.29–5.27 (m, 1H, 
H2C=CHCHO(P)CH2), 5.22 (dt, J = 10.6, 1.2 Hz, 1H, H2C=CHCHO(P)CH2), 5.17 (dt, J = 









H2C=CHCHO(P)CH2 ), 4.60–4.54 (m, 1H, CHO(P)CH2OBn), 4.52 (d, J = 12.0 Hz, 1H, 
OCH2Ph), 4.45 (d, J = 12.0 Hz, 1H, OCH2Ph), 3.56 (ddd, J = 10.7, 3.9, 1.3 Hz, 1H, 
CHO(P)CH2OBn), 3.52 (dd, J = 10.6, 5.6 Hz, 1H, CHO(P)CH2OBn), 2.18–2.07 (m, 2H, 
H2C=CHCH2CH2), 2.08–2.02 (m, 1H, H2C=CHCHO(P)CH2CHO[P]), 1.96 (dddd, J = 14.7, 
5.6, 3.8, 1.8 Hz, 1H, H2C=CHCHO(P)CH2CHO[P]), 1.86 – 1.76 (m, 1H, CH2CH2CHO[P] 
CH2OBn), 1.76–1.68 (m, 1H, CH2CH2CHO[P] CH2OBn); 
13C NMR (126 MHz, CDCl3) δ 137.9, 137.5, 135.3 (d, JCP = 5.9 Hz), 135.2 (d, JCP = 1.8 
Hz), 128.4 (2 C), 127.7 (2 C), 127.68, 117.9, 117.1, 115.2, 77.9 (d, JCP = 6.7 Hz), 77.6 (d, 
JCP = 6.2 Hz), 75.8 (d, JCP = 6.2 Hz), 73.2, 71.7 (d, JCP = 4.1 Hz), 35.3 (d, JCP = 7.4 Hz), 
31.4 (d, JCP = 5.0 Hz), 29.2; 
31P NMR (162 MHz, CDCl3) δ –7.9; 






Yield: 38% (94 mg isolated starting from 120 mg of monochlorophosphate); 
FTIR (thin film): 2929, 1281, 1099, 995, 960, 739 cm-1; 
Optical Rotation: [α]D = –51.0 (c = 1.05, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.34–7.20 (m, 5H, aromatic), 5.96 (dddd, J = 17.4, 10.7, 6.0, 
0.9 Hz, 1H, H2C=CHCHO(P)CH2), 5.85 (dddd, J = 17.3, 10.6, 5.2, 1.6 Hz, 1H, 
H2C=CHCHO(P)CH2), 5.74 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H, H2C=CHCH2CH2), 5.39 (ddd, 
J = 17.1, 1.6, 0.9 Hz, 1H, H2C=CHCHO(P)CH2 ), 5.29 (dt, J = 17.2, 1.2 Hz, 1H, 
H2C=CHCHO(P)CH2), 5.23 (dt, J = 10.7, 1.2 Hz, 1H, H2C=CHCHO(P)CH2), 5.17 (dt, J = 
10.6, 1.1 Hz, 1H, H2C=CHCHO(P)CH2), 5.02–4.89 (m, 4H, H2C=CHCH2CH2, 








12.0 Hz, 1H, OCH2Ph), 4.47 (d, J = 12.1 Hz, 1H, OCH2Ph), 3.56 (d, J = 4.8 Hz, 2H, 
CHO(P)CH2OBn), 2.20–1.96 (m, 4H, H2C=CHCH2CH2, H2C=CHCHO(P)CH2CHO[P]), 
1.84–1.69 (m, 2H, CH2CH2CHO[P]CH2OBn); 
13C NMR (126 MHz, CDCl3) δ 138.1, 137.5, 135.3 (d, JCP = 3.7 Hz), 135.1 (d, JCP = 7.2 
Hz), 128.4 (2C), 127.7 (2C), 127.6, 117.8, 117.5, 115.3, 77.9 (d, JCP = 6.4 Hz), 77.6 (d, JCP 
= 6.7 Hz), 76.2 (d, JCP = 6.1 Hz), 73.2, 71.6 (d, JCP = 3.9 Hz), 35.3 (d, JCP = 7.5 Hz), 31.4 (d, 
JCP = 5.1 Hz), 29.2; 
31P NMR (162 MHz, CDCl3) δ –8.1; 
HRMS calcd. for C20H27O5PNa (M+Na)+ 401.1494; found 401.1471 (TOF MS ES+). 
(1S,3S,8S,10S,Z)-3-((benzyloxy)methyl)-10-vinyl-2,11,12-trioxa-1-phosphabicyclo 
[6.3.1]dodec-6-ene 1-oxide (cis-2.12.4): 
 
 
Yield: 60% (20 mg isolated starting from 36 mg of triene); 
FTIR (thin film): 2924, 2359, 1718, 1452, 1283, 1117, 1092, 989, 852, 565 cm-1; 
Optical Rotation: [α]D = –5.03 (c =0.78, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.31–7.20 (m, 5H, aromatic), 5.83–5.78 (m, 1H, H2C-
HC=CHCHO(P)CH2), 5.78–5.72 (m, 1H, H2CHC=CHCHO(P)CH2), 5.39–5.28 (m, 2H, 
H2C=CHCHO[P], HC=CHCHO(P)CH2), 5.20 (dt, J = 10.6, 1.2 Hz, 1H, H2C=CHCHO[P]), 
5.10 (d, J = 11.8 Hz, 1H), 5.02 (ddd, J = 11.8, 5.5, 1.4 Hz, 1H, H2C=CH-CHO(P)CH2), 
4.83–4.74 (m, 1H, CHO(P)CH2OBn), 4.55 (d, J = 12.1 Hz, 1H, OCH2Ph), 4.47 (d, J = 12.1 
Hz, 1H, OCH2Ph), 3.49 (dd, J = 10.4, 4.5 Hz, 1H, CHO(P)CH2OBn), 3.45 (dd, J = 10.4, 5.3 
Hz, 1H, CHO(P)CH2OBn), 2.92–2.83 (m, 1H, HC=CHCH2CH2), 2.19–2.13 (m, 1H, 
H2C=CHCHO(P)CH2CHO[P]), 2.13–2.07 (m, 1H, HC=CH-CH2CH2), 1.85–1.77 (m, 1H, 










13C NMR (126 MHz, CDCl3) δ 138.0, 137.3, 135.2 (d, JCP = 9.8 Hz), 128.3 (2C), 127.7 
(2C), 127.6, 124.2, 117.3 (d, JCP = 1.4 Hz), 79.7 (d, JCP = 5.6 Hz), 77.02 (d, JCP = 7.7 Hz), 
76.8 (d, JCP = 6.5 Hz), 73.2, 72.7 (d, JCP = 4.7 Hz), 37.4 (d, JCP = 6.5 Hz), 29.3 (d, JCP = 2.3 
Hz), 25.4; 
31P NMR (162 MHz, CDCl3) δ –8.4; 
HRMS calcd. for C18H23O5PNa (M+Na)+ 373.1181; found 373.1161(TOF MS ES+).  
(1R,3S,8R,10R,Z)-3-((benzyloxy)methyl)-10-vinyl-2,11,12-trioxa-1-
phosphabicyclo[6.3.1]dodec-6-ene 1-oxide (trans-2.12.5): 
 
 
Yield: 69% (6 mg isolated starting from 10 mg of triene); 
FTIR (thin film): 2924, 1279, 1132, 1109, 1012, 746 cm-1; 
Optical Rotation: [α]D = –52.55 (c = 0.25, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.38–7.28 (m, 5H, aromatic), 5.93 (dddd, J = 17.1, 10.5, 5.6, 
1.8 Hz, 1H, H2C-HC=CHCHO(P)CH2), 5.69 (dddd, J = 17.5, 11.9, 6.4, 2.8 Hz, 1H, H2C-
HC=CHCHO(P)CH2), 5.50 (dt, J = 12.0, 1.2 Hz, 1H, H2C=CHCHO[P] ), 5.44 (dt, J = 17.1, 
1.1 Hz, 1H, H2C=CHCHO[P]), 5.41–5.33 (m, 1H, HC=CHCHO(P)CH2), 5.29 (dt, J = 10.5, 
1.1 Hz, 1H, H2C=CHCHO[P]), 5.19–5.12 (m, 1H, H2C=CH-CHO(P)CH2), 4.59 (d, J = 11.8 
Hz, 1H, OCH2Ph), 4.56 (d, J = 11.8 Hz, 1H, OCH2Ph), 4.38 (ttd, J = 11.5, 5.6, 1.9 Hz, 1H, 
CHO(P)CH2OBn), 3.66 (dd, J = 10.2, 5.8 Hz, 1H, CHO(P)CH2OBn), 3.53 (ddd, J = 10.2, 
5.4, 1.6 Hz, 1H, CHO(P)CH2OBn), 3.19 (qd, J = 13.1, 4.0 Hz, 1H, HC=CHCH2CH2), 2.33 
(ddd, J = 14.8, 12.0, 4.9 Hz, 1H, H2C=CH-CHO(P)CH2CHO[P]), 2.10–2.02 (m, 1H, 
HC=CHCH2CH2), 1.98 (dq, J = 14.8, 2.7 Hz, 1H, H2C=CHCHO(P)CH2CHO[P]), 1.84 (ddt, 









13C NMR (126 MHz, CDCl3) δ 137.9, 135.5 (d, JCP = 4.5 Hz), 132.7, 128.5, 128.3 (2C), 
127.63, 127.6 (2C), 117.6, 78.9 (d, JCP = 7.6 Hz), 77.2 (d, JCP = 7.8 Hz), 75.1 (d, JCP = 8.6 
Hz), 73.6, 72.9 (d, JCP = 7.9 Hz), 36.6 (d, JCP = 10.9 Hz), 29.5, 23.1; 
31P NMR (162 MHz, CDCl3) δ –15.17; 
HRMS calcd. for C18H23O5PNa (M+Na)+ 373.1181; found 373.1173 (TOF MS ES+). 
(4R,6R)-2-(((R)-1-(benzyloxy)pent-4-en-2-yl)oxy)-4,6-bis(2-methylallyl)-1,3,2-
dioxaphosphinane 2-oxide (2.13.1): 
 
 
Yield: 47% (89 mg isolated starting from 120 mg of monochlorophosphate); 
FTIR (thin film): 2922, 2359, 1290, 1101, 1005, 986 cm-1;  
Optical Rotation: [α]D = –53.2 (c = 1.04, CHCl3);  
1H NMR (400 MHz, CDCl3) δ (ppm) 7.40–7.28 (m, 5H), 5.80 (ddt, J = 17.2, 10.2, 7.1 Hz, 
1H), 5.17–5.07 (m, 2H), 4.91–4.80 (m, 2H), 4.79–4.73 (m, 2H), 4.73–4.61 (m, 3H), 4.59 (d, 
J = 11.9 Hz, 1H), 4.53 (d, J = 12.0 Hz, 1H), 3.63–3.54 (m, 2H), 2.65 (dd, J = 14.1, 6.9 Hz, 
1H), 2.54 (t, J = 6.7 Hz, 2H), 2.49 (dd, J = 14.1, 6.4 Hz, 1H), 2.37 (dd, J = 14.2, 7.6 Hz, 
1H), 2.28 (dd, J = 14.1, 7.3 Hz, 1H), 1.96 (dddd, J = 13.3, 8.2, 4.9, 1.2 Hz, 1H), 1.86 (dddd, 
J = 14.6, 5.3, 3.7, 1.8 Hz, 1H), 1.75 (s, 3H), 1.68 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 140.5, 140.3, 137.9, 132.7, 128.4 (2C), 127.7, 127.6 (2C), 
118.4, 114.2 (d, JCP = 2.5 Hz), 76.8 (d, JCP = 6.0 Hz), 76.3 (d, JCP = 6.9 Hz), 74.3 (d, JCP = 
6.6 Hz), 73.3, 71.3 (d, JCP = 5.2 Hz), 43.8 (d, JCP = 7.6 Hz), 42.7 (d, JCP = 3.1 Hz), 36.8 (d, 
JCP = 4.1 Hz), 33.2 (d, JCP = 6.9 Hz), 29.7, 22.6, 22.4; 
31P NMR (162 MHz, CDCl3) δ –7.37; 











phosphabicyclo[6.3.1]dodec-5-ene 1-oxide (2.13.2):2  
 
 
Yield: 36% (53% brsm, 9.5 mg isolated starting from 30 mg of triene with 10 mg unreacted starting 
triene); 
FTIR (thin film): 2922, 2853, 2359, 1448, 1294, 1105, 1074, 995, 972, 912, 897, 741, 698 cm-1;  
Optical Rotation: [α]D = –13.9 (c = 0.42, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 7.39–7.27 (m, 5H), 5.61 (t, J = 8.2 Hz, 1H), 4.92–4.84 (m, 
2H), 4.81 (s, 1H), 4.79–4.68 (m, 1H), 4.60 (d, J = 12.0 Hz, 1H), 4.56 (d, J = 12.0 Hz, 1H), 
4.39 (ddd, J = 15.4, 10.5, 5.1 Hz, 1H), 3.61 (dd, J = 10.0, 4.4 Hz, 1H), 3.51 (dd, J = 10.0, 
6.4 Hz, 1H), 3.35 (t, J = 13.0 Hz, 1H), 2.52 (dd, J = 14.2, 6.6 Hz, 1H), 2.48–2.39 (m, 1H), 
2.36–2.29 (m, 1H), 2.28 (dd, J = 6.1, 2.2 Hz, 1H), 2.26–2.17 (m, 1H), 1.79 (s, 6H), 1.84–
1.60 (m, 2H); 
13C NMR (126 MHz, CDCl3) δ 140.1, 137.9, 134.6, 128.4 (2C), 127.73 (2C), 127.71, 124.1, 
114.2, 77.1 (d, JCP = 6.2 Hz), 74.9 (d, JCP = 6.8 Hz), 74.6 (d, JCP = 7.3 Hz), 73.3, 72.7 (d, JCP 
= 4.2 Hz), 44.4 (d, JCP = 9.2 Hz), 36.1, 34.4 (d, JCP = 6.3 Hz), 30.3 (d, JCP = 3.1 Hz), 22.8, 
22.5; 
31P NMR (162 MHz, CDCl3) δ –9.86; 
HRMS cald. for (C21H29O5P)2Na (2M+Na)+  807.3403; found 807.3442 (TOF MS ES+). 
  
                                                
[2] CCDC 905669 contains the supplementary crystallographic data for this compound.  This X-ray 
crystallography data has been published in:  Maitra, S.; Markley, J. L.; Chegondi, R.; Hanson, P. R. 
Phosphate Tether-Mediated Ring-Closing Metathesis for the Generation of Medium to 











methylallyl)-1,3,2-dioxaphosphinane 2-oxide (2.13.3):  
 
Yield: 46% (91 mg isolated starting from 120 mg of monochlorophosphate); 
FTIR (thin film): 2954, 2912, 1617, 1281, 1245, 1040, 100, 758, 712 cm-1;  
Optical Rotation: [α]D  = –31.9 (c = 0.66, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 8.22 (d, J = 6.9 Hz, 2H), 7.48 (d, J = 8.1 Hz, 2H), 5.80–5.72 
(m, 1H), 5.38 (t, J = 7.4 Hz, 1H), 5.09 (d, J = 10.4 Hz, 1H), 5.01 (d, J = 17.2 Hz, 1H), 4.89 
(s, 1H), 4.80–4.73 (m, 1H), 4.78 (s, 1H), 4.74 (s, 1H), 4.62 (s, 1H), 4.40–4.33 (m, 1H), 2.76–
2.68 (m, 1H), 2.62 (dd, J = 14.1, 6.8 Hz, 1H), 2.38 (dd, J = 14.2, 7.6 Hz, 1H), 2.30 (dd, J = 
14.3, 6.8 Hz, 1H), 2.19 (dd, J = 14.2, 6.8 Hz, 1H), 2.01–1.93 (m, 1H), 1.90–1.82 (m, 1H), 
1.76 (s, 3H), 1.55 (s, 3H), 1.00 (dd, J = 6.8, 1.5 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 147.6, 146.2 (d, JCP = 2.6 Hz), 140.2, 139.9, 137.7, 127.7, 
123.4, 117.0, 114.4, 114.2, 82.6 (d, JCP = 5.9 Hz), 76.2 (d, JCP = 6.9 Hz), 74.7 (d, JCP = 6.7 
Hz), 44.3 (d, JCP = 6.1 Hz), 43.5 (d, JCP = 7.2 Hz), 43.0 (d, JCP = 3.6 Hz), 33.3 (d, JCP = 6.9 
Hz), 22.5, 22.4, 15.7; 
31P NMR (162 MHz, CDCl3) δ –6.5; 
HRMS cald. for C22H30NO6PNa (M+Na)+  458.1708; found 429.1714 (TOF MS ES+). 
(4S,6S)-2-(((1R,2S)-2-methyl-1-(4-nitrophenyl)but-3-en-1-yl)oxy)-4,6-bis(2-
methylallyl)-1,3,2-dioxaphosphinane 2-oxide (2.13.4):  
 
Yield: 81% (160 mg isolated starting from 120 mg of monochlorophosphate); 


















Optical Rotation: [α]D  = –41.4 (c = 1.03, CHCl3);  
1H NMR (400 MHz, CDCl3) δ (ppm) δ 8.21 (d, J = 8.8 Hz, 2H), 7.48 (d, J = 8.8 Hz, 2H), 
5.59 (ddd, J = 17.4, 10.4, 7.0 Hz, 1H), 5.31 (dd, J = 8.5, 7.5 Hz, 1H), 5.00 (d, J = 10.4 Hz, 
1H), 4.95 (ddd, J = 17.2, 1.3, 1.3 Hz, 1H), 4.89 (dd, J = 1.3, 1.3 Hz, 1H), 4.80–4.72 (m, 1H), 
4.78 (s, 1H), 4.73 (dd, J = 1.4, 1.4 Hz, 1H), 4.60 (s, 1H), 4.34–4.26 (m, 1H), 2.79–2.72  (m, 
1H), 2.63 (dd, J = 14.1, 6.9 Hz, 1H), 2.37 (dd, J = 14.1, 7.5 Hz, 1H), 2.27 (dd, J = 14.2, 6.8 
Hz, 1H), 2.17 (ddd, J = 14.2, 6.9, 1.0 Hz, 1H), 1.96 (dddd, J = 14.7, 8.3, 5.0, 1.1 Hz,  1H), 
1.83 (dddd, J = 14.7, 5.2, 3.7, 1.8 Hz, 1H), 1.77 (s, 3H), 1.52 (s, 3H), 1.14 (d, J = 6.8 Hz, 
3H); 
13C NMR (126 MHz, CDCl3) δ 147.7, 146.1 (d, JCP = 2.5 Hz), 140.1, 139.9, 137.4, 128.0, 
123.4, 117.2, 114.4, 114.2, 82.6 (d, JCP = 5.9 Hz), 76.3 (d, JCP = 6.9 Hz), 74.6 (d, JCP = 6.6 
Hz), 44.3 (d, JCP = 6.4 Hz), 43.6 (d, JCP = 7.4 Hz), 43.0 (d, JCP = 3.5 Hz), 33.3 (d, JCP = 6.9 
Hz), 22.5, 22.3, 15.7; 
31P NMR (162 MHz, CDCl3) δ (ppm) –6.56; 
HRMS cald for C22H30NO6PNa (M+Na)+ 458.1708; found 429.1706 (TOF MS ES+). 
(1R,3R,4R,8S,10S,Z)-4,6-dimethyl-10-(2-methylallyl)-3-(4-nitrophenyl)-2,11,12-trioxa-
1-phosphabicyclo[6.3.1]dodec-5-ene 1-oxide (cis,anti-2.13.5):3  
 
 
Yield: 61% (17 mg isolated starting from 30 mg of triene); 
FTIR (thin film): 2982, 2916, 1614, 1523, 1351, 1242, 1082, 1042, 962, 750, 732 cm-1;  
Optical Rotation: [α]D = –30.0 (c = 0.39, CHCl3);  
                                                
[3] CCDC 905670 contains the supplementary crystallographic data for this compound.  This X-ray 
crystallography data has been published in:  Maitra, S.; Markley, J. L.; Chegondi, R.; Hanson, P. R. 
Phosphate Tether-Mediated Ring-Closing Metathesis for the Generation of Medium to 











1H NMR (400 MHz, CDCl3) δ 8.24 (d, J = 8.7 Hz, 2H), 7.49 (d, J = 8.7 Hz, 2H), 5.33 (d, J 
= 7.4 Hz, 1H), 5.06 (t, J = 9.4 Hz, 1H), 5.01–4.94 (m, 1H), 4.89 (s, 1H), 4.89–4.77 (m, 1H), 
4.81 (s, 1H), 3.52 (t, J = 12.9 Hz, 1H), 2.91–2.82 (m, 1H), 2.51 (dd, J = 14.5, 7.1 Hz, 1H), 
2.35–2.25 (m, 2H), 1.96 (dd, J = 13.0, 4.2 Hz, 1H), 1.84 (s, 3H), 1.80 (s, 3H), 1.76 (d, J = 
14.6 Hz, 1H), 0.65 (d, J = 7.1 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 147.8, 146.4 (d, JCP = 3.5 Hz), 139.9, 133.6, 131.8, 127.8, 
123.8, 114.1, 83.2 (d, JCP = 6.4 Hz), 75.3 (d, JCP = 7.0 Hz), 74.5 (d, JCP = 7.4 Hz), 44.2 (d, 
JCP = 9.1 Hz), 38.0 (d, JCP = 4.2 Hz), 36.6, 34.1 (d, JCP = 6.3 Hz), 22.8, 22.8, 18.7; 
31P NMR (162 MHz, CDCl3) δ –9.73; 
HRMS cald for C20H26NO6P (M+H)+ 408.1576; found 408.1574 (TOF MS ES+). 
(4S,6S)-2-(((2S,3S,4S)-3-hydroxy-2,4-dimethylhex-5-en-1-yl)oxy)-4,6-divinyl-1,3,2-
dioxaphosphinane 2-oxide (2.14.2a):  
 
Yield: 65% (99 mg isolated starting from 100 mg of monochlorophosphate); 
FTIR (thin film): 2959, 2910, 1650, 1392, 1272, 1118, 1012, 927, 877 cm-1; 
Optical Rotation: [α]D = +56.2 (c = 1.5, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 5.97 (ddd, J = 16.7, 10.6, 6.0 Hz, 1H), 5.85 (dddd, J = 17.3, 
10.6, 5.2, 1.6 Hz, 1H), 5.71 (ddd, J = 17.3, 10.2, 8.4 Hz, 1H), 5.41 (dd, J = 17.1, 1.1 Hz, 
1H), 5.32 (dd, J = 17.2, 1.0 Hz, 1H), 5.25 (ddd, J = 10.6, 6.6, 1.0 Hz, 2H), 5.09–5.03 (m, 
2H), 5.02–4.91 (m, 2H), 4.11–4.05 (m, 1H), 3.92 (ddd, J = 10.0, 7.7, 6.1 Hz, 1H), 3.38 (dd, 
J = 8.8, 2.8 Hz, 1H), 2.25–2.17 (m, 1H), 2.12 (dddd, J = 14.6, 8.1, 4.8, 1.5 Hz, 2H), 2.03–
1.97 (m, 2H), 0.91 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 6.9 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 141.6, 135.0 (d, JCP = 1.8 Hz), 135.0 (d, JCP = 3.1 Hz), 
118.2, 117.6, 116.2, 77.6 (d, JCP = 6.7 Hz), 76.4 (d, JCP = 6.0 Hz), 72.6, 70.3 (d, JCP = 6.0 
Hz), 41.8, 35.5 (d, JCP = 6.1 Hz), 35.1 (d, JCP = 7.7 Hz), 16.4, 8.8; 
31P NMR (162 MHz, CDCl3) δ –6.62; 








phosphabicyclo[7.3.1]tridec-7-ene 1-oxide (2.14.4a):  
 
 
Yield: 62% (5 mg isolated starting from 9 mg of triene); 
FTIR (thin film): 2962, 2958, 1459, 1245, 1012 cm-1; 
Optical Rotation: [α]D = +47.6 (c = 0.105, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 6.21 (ddd, J = 16.1, 8.7, 1.8 Hz, 1H), 5.87 (dddd, J = 17.9, 
9.9, 4.8, 1.7 Hz, 1H), 5.83 (dd, J = 15.4, 4.6 Hz, 1H), 5.44 (ddd, J = 17.1, 1.1, 1.1 Hz, 1H), 
5.29 (ddd, J = 10.7, 1.1, 1.0 Hz, 1H), 5.19–5.07 (m, 2H), 4.28 (dd, J = 10.9, 5.6 Hz, 1H), 
3.95 (dd, J = 11.1, 5.0 Hz, 1H), 3.73 (d, J = 5.9 Hz, 1H), 2.71–2.61 (m, 1H), 2.24 (ddd, J = 
14.6, 12.1, 5.2 Hz, 1H), 2.06–1.97 (m, 1H), 1.83 (ddd, J = 14.6, 3.7, 2.1 Hz, 1H), 1.69 (s, 
1H), 1.16 (d, J = 7.1 Hz, 3H), 1.11 (d, J = 7.2 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 139.9, 135.3 (d, JCP = 10.1 Hz), 127.7, 117.1, 79.4, 77.2, 
76.3 (d, JCP = 6.4 Hz), 75.1 (d, JCP = 7.0 Hz), 64.2, 39.4, 37.3 (d, JCP = 10.1 Hz), 35.5 (d, JCP 
= 5.6 Hz), 13.6; 
31P NMR (162 MHz, CDCl3) δ –7.10; 
HRMS: cald. for C13H21O5PNa (M+Na)+ 311.1024; found 311.0998 (TOF MS ES+). 
(4S,6S)-2-(((2S,3S,4S)-3-((tert-butyldimethylsilyl)oxy)-2,4-dimethylhex-5-en-1-yl)oxy)-



















Yield: 89% (156 mg isolated starting from 80 mg of monochlorophosphate); 
FTIR (thin film): 2951, 2919, 1491, 1256, 1231, 1109, 1000, 919, 853, 829 cm-1; 
Optical Rotation: [α]D = +37.0 (c = 1.1, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 6.01 (ddd, J = 16.6, 10.6, 5.8 Hz, 1H), 5.92 (dddd, J = 15.9, 
10.6, 5.2, 1.5 Hz, 1H), 5.82 (ddd, J = 17.9, 10.2, 8.0 Hz, 1H), 5.46 (ddd, J = 17.2, 1.3, 0.8 
Hz, 1H), 5.38 (dd, J = 17.2, 0.9 Hz, 1H), 5.30 (dd, J = 10.6, 0.9 Hz, 2H), 5.09–5.02 (m, 1H), 
5.04–4.97 (m, 2H), 5.01–4.93 (m, 1H), 4.03–3.93 (m, 2H), 3.63 (dd, J = 4.5, 3.7 Hz, 1H), 
2.37 (dq, J = 14.0, 7.0 Hz, 1H), 2.18 (dddd, J = 14.5, 8.1, 4.8, 1.5 Hz, 1H), 2.04 (dddd, J = 
14.3, 5.2, 3.7, 1.7 Hz, 2H), 1.01 (d, J = 7.0 Hz, 3H), 0.94 (d, J = 6.9 Hz, 3H), 0.90 (s, 9H), 
0.06 (s, 6H); 
13C NMR (126 MHz, CDCl3) δ 141.2, 135.1 (d, JCP = 3.2 Hz), 135.0 (d, JCP = 7.1 Hz), 
117.9, 117.5, 114.6, 77.4 (d, JCP = 6.7 Hz), 76.1 (d, JCP = 6.1 Hz), 75.3, 70.6 (d, JCP = 6.0 
Hz), 42.5, 38.0 (d, JCP = 6.7 Hz), 35.1 (d, JCP = 7.6 Hz), 26.0, 18.3, 17.3, 11.8, -3.8, -4.1; 
31P NMR (162 MHz, CDCl3) δ –7.05; 
HRMS: cald. for C21H39O5PSiNa (M+Na)+ 453.2202; found 453.2189 (TOF MS ES+). 
(1S,4S,5S,6S,9S,11S,E)-5-((tert-butyldimethylsilyl)oxy)-4,6-dimethyl-11-vinyl-2,12,13-
trioxa-1-phosphabicyclo[7.3.1]tridec-7-ene 1-oxide (2.14.4b): 
 
 
Yield: 72% (101 mg isolated starting from 150 mg of triene); 
FTIR (thin film): 2956, 2929, 1471, 1276, 1257, 1103, 1001, 927, 862, 837 cm-1; 
Optical Rotation: [α]D = +36.5 (c = 3.75, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 6.22 (dd, J = 15.5, 9.7 Hz, 1H), 5.87 (dddd, J = 17.4, 9.9, 
4.8, 1.8 Hz, 1H), 5.75 (dd, J = 16.0, 4.7 Hz, 1H), 5.45 (ddd, J = 17.0, 1.2, 1.0 Hz, 1H), 5.27 












(dd, J = 5.9, 2.1 Hz, 1H), 2.49 (s, 1H), 2.22 (ddd, J = 14.6, 12.2, 5.2 Hz, 1H), 2.10–1.96 (m, 
1H), 1.81 (dd, J = 14.5, 1.5 Hz, 1H), 1.09 (d, J = 6.9 Hz, 3H), 1.01 (d, J = 7.4 Hz, 3H), 0.92 
(s, 9H), 0.08 (s, 3H), 0.03 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 135.4 (d, JCP = 10.0 Hz), 127.1, 116.9, 80.0, 77.2 (d, JCP = 
6.1 Hz), 76.1 (d, JCP = 6.5 Hz), 75.1 (d, JCP = 7.0 Hz), 70.6 (d, JCP = 5.9 Hz), 42.5, 39.5, 
35.6 (d, JCP = 5.7 Hz), 29.6, 26.0, 25.9, 18.1, -4.2, -4.8; 
31P NMR (162 MHz, CDCl3) δ –7.16; 
HRMS: cald. for C19H35O5PSiNa (M+Na)+ 425.1889; found 425.1885 (TOF MS ES+). 
(4R,6R)-2-(((2S,3S,4S)-3-((4-methoxybenzyl)oxy)-2,4-dimethylhex-5-en-1-yl)oxy)-4,6-
divinyl-1,3,2-dioxaphosphinane 2-oxide (2.14.3):  
 
Yield: 68% (150 mg isolated starting from 100 mg of monochlorophosphate); 
FTIR (thin film): 2971, 1651, 1521, 1282, 1249, 1112, 1008, 964, 927, 827 cm-1; 
Optical Rotation: [α]D = –16.4 (c = 1.8, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 9.0 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 6.05–5.87 
(m, 3H), 5.46 (ddd, J = 17.1, 1.5, 0.9 Hz, 1H), 5.37 (ddd, J = 17.1, 1.5 0.9 Hz, 1H), 5.29 
(dddd, J = 10.8, 9.1, 1.1, 1.1 Hz, 2H), 5.11 (ddd, J = 17.3, 1.7, 1.4 Hz, 1H), 5.08–5.04 (m, 
1H), 5.04 (ddd, J = 10.3, 1.6, 1.1 Hz, 1H), 4.98–4.89 (m, 1H), 4.50 (dd, J = 31.2, 10.5 Hz, 
2H), 4.28–4.07 (m, 2H), 3.80 (s, 3H), 3.27 (dd, J = 6.9, 4.9 Hz, 1H), 2.52–2.42 (m, 1H), 
2.16 (dddd, J = 14.0, 7.7, 4.7, 1.5 Hz, 1H), 2.10–2.00 (m, 2H), 1.06 (d, J = 7.0 Hz, 3H), 1.05 
(d, J = 7.1 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 159.1, 142.1, 135.1 (d, JCP = 3.5 Hz), 135.0 (d, JCP = 6.8 
Hz), 130.74, 129.3, 117.8, 117.5, 114.3, 113.7, 83.8, 77.3 (d, JCP = 4.1 Hz), 76.1 (d, JCP = 
6.1 Hz), 74.3, 70.1 (d, JCP = 6.1 Hz), 55.2, 40.1, 37.0 (d, JCP = 7.6 Hz), 35.1 (d, JCP = 7.6 
Hz), 14.6, 14.1; 







HRMS: cald. for C23H33O6PNa (M+Na)+ 459.1912; found 459.1908 (TOF MS ES+). 
(1R,4S,5S,6S,9R,11R,E)-5-((4-methoxybenzyl)oxy)-4,6-dimethyl-11-vinyl-2,12,13-
trioxa-1-phosphabicyclo[7.3.1]tridec-7-ene 1-oxide (2.14.5):  
 
 
Yield: 75% (28 mg isolated starting from 40 mg of triene); 
FTIR (thin film): 2979, 1659, 1515, 1279, 1239, 1111, 1002, 957, 922, 821 cm-1; 
Optical Rotation: [α]D = –18.5 (c = 0.26, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 8.0 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 5.88–5.77 
(m, 2H), 5.73 (dd, J = 15.8, 3.9 Hz, 1H), 5.36 (d, J = 17.0 Hz, 1H), 5.24 (d, J = 10.5 Hz, 
1H), 5.12 (ddd, J = 24.4, 5.1, 3.8 Hz, 1H), 5.04 (d, J = 7.6 Hz, 1H), 4.51 (d, J = 10.7 Hz, 
1H) 4.40 (d, J = 10.7, 1H), 4.18 (dd, J = 10.4, 8.5 Hz, 1H), 3.90 (dd, J = 11.0, 6.6 Hz, 1H), 
3.82 (s, 3H), 3.11 (d, J = 7.2, 1H), 2.55 (br.s, 1H), 2.33 (br.s, 1H), 2.20 (ddd, J = 14.5, 12.2, 
5.3 Hz, 1H), 1.78 (d, J = 14.4 Hz, 1H), 1.12 (d, J = 6.6 Hz, 3H), 1.07 (d, J = 7.3 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 159.3, 139.0, 135.3 (d, JCP = 9.9 Hz), 130.2, 129.5, 127.0, 
117.0, 113.8, 87.4, 77.2 (d, JCP = 6.1 Hz), 76.4 (d, JCP = 6.4 Hz), 75.3 (d, JCP = 6.0 Hz), 
72.0, 65.7, 55.3, 35.6 (d, JCP = 3.2 Hz), 35.5, 34.60 (d, JCP = 8.9 Hz), 17.9; 
31P NMR (162 MHz, CDCl3) δ –8.02; 





















Yield: 30% (68 mg isolated starting from   110 mg of monochlorophosphate); 
FTIR (thin film): 2928, 2858, 1639, 1454, 1285, 1119, 999, 926, 737, 698 cm-1;  
Optical Rotation: [α]D =  +45.54 (c = 0.92, CHCl3);  
1H NMR (500 MHz, Chloroform-d) 7.37–7.27 (m, 5H, aromatic), 6.07 (dddd, J = 17.0, 
10.6, 6.3, 0.8 Hz, 1H, H2C=CH-CHO(P)CH2), 5.87–5.81 (m, 1H, H2C=CHCHO(P)CH2), 
5.78 (ddt, J = 17.1, 10.2, 6.7 Hz, 1H, H2C=CHCH2CH2), 5.37 (dt, J = 5.3, 1.3 Hz, 1H, 
H2C=CH-CHO(P)CH2), 5.34 (dt, J = 5.3, 1.3 Hz, 1H, H2C=CHCHO(P)CH2), 5.28 (dt, J = 
10.6, 1.2 Hz, 1H, H2C=CHCHO(P)CH2), 5.23 (dt, J = 10.6, 1.3 Hz, 1H, 
H2C=CHCHO(P)CH2), 5.06–5.00 (m, 2H, H2C=CHCHO(P)CH2), 5.00–4.90  (m, 2H, 
H2C=CHCH2CH2), 4.65–4.58 (m, 1H, CHO(P)CH2OBn), 4.58 (d, J = 11.9 Hz, 1H, 
OCH2Ph), 4.51 (d, J = 11.9 Hz, 1H, OCH2Ph), 3.61 (ddd, J = 10.7, 3.9, 1.5 Hz, 1H, 
CHO(P)CH2OBn), 3.57 (dd, J = 10.6, 5.8 Hz, 1H, CHO(P)CH2OBn), 2.11 (dddd, J = 14.4, 
7.9, 4.8, 1.6 Hz, 1H, H2C=CHCHO(P)CH2CHO[P]), 2.08–2.05 (m, 1H, 
H2C=HCH2CH2CH2C), 2.02 (dddd, J = 14.7, 5.5, 3.9, 1.8 Hz, 2H, H2C=HCH2CH2CH2C, 
H2C=CHCHO(P)CH2CHO[P]), 1.81–1.65 (m, 2H, H2CH2CCHO(P)CH2OBn), 1.49–1.33 
(m, 4H, H2C=HCH2CH2CH2CH2CCHO(P)CH2OBn); 
13C NMR (126 MHz, CDCl3) δ 138.7, 137.9, 135.3 (d, JCP = 4.2 Hz), 135.2, 128.3 (2C), 
127.7(2C), 127.66, 117.8, 117.1, 114.4, 78.2 (d, JCP = 6.1 Hz), 77.9 (d, JCP = 6.7 Hz), 75.7 
(d, JCP = 6.0 Hz), 73.2, 71.8 (d, JCP = 4.4 Hz), 35.3 (d, JCP = 7.6 Hz), 33.5, 32.1 (d, JCP = 4.7 
Hz), 28.7, 24.4; 
31P NMR (162 MHz, CDCl3) δ –7.90; 













Yield: 30% (65 mg isolated starting from 110 mg of monochlorophosphate); 
FTIR (thin film): 2926, 2858, 2391, 1283, 1119, 1082, 1005, 928, 737, 698 cm-1;  
Optical Rotation: [α]D = –57.3 (c = 0.55, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 7.38–7.27 (m, 5H, aromatic), 6.02 (dddd, J = 17.3, 10.6, 5.9, 
0.7 Hz, 1H, H2C=CHCHO(P)CH2), 5.92 (dddd, J = 17.3, 10.6, 5.2, 1.6 Hz, 1H, H2C=CH-
CHO(P)CH2), 5.79 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H, H2C=CHCH2CH2), 5.46 (dt, J = 17.1, 
1.3 Hz, 1H, H2C=CHCHO(P)CH2), 5.36 (dt, J = 17.1, 1.2 Hz, 1H, H2C=CHCHO(P)CH2), 
5.30 (dt, J = 10.7, 1.2 Hz, 1H, H2C=CHCHO(P)CH2), 5.23 (dt, J = 10.6, 1.2 Hz, 1H, 
H2C=CHCHO(P)CH2), 5.05 (dddd, J = 12.9, 7.3, 4.4, 1.5 Hz, 1H, H2C=CHCHO(P)CH2), 
5.02 – 4.95 (m, 2H, H2C=CHCHO(P)CH2, H2C=CHCH2CH2), 4.93 (ddt, J = 10.2, 2.3, 1.2 
Hz, 1H, H2C=CHCH2CH2), 4.70 – 4.60 (m, 1H, CHO(P)CH2OBn), 4.60 (d, J = 12.0 Hz, 1H, 
OCH2Ph), 4.54 (d, J = 12.0 Hz, 1H, OCH2Ph), 3.62 (d, J = 1.9 Hz, 1H, CHO(P)CH2OBn), 
3.62 (d, J = 1.6 Hz, 1H, CHO(P)CH2OBn), 2.14 (dddd, J = 14.1, 7.6, 4.8, 1.6 Hz, 1H, 
H2C=CHCHO(P)CH2CHO[P]), 2.10–2.06 (m, 1H, H2C=CHCHO(P)CH2CHO[P]), 2.06–
2.01 (m, 2H, H2C=HCH2CH2CH2C), 1.75–1.70 (m, 2H, H2CH2CCHO(P)CH2OBn), 1.53–
1.29 (m, 4H, H2C=HCH2CH2CH2CH2CCHO(P)CH2OBn); 
13C NMR (126 MHz, CDCl3) δ 138.7, 138.1, 135.3 (d, JCP = 3.7 Hz), 135.1 (d, JCP = 7.2 
Hz), 128.3 (2C), 127.6 (2C), 127.58, 117.7, 117.4, 114.5, 78.5 (d, JCP = 6.4 Hz), 77.5 (d, JCP 
= 6.7 Hz), 76.1 (d, JCP = 6.2 Hz), 73.2, 71.7 (d, JCP = 4.0 Hz), 35.3 (d, JCP = 7.5 Hz), 33.5, 
32.0 (d, JCP = 5.0 Hz), 28.6, 24.4. 
31P NMR (162 MHz, CDCl3) δ –8.0; 
HRMS cald for C22H31O5PNa (M+Na)+ 429.1807; found 429.1793 (TOF MS ES+). 
(1S,3S,10S,12S,E)-3-((benzyloxy)methyl)-12-vinyl-2,13,14-trioxa-1-










Yield: 69% (3.5 mg isolated starting from 5.5 mg of triene); E/Z: 20:1) 
FTIR (thin film): 2929, 1280, 1099, 995,921, 739 cm-1;  
Optical Rotation: [α]D = + 66.25 (c = 0.48, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 7.38–7.28 (m, 5H, aromatic), 6.02 (ddd, J = 15.4, 10.7, 4.6 
Hz, 1H, HC=CHCH2CH2), 5.94–5.81 (m, 2H, H2C=CHCHO(P)CH2, HC=CH-CH2CH2), 
5.45 (d, J = 17.2 Hz, 1H, H2C=CHCHO(P)CH2), 5.28 (d, J = 10.6 Hz, 1H, 
H2C=CHCHO(P)CH2), 5.19 (dd, J = 11.7, 5.0 Hz, 1H, ), 5.09 (dt, J = 23.9, 6.4 Hz, 1H), 
4.68 (q, J = 5.9 Hz, 1H, CHO(P)CH2OBn), 4.59 (d, J = 12.1 Hz, 1H, OCH2Ph), 4.54 (d, J = 
12.1 Hz, 1H, OCH2Ph), 3.65 (dd, J = 10.2, 5.4 Hz, 1H, CHO(P)CH2OBn), 3.57 (dd, J = 
10.2, 6.3 Hz, 1H, CHO(P)CH2OBn), 2.44–2.35 (m, 1H, HC=CHCH2CH2), 2.31–2.20 (m, 
1H, H2CH2CCHO(P)CH2OBn), 2.03–1.90 (m, 1H, HC=CHCH2CH2), 1.84 (d, J = 15.0 Hz, 
1H, H2CH2CCHO(P)CH2OBn), 1.79–1.66(m, 3H, H2CH2CCHO(P)CH2OBn, 
H2C=HCH2CH2CH2CH2CCHO(P)CH2OBn), 1.65–1.53 (m, 1H, H2C=HCH2CH2CH2CH2C 
CHO(P)CH2OBn), 1.44–1.36 (m, 1H, H2C=HCH2CH2CH2CH2CCHO(P)CH2OBn), 1.25–
1.13 (m, 1H, H2C=HCH2CH2CH2CH2CCHO(P)CH2OBn); 
13C NMR (126 MHz, CDCl3) δ 138.8, 138.1, 135.4 (d, JCP = 9.9 Hz), 128.3 (2C), 127.9, 
127.7 (2C), 127.6 (d, JCP = 3.7 Hz), 117.1, 76.9, 76.6 (d, JCP = 6.4 Hz), 76.0 (d, JCP = 6.4 
Hz), 73.1, 70.8 (d, JCP = 4.9 Hz), 34.9 (d, JCP = 6.1 Hz), 32.3, 30.9 (d, JCP = 4.2 Hz), 24.2, 
19.7; 
31P NMR (162 MHz, CDCl3) δ –9.17; 















































































































































































































































































































































































































































































































































































































































































































































































































5.2: A Modular Phosphate Tether-Mediated Divergent Strategy to Complex Polyols  
(Chapter 3) 
 
General procedure for RCM/CM/hydrogenation (Procedure A) 
 To a stirring solution of triene (S,S) in freshly distilled, freeze-degas-thawed 
dichloroethane4 (0.007 M) was added Hoveyda-Grubbs 2nd Gen. catalyst (HG-II) (3 mol%) 
and the reaction was refluxed for 2 hours.  After completion of RCM (monitored by TLC), 
the solvent was removed under reduced pressure and olefin cross partner [3–5 equivalent 
with respect to the triene (S,S)] dissolved in freeze-degas-thawed CH2Cl2 (0.1 M) was 
introduced, followed by addition of HG-II (3–5 mol%). It should be noted that the use of 
dichloromethane was critical for successful cross-metathesis reaction in order to avoid the 
formation of isomerized ketone by-products.  Cross-metathesis (CM) reaction in 
dichloroethane provided the isomerized ketone by-product (confirmed by 1H and 13C 
spectra) and the cross-metathesis product with 1:1 ratio both at 70 ºC and 90 ºC.  The 
reaction was refluxed for an additional 2–3 hours upon which the reaction showed the CM 
product formation along with some amounts of RCM starting material (S,S,SP).  The reaction 
mixture was cooled to RT and o-nitrobenzenesulfonyl hydrazine (o-NBSH) (12 equiv.) and 
Et3N (2 mL/g of o-NBSH) were added, upon which the reaction was stirred at RT overnight. 
The reaction mixture was quenched with sat. NaHCO3 (1 mL), and diluted with CH2Cl2 (10 
mL).  The aqueous layer was washed with CH2Cl2 (3x5 mL) and the combined organic 
layers were dried (Na2SO4), concentrated under reduced pressure and purified using flash 
column chromatography. 
  
                                                
(4) In CH2Cl2, the RCM appeared to be slower in the presence of HG-II. 
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General procedure for RCM/CM/hydrogenation (Procedure B) 
 To a stirring solution of triene (S,S) in freshly distilled, freeze-degas-thawed CH2Cl2 
(0.007 M) was added HG-II (3 mol%) and the reaction was refluxed for 2 hours.  After 
completion of RCM (monitored by TLC), the solvent was removed and olefin cross partner 
[3 equivalent with respect to the triene (S,S)] dissolved in freeze-degas-thawed CH2Cl2 (0.1 
M) was introduced, followed by addition of HG-II (3 mol%).  It should be noted that the use 
of dichloromethane was critical for successful CM reaction in order to avoid the formation 
of isomerized ketone by-products.  Cross-metathesis reaction in dichloroethane provided the 
isomerized ketone by-product (confirmed by 1H and 13C spectra) and the CM product with 
1:1 ratio both at 70 ºC and 90 ºC. The reaction was refluxed for an additional 2–3 hours 
upon which the reaction showed the CM product formation along with some amounts of 
RCM starting material (S,S,SP).  The reaction mixture was cooled to RT and o-
nitrobenzenesulfonyl hydrazine (o-NBSH) (12 equiv.) and Et3N (2 mL/g of o-NBSH) were 
added, upon which the reaction was stirred at RT overnight. The reaction mixture was 
quenched with sat. NaHCO3 (1 mL), and diluted with CH2Cl2 (10 mL).  The aqueous layer 
was washed with CH2Cl2 (3x5 mL) and the combined organic layers were dried (Na2SO4), 




General procedure for RCM/CM/hydrogenation and subsequent reduction with 
LiAlH4 (Procedure C) 
The above-mentioned procedure for one-pot RCM/CM/hydrogenation was followed 
and the crude product was purified using flash column chromatography.5  To a stirring 
solution of the hydrogenated product in dry THF (0.5 M), LiAlH4 (2–4 equiv.) was added 
portion wise at 0 ºC and the reaction was stirred at 0 ºC for 2 hours.  After the completion of 
reduction, the reaction was quenched via slow sequential addition of H2O (1 mL/g of 
LiAlH4), 10% NaOH (1 mL/g of LiAlH4), and H2O (3 mL/g of LiAlH4) [Feiser workup],6 
and the ice bath was removed and the reaction was stirred for 2 h.  The reaction was filtered 
through Celite® and washed with EtOAc (2x5 mL). The combined organic layers were 
concentrated under reduced pressure and purified using flash column chromatography. 
 
General procedure for RCM/CM/LiAlH4 reduction (Procedure D) 
To a stirring solution of triene (S,S) in freshly distilled, freeze-degas-thawed 
dichloroethane (0.007 M) was added HG-II (3 mol%) and the reaction was refluxed for 2 
hours.  After completion of RCM (monitored by TLC), the solvent was removed and olefin 
cross partner [3–5 equivalent with respect to the triene (S,S)] dissolved in freeze-degas-
thawed CH2Cl2 (0.1 M) was introduced, followed by addition of HG-II (3–6 mol%). The 
reaction was refluxed for an additional 2–3 hours upon which the reaction showed the CM 
product formation along with some amounts of RCM starting material (S,S,SP).  After the 
                                                
(5) Purification was necessary at this stage for subsequent successful LAH reduction. 
(6) Fieser, L.F.; Fieser, M. Reagents for Organic Synthesis Vol. 1, Wiley, New York 1967, pp 581–
595. 
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completion of CM, the solvent was evaporated under reduced pressure. The crude reaction 
mixture was then dissolved in dry THF (0.5 M) and cooled to 0 ºC.  To this solution LiAlH4 
(4 equiv.) was added portion wise and the reaction was stirred at 0 ºC for 2 hours.  After the 
completion of reduction, the reaction was quenched via slow sequential addition of H2O (1 
mL/g of LiAlH4), 10% NaOH (1 mL/g of LiAlH4), and H2O (3 mL/g of LiAlH4) [Feiser 
workup], and the ice bath was removed and the reaction was stirred for 2 h.  The reaction 
was filtered through Celite® and washed with EtOAc (2x5 mL). The combined organic 
layers were concentrated under reduced pressure and purified using flash column 
chromatography. 
General procedure for RCM/CM/LiAlH4 reduction (Procedure E) 
To a stirring solution of triene (S,S) in freshly distilled, freeze-degas-thawed CH2Cl2 
(0.007 M) was added HG-II (3 mol%) and the reaction was refluxed for 2 hours. After 
completion of RCM (monitored by TLC), the solvent was removed and olefin cross partner 
[3 equivalent with respect to the triene (S,S)] dissolved in freeze-degas-thawed CH2Cl2 (0.1 
M) was introduced, followed by addition of Hoveyda-Grubbs 2nd Gen. catalyst (3 mol%).  
The reaction was refluxed for an additional 2–3 hours upon which the reaction showed the 
CM product formation along with some amounts of RCM starting material (S,S,SP).  After 
the completion of CM, the solvent was evaporated under reduced pressure.  The crude 
reaction mixture was then dissolved in dry THF (0.5 M) and cooled to 0 ºC. To this solution 
LiAlH4 (4 equiv.) was added portion wise and the reaction was stirred at 0 ºC for 2 hours.  
After the completion of reduction, the reaction was quenched via slow sequential addition of 
H2O (1 mL/g of LiAlH4), 10% NaOH (1 mL/g of LiAlH4), and H2O (3 mL/g of LiAlH4) 
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[Feiser workup], and the ice bath was removed and the reaction was stirred for 2 h.  The 
reaction was filtered through Celite® and washed with EtOAc (2x5 mL).  The combined 
organic layers were concentrated under reduced pressure and purified using flash column 
chromatography. 
 
General procedure for RCM/CM/ LiAlH4 reduction and subsequent global 
hydrogenation (Procedure F) 
The above-mentioned procedure (D or E) was followed to obtain the reduced product and 
the crude product was dissolved in CH2Cl2 (0.1 M) and o-nitrobenzenesulfonyl hydrazine 
(o-NBSH) (20 equiv.) and Et3N (2 mL/g of o-NBSH) were added, upon which the reaction 
was stirred at RT overnight.  The reaction mixture was quenched with sat. NaHCO3 (1 mL) 
and diluted with CH2Cl2 (10 mL).  The aqueous layer was washed with CH2Cl2 (3x5 mL) 
and the combined organic layers were dried (Na2SO4), concentrated under reduced pressure 





methylbutyl)-2,9,10-trioxa-1-phosphabicyclo[4.3.1]dec-4-ene 1-oxide (3.6.3):  
 
Synthesized by following procedure A 
Yield: 40% over 3 reactions (72% avg/rxn, 12.4 mg isolated starting from 20 mg of triene) 
FTIR (thin film):  3400, 2974, 2285, 1630, 1288, 1209, 1101, 977, 848 cm-1; 
Optical Rotation: [α]D = + 17.34(c = 1, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.50–7.43 (m, 2H, aromatic), 7.40–7.29 (m, 5H, aromatic), 
7.21–7.16 (m, 2H, aromatic), 6.01 (ddd, J = 11.9, 3.0, 2.1 Hz, 1H, CH=CHCHOPCH2OBn), 
5.56 (ddd, J = 11.9, 3.9, 2.4 Hz, 1H, CH=CHCHOPCH2OBn), 5.27 (dddd, J = 5.3, 5.3, 2.6, 
2.6 Hz, 1H, CH=CHCHOPCH2OBn), 5.18 (dddd, JPH, = 24.6, JHH  =6.2, 4.1, 1.9 Hz, 1H, 
CH2CHOPCH=CH), 4.65–4.58 (m, 2H, CH2OCH2Ph), 4.58–4.47 (m, 2H, 4-BrC6H4CHOH, 
CH2CH2CHOP), 3.71 (ddd, J = 10.3, 5.1, 1.2 Hz, 1H, CH2OBn), 3.61 (dd, J = 10.2, 6.0 Hz, 
1H, CH2OBn), 2.16 (ddd, J = 14.7, 12.0, 6.2 Hz, 1H, CHOPCH2CHOP), 1.88 (d, J = 3.5 Hz, 
1H, OH), 1.87–1.71 (m, 2H, 4-BrC6H4CHOHCH(CH3)CH2, CH2CHOPCH2CHOP), 1.67 
(ddd, J = 14.6, 3.5, 2.0 Hz, 1H, CHOPCH2CHOP), 1.58–1.48 (m, 1H, 
CH2CHOPCH2CHOP), 1.48–1.40 (m, 1H, CH2CH2CHOPCH2CHOP), 1.39–1.30 (m, 1H, 
CH2CH2CHOPCH2CHOP), 0.88 (d, J = 6.7 Hz, 3H, 4-BrC6H4CHOHCH(CH3)CH2); 
13C NMR (126 MHz, CDCl3) δ 142.4, 137.5, 131.3 (2C), 129.9, 129.6, 128.5 (2C), 128.0 
(2C), 127.9, 127.7 (2C), 121.1, 77.3 (d, JCP = 6.8 Hz), 77.0, 76.8 (d, JCP = 7.2 Hz), 73.5, 
72.2 (d, JCP = 6.1 Hz), 71.2 (d, JCP = 12.2 Hz), 39.9, 34.8 (d, JCP = 6.0 Hz), 33.5 (d, JCP = 9.3 
Hz), 27.9, 14.0; 
31P NMR (162 MHz, CDCl3) δ –5.30; 
















Synthesized by following procedure C 
Yield: 26% over 4 reactions (71% avg/rxn, 10 mg isolated starting from 28 mg of triene); 
FTIR (thin film):  3365, 3294, 2943, 2872, 2349, 2872, 1631, 1485, 1454, 1070, 1028, 827, 
750, 698 cm-1; 
Optical Rotation: [α]D = + 5.0 (c = 0.12, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.50–7.44 (m, 2H, aromatic), 7.39–7.28 (m, 5H, aromatic), 
7.22–7.17 (m, 2H, aromatic), 5.71 (ddd, J = 11.5, 7.3, 1.4 Hz, 1H, 
CHOHCH=CHCHOHCH2OBn), 5.50 (ddd, J = 11.4, 7.3, 1.3 Hz, 1H, 
CHOHCH=CHCHOHCH2OBn), 4.85–4.77 (m, 1H, CHOHCH=CHCHOHCH2OBn), 4.75–
4.69 (m, 1H, CHOHCH=CHCHOHCH2OBn), 4.62–4.54 (m, 3H, 4-
BrC6H4CHOHCH(CH3)CH2,  CH2OCH2Ph), 3.88 (bs, 1H, OH), 3.76–3.68 (m, 1H, 
CH2CHOHCH2CHOHCH=CH), 3.50 (dd, J = 9.4, 4.1 Hz, 1H, CH2OBn), 3.45 (dd, J = 9.4, 
7.6 Hz, 1H, CH2OBn), 1.84–1.74 (m, 1H, 4-BrC6H4CHOHCH(CH3)CH2), 1.72–1.68 (m, 
1H, OH), 1.67–1.62 (m, 2H, CHOHCH2CHOH), 1.46–1.37 (m, 2H, 
CH2CH2CHOHCH2CHOH), 1.26 (s, 4H, OH, CH2CH2CHOHCH2CHOH), 0.88 (d, J = 6.8 
Hz, 3H, 4-BrC6H4CHOHCH(CH3)CH2). 
13C NMR (126 MHz, CDCl3) δ 142.5, 137.5, 136.5, 131.2 (2C), 129.2, 128.5 (2C), 128.0 
(2C), 127.99, 127.9 (2C), 120.9, 76.9, 73.6, 73.5, 67.3, 66.2, 62.9, 42.6, 40.0, 28.9, 28.8, 
14.3. 
















Synthesized by following procedure D 
Yield: 35% over 3 reactions (70% avg/rxn, 9.7 mg isolated starting from 20 mg of triene) 
FTIR (thin film): 3440, 3417, 3386, 2390, 1643, 1633, 1054, 698, 522 cm-1; 
Optical Rotation: [α]D = –4.81 (c = 0.22, CHCl3) 
1H NMR (500 MHz, CDCl3) δ 7.47–7.43 (m, 2H, aromatic), 7.37–7.29 (m, 5H, aromatic), 
7.18–7.12 (m, 2H, aromatic), 5.68 (ddd, J = 11.4, 7.6, 1.4 Hz, 1H, 
CHOHCH=CHcisCHOHCH2OBn), 5.61 (ddd, J = 15.6, 7.0, 1.0 Hz, 1H, 
CH=CHtransCHOHCH2CHOH), 5.53 (d, J = 6.2 Hz, 1H, CH=CHtransCHOHCH2CHOH), 
5.48 (ddd, J = 11.4, 7.4, 1.3 Hz, 1H, CH=CHcisCHOHCH2CHOH), 4.76 (dd, J = 7.9, 2.9 Hz, 
1H, CHOHCH=CHCHOHCH2OBn), 4.68 (ddd, J = 7.5, 4.1, 1.4 Hz, 1H, 
CHOHCH=CHCHOHCH2OBn), 4.59 (d, J = 5.1 Hz, 1H, 4-BrC6H4CHOHCH(CH3)CH2), 
4.56 (bs, 2H, CH2OBn ), 4.35 (dd, J = 6.6, 10.4 Hz, 1H, CH=CHCHOHCH2CHOH), 3.55 (s, 
1H, OH), 3.48 (dd, J = 9.5, 4.1 Hz, 1H, CH2OBn), 3.44 (dd, J = 9.5, 7.5 Hz, 1H, CH2OBn), 
3.16 (s, 1H, OH), 2.90 (s, 1H, OH), 2.52 (dd, J = 12.6, 6.7 Hz, 1H, 4-
BrC6H4CHOHCH(CH3)CH2 ), 2.46 (s, 1H, OH), 1.74 (ddd, J = 14.4, 8.7, 3.8 Hz, 1H, 
CHOHCH2CHOH), 1.61 (ddd, J = 14.3, 7.5, 3.3 Hz, 1H, CHOHCH2CHOH), 0.96 (d, J = 
6.8 Hz, 3H, 4-BrC6H4CHOHCH(CH3)CH2); 
13C NMR (126 MHz, CDCl3) δ 141.6, 137.5, 136.3, 133.8, 132.5, 131.1 (2C), 129.2, 128.5 
(2C), 128.1 (2C), 127.9, 127.9 (2C), 121.0, 76.6, 73.6, 73.5, 70.1, 67.2, 65.7, 43.3, 42.8, 
14.0; 















Synthesized by following procedure A 
Yield: 35% over 3 reactions (70% avg/rxn, 14.2 mg isolated staring from 30 mg of triene); 
FTIR (thin film): 3520, 3444, 2395, 1633, 1286, 1101, 973, 734 cm-1; 
Optical Rotation: [α]D = +21.57(c = 0.26, CHCl3);  
1H NMR (500 MHz, CDCl3) δ 7.42–7.28 (m, 10H, aromatic), 6.02 (ddd, J = 11.9, 3.0, 2.1 
Hz, 1H,CH=CHCHOPCH2OBn), 5.57 (ddd, J = 11.9, 3.9, 2.4 Hz, 1H, 
CH=CHCHOPCH2OBn), 5.28 (ddddd, J = 5.3, 5.3, 2.7, 2.7, 2.7 Hz, 1H, 
CH=CHCHOPCH2OBn), 5.19 (ddddd, JPH = 24.5, JHH = 6.2, 4.1, 1.8, 1.8 Hz, 1H, 
CH2CHOPCH=CH), 4.66–4.52 (m, 5H, CH2OCH2Ph, CH2CH2CH2CHOP), 3.84–3.77 (m, 
1H, CH2CHOHCH2OBn), 3.72 (ddd, J = 10.2, 5.1, 1.1 Hz, 1H, CH2OBn), 3.61 (dd, J = 
10.2, 6.1 Hz, 1H, CH2OBn), 3.50 (dd, J = 9.4, 3.1 Hz, 1H, CH2OBn), 3.32 (dd, J = 9.4, 7.9 
Hz, 1H, CH2OBn), 2.34 (d, J = 3.4 Hz, 1H, BnOCH2CHOHCH2CH2CH2CHOP), 2.22–2.12 
(m, 2H, CHOPCH2CHOP), 1.83–1.55 (m, 4H, BnOCH2CHOHCH2CH2CH2CHOP), 1.52–
1.37 (m, 2H, BnOCH2CHOHCH2CH2CH2CHOP); 
13C NMR (126 MHz, CDCl3) δ 137.8, 137.5, 129.9, 129.6, 128.5 (4C), 127.9, 127.8, 127.7 
(4C), 77.3 (d, JCP = 6.7 Hz), 76.6 (d, JCP = 6.8 Hz), 74.4, 73.5, 73.4, 72.1 (d, JCP = 6.0 Hz), 
71.2 (d, JCP = 12.2 Hz), 70.0, 35.4 (d, JCP = 9.3 Hz), 34.7 (d, JCP = 6.0 Hz), 32.4, 20.5; 
31P NMR (162 MHz, CDCl3) δ –5.46; 

















Synthesized by following procedure C 
Yield: 23% over 4 reactions (69% avg/rxn, 8 mg isolated starting from 20 mg of triene); 
FTIR (thin film): 3400, 3290, 2943, 2350, 1631, 1480, 1070, 750, 698 cm-1; 
Optical Rotation: [α]D = + 6.32(c = 0.19, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.40–7.28 (m, 10H, aromatic), 5.70 (ddd, J = 11.5, 7.5, 1.4 
Hz, 1H, CHOHCH=CHCHOHCH2OBn), 5.48 (ddd, J = 11.4, 7.4, 1.4 Hz, 1H, 
CHOHCH=CHCHOHCH2OBn), 4.80 (ddd, J = 10.4, 7.3, 3.4 Hz, 1H, 
CHOHCH=CHCHOHCH2OBn), 4.75–4.67 (m, 1H, CHOHCH=CHCHOHCH2OBn), 4.59–
4.53 (m, 4H, CH2OCH2Ph), 3.97–3.88 (m, 1H, CH2CHOHCH2CHOHCH=CH), 3.88–3.79 
(m, 1H, BnOCH2CHOHCH2CH2CH2), 3.56–3.41 (m, 4H, CH2OBn), 3.40–3.29 (m, 2H, 
BnOCH2CHOHCH2CH2CH2), 1.66 (ddd, J = 14.5, 7.5, 2.6 Hz, 1H, CHOHCH2CHOH), 
1.63–1.57 (m, 3H, CHOHCH2CHOH, BnOCH2CHOHCH2CH2CH2, OH), 1.53–1.35 (m, 6H, 
BnOCH2CHOHCH2CH2CH2CHOH); 
13C NMR (126 MHz, CDCl3) δ 137.9, 137.6, 136.5, 129.2, 128.5 (2C), 128.46 (2C), 127.9, 
127.85 (2C), 127.8, 127.7 (2C), 74.5, 73.6, 73.4, 73.3, 70.23, 68.8, 67.1, 66.1, 42.7, 37.2, 
32.8, 21.5; 





Synthesized by following procedure D 










FTIR (thin film):  3408, 3402, 3385, 2918, 2852, 2349, 1637, 1632, 1072, 1027, 972, 737, 
698 cm-1; 
Optical Rotation: [α]D = +5.92(c = 0.14, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.42–7.28 (m, 10H, aromatic), 5.75–5.64 (m, 2H, 
CHOHCH=CHCHOHCH2OBn), 5.62–5.53 (m, 1H, BnOCH2CHOHCH2CH=CHCHOH), 
5.48 (ddd, J = 11.3, 7.4, 1.3 Hz, 1H, BnOCH2CHOHCH2CH=CHCHOH), 4.78 (ddd, J = 
7.8, 7.8, 3.0 Hz, 1H, CHOHCH=CHCHOHCH2OBn), 4.70 (dddd, J = 7.5, 7.5, 4.3, 1.4 Hz, 
1H, CHOHCH2CHOHCH=CHCHOHCH2OBn), 4.59–4.52 (m, 4H, CH2OCH2Ph), 4.42–
4.35 (m, 1H, CHOHCH2CH=CHCHOH), 3.90–3.82 (m, 1H, BnOCH2CHOHCH2CH=CH), 
3.54–3.40 (m, 4H, BnOCH2CHOH, OH), 3.36 (dd, J = 9.5, 7.3 Hz, 2H, BnOCH2CHOH), 
2.30–2.13 (m, 4H, BnOCH2CHOHCH2CH=CH ), 1.77 (ddd, J = 14.3, 8.6, 3.6 Hz, 1H, 
CHOHCH2CHOH), 1.64 (ddd, J = 14.4, 7.7, 3.3 Hz, 1H, CHOHCH2CHOH); 
13C NMR (126 MHz, CDCl3) δ 137.8, 137.6, 136.3, 135.5, 129.3, 128.5 (2C), 128.4 (2C), 
127.9, 127.85 (2C), 127.8, 127.7 (2C), 126.7, 77.2, 73.9, 73.6, 73.4, 73.3, 69.9, 67.1, 65.6, 
42.6, 36.2; 





Synthesized by following procedure F 
Yield: 34% over 4 reactions (77% avg/rxn, 12 mg isolated starting from 28 mg of triene); 
FTIR (thin film):  3283, 2943, 2394, 1454, 1093, 1076, 737 cm-1; 
Optical Rotation: [α]D = + 2.80 (c = 0.25, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.40–7.29 (m, 10H, aromatic), 4.60–4.52 (m, 4H, 
CH2OCH2Ph), 4.04–3.91 (m, 2H, CHOHCH2CHOH), 3.92–3.76 (m, 2H, CHOHCH2OBn), 







BnOCH2CHOH), 2.80 (s, 1H, OH), 2.61 (s, 1H, OH), 2.40 (bs, 1H, OH), 1.70–1.37 (m, 
13H, aliphatic, OH). 
13C NMR (126 MHz, CDCl3) δ 137.9, 137.8, 128.5 (4C), 127.9, 127.8, 127.77 (2C), 127.75 
(2C), 74.3, 74.5, 73.3 (2C), 70.4, 70.3, 69.3, 69.0, 42.3, 37.2, 33.5, 32.8, 29.1, 21.6. 




























































































































5.3. Phosphate tether-mediated approach towards the synthesis of the C9–C25 








To a solution of α,β-unsaturated furan 4.20.4 (1 mmol) dissolved in tBuOH-H2O (1:1, 0.2 M 
each) were added AD-mix-α (1.4 g/mmol) and CH3SO2NH2 (2 mmol) at room temperature. 
The orange colored reaction mixture was then stirred at room temperature for 24 hours. The 
reaction mixture was quenched with solid Na2SO3 and stirred vigorously for several hours 
till the disappearance of the yellow color. The reaction mixture was filtered through celite, 
the aqueous layer was extracted with EtOAc (2 X 20 mL) and evaporated after drying over 
Na2SO4. The crude product was purified via flash chromatography 
Yield: 78% (886 mg isolated as a cream colored solid from 1g of α,β-unsaturated furan 
4.20.4); 
FTIR (thin film): 3344, 1732, 1497, 1319, 1119, 1014, 795 cm-1; 
Optical Rotation: [α]D = +3.13 (c = 0.6, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 6.40 (dd, J = 3.3, 0.9 Hz, 1H), 6.28 (d, J = 3.3 Hz, 1H), 4.98 
(d, J = 2.7 Hz, 1H), 4.49 (d, J = 2.7 Hz, 1H), 4.32 (d, J = 7.1 Hz, 1H), 4.29 (d, J = 7.1 Hz, 
1H), 3.10 (s, 1H), 1.32 (t, J = 7.1 Hz, 3H), 1.20 (d, J = 6.1 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 172.2, 154.9, 121.6, 112.1, 110.4, 72.2, 68.7, 62.6, 14.1; 













(not numbered in the scheme)
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To a solution of dihydroxyled bromofuran 4.20.4A(1 mmol) in CH2Cl2 (0.02 M) was added 
2,2-DMP (0.09M) and PPTS (catalytic amount) at room temperature. The reaction was 
stirred at room temperature for 24 hours till the TLC showed complete consumption of 
starting material. The reaction was quenched with solid NaHCO3 and the solvent was 
evaporated. The crude product was purified via flash chromatography 
Yield: 79% (isolated as a colorless oil from 117 mg of dihydroxyled bromofuran 4.20.4A); 
FTIR (thin film): 1952, 1751, 1466, 1381, 1196, 1103, 1018, 756 cm-1; 
Optical Rotation: [α]D = +90.4 (c = 0.13, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 6.43 (d, J = 3.4 Hz, 1H), 6.31 (d, J = 3.3 Hz, 1H), 5.12 (d, J 
= 7.5 Hz, 1H), 4.72 (d, J = 7.5 Hz, 1H), 4.26 (dd, J = 7.1, 3.2 Hz, 1H), 4.24 (dd, J = 7.1, 3.1 
Hz, 1H), 1.56 (s, 3H), 1.53 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 169.6, 151.8, 123.1, 112.3, 112.2, 112.1, 77.4, 74.0, 61.7, 
26.7, 26.1, 14.1; 























To a solution of bicyclo[4.3.1]phosphate 4.20.1 dissolved in THF (0.12 M) was added 9-
BBN (3 mmol, dissolved in THF, 0.5M) dropwise. The resulting mixture was left stirring at 
room temperature for 3 h till the disappearance of the starting material monitored by TLC. 
Reaction mixture was quenched by the addition of NaBO3•4H2O (9 mmol) and H2O (1.8 M) 
at 0 ºC. After removing the ice-bath the reaction was stirred at room temperature and 
additional H2O (0.9 M) was added. After completion of the oxidation as monitored by TLC, 
the crude solution was dried over Na2SO4 and filtered through celite. The crude product was 
purified via flash chromatography. 
Yield: 84% (1.6 g isolated as white solid starting from 1.78g of bicyclic phosphate);  
FTIR (thin film): 3418, 1360, 1286, 1059, 910, 771 cm-1; 
Optical Rotation: [α]D =  –94.5 (c = 1.75, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 5.97 (dddd, J = 12.0, 6.8, 3.2, 2.1 Hz, 1H), 5.54 (ddd, J = 
11.9, 4.0, 2.6 Hz, 1H), 5.15 (dqd, J PH= 24.6, 4.0, 1.9 Hz, 1H), 4.93 (ddq, J = 14.3, 5.6, 2.8 
Hz, 1H), 4.77 (dddt, J = 11.9, 8.5, 3.5, 1.6 Hz, 1H), 4.32 (ddd, J = 27.8, 14.7, 6.7 Hz, 1H), 
3.75 (td, J = 9.6, 8.4, 4.5 Hz, 1H), 3.69 (dt, J = 10.8, 5.3 Hz, 1H), 2.53 (s, 1H), 2.18 (ddd, J 
= 14.7, 11.9, 6.2 Hz, 1H), 1.90 (ddt, J = 13.7, 9.2, 4.9 Hz, 1H), 1.82–1.77 (m, 1H), 1.74 (dq, 
J = 14.8, 1.9 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 129.8, 127.8, 77.4 (d, JCP = 6.5 Hz), 74.4 (d, JCP = 6.5 Hz), 
63.0 (d, JCP = 6.5 Hz), 57.6, 38.1 (d, JCP = 9.1 Hz), 34.9 (d, JCP = 6.0 Hz); 












(not numbered in the scheme)
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To a solution of alcohol 4.20.1A (1 mmol) dissolved in CH2Cl2 (0.1 M) were added Ag2O 
(4.5 mmol) and BnBr (3.3 mmol) at room temperature. The reaction was stirred for 15 hours 
at room temperature after which the TLC showed 80% consumption of starting material. An 
additional batch of Ag2O (3 mmol) and BnBr (2.2 mmol) were added to the reaction mixture 
and stirred for 5 hours after which the TLC showed complete consumption of starting 
material. The reaction was filtered through celite and evaporated. The crude product was 
purified via flash chromatography. 
Yield: 88% (2.05 g isolated as colorless oil from 1.7 g); 
FTIR (thin film): 2928, 2359, 1298, 1261, 1094, 1067, 972, 741 cm-1; 
Optical Rotation: [α]D = –83.47(c = 0.54, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.41–7.28 (m, 5H), 6.04 (dddd, J = 12.0, 6.8, 3.2, 2.1 Hz, 
1H), 5.58 (ddd, J = 11.8, 4.0, 2.5 Hz, 1H), 5.26–5.13 (m, 1H), 5.02 (ddq, J = 14.8, 5.7, 2.7 
Hz, 1H), 4.84 (dddd, J = 11.9, 8.2, 3.9, 1.8 Hz, 1H), 4.51 (d, J = 2.0 Hz, 2H), 4.39 (ddd, J = 
27.7, 14.8, 6.7 Hz, 1H), 3.66 (ddd, J = 9.6, 8.8, 4.5 Hz, 1H), 3.60 (dt, J = 9.8, 5.1 Hz, 1H), 
2.22 (ddd, J = 14.6, 12.0, 6.2 Hz, 1H), 2.05–1.96 (m, 1H), 1.91 (dddt, J = 14.2, 8.6, 5.3, 4.2 
Hz, 1H), 1.76 (dtd, J = 14.6, 2.3, 1.4 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 138.1, 129.8, 128.4 (2C), 127.9, 127.7, 127.67 (2C), 77.2, 
74.0 (d, JCP = 6.7 Hz), 73.2, 65.0, 63.0 (d, JCP = 6.4 Hz), 36.0 (d, JCP = 9.5 Hz), 35.0 (d, JCP 
= 6.1 Hz); 























 To a flask containing CuCN (3 mmol) and LiCl (7 mmol), weighted inside the glove box, 
was added THF (0.1 M) and stirred at room temperature for 15 minutes. A pale green 
coloration was observed. The reaction was cooled to –30 ºC followed by slow addition of a 
2.0M solution of Me2Zn in THF (3 mmol). The reaction mixture turned colorless. The 
reaction was stirred for 35-40 minutes at –30 ºC at which point a solution of bicyclic 
phosphate 4.18.5 in THF (0.1 M) was cannulated into the flask with the cuprate. The 
reaction was removed from the dry ice bath and allowed to warm to room temperature. 
Upon completion after 2.5 hours, the reaction is acidified to a pH of 1 with 10% aq. HCl 
(0.16 M). The reaction was stirred for 15 minutes and the aqueous layer was extracted with 
CH2Cl2 (4x 20) and the combined organic layers washed with H2O (1x 3). The reaction was 
concentrated under reduced pressure and then filtered through a celite pad again to get rid of 
the salt particles. The celite layer was washed with EtOAc and evaporated again to afford as 
yellowish colored clear oil that was carried on without further purification.  
To a flask containing the crude acid was added THF (0.08 M). The reaction mixture was 
cooled to 0 ºC followed by the addition of a 65% solution of Red-Al in toluene (6 mmol). 
The reaction was brought to rt and stirred for 12 hours. The reaction was quenched with 
NH4Cl (sat’d aq.) and extracted with CH2Cl2 (6x). The organic layer was dried over 
anhydrous Na2SO4 and the solvent was evaporated. The crude product was purified via flash 
chromatography. 














(not numbered in the scheme)
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FTIR (thin film):  3408, 2939, 2868, 2359, 2341, 1637, 1454, 1094, 912, 
735, 696, 667 cm-1; 
Optical Rotation: [α]D = +12.39 (c = 1.34, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.32–7.18 (m, 5H), 5.76–5.68 (m, 1H), 5.08–5.01 (m, 2H), 
4.47 (s, 2H), 4.15–4.04 (m, 1H), 3.72–3.65 (m, 2H), 3.62 (ddd, J = 9.4, 8.5, 4.2 Hz, 1H), 
3.49–3.42 (m, 1H), 2.56 (s, 1H), 2.21–2.13 (m, 1H), 1.89–1.81 (m, 1H), 1.66 (dddd, J = 
14.5, 5.5, 4.3, 2.8 Hz, 1H), 1.57–1.54 (m, 2H), 0.96 (d, J = 6.8 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 140.5, 137.8, 128.4 (2C), 127.7, 127.6 (2C), 116.0, 73.3, 
71.6, 69.2, 69.0, 44.3, 39.9, 36.3, 16.0; 





To a solution containing diol 4.18.5A (1 mmol) dissolved in CH2Cl2 (0.27 M), was added 
2,2-DMP (0.27 M) and PPTS (0.05 mmol) and the reaction was stirred for 1 hour at room 
temperature. Upon completion of the reaction, (<10% starting material remaining after 1 
hour), the reaction was first diluted with CH2Cl2 and quenched with NaHCO3 (satd.), dried 
over Na2SO4. The solvent was evaporated and purified via flash chromatography. 
Yield: 87% (445 mg isolated as colorless oil from 444 mg of diol 4.18.5A);  
FTIR (thin film):  2984, 2937, 2870, 2341, 1454, 1379, 1225, 1099, 989, 912, 735,  
696 cm-1; 
Optical Rotation: [α]D =  +23.8 (c = 0.4, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.39–7.27 (m, 5H), 5.84 (ddd, J = 17.7, 10.5, 7.2 Hz, 1H), 
5.06–5.03 (m, 1H), 5.03–5.01 (m, 1H), 4.54–4.46 (m, 2H), 3.95 (dq, J = 9.8, 6.4 Hz, 1H), 










(not numbered in the scheme) 4.22.1
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2H), 1.71 (ddd, J = 12.7, 9.6, 5.9 Hz, 1H), 1.51 (ddd, J = 12.7, 9.8, 6.2 Hz, 1H), 1.33 (s, 
3H), 1.32 (s, 3H), 1.00 (d, J = 6.9 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 140.8, 138.5, 128.4 (2C), 127.7 (2C), 127.5, 114.4, 100.3, 
73.1, 69.9, 66.7, 63.9, 42.0, 36.1, 36.0, 24.7, 24.3, 15.2; 






The boronic ester was synthesized following similar literature reports.1  To a solution of 
protected diol 4.22.1 (1 mmol) and vinylboronic acid pinacol ester (1.6 mmol) dissolved in 
degassed toluene (0.2 M) at 80 ºC was added dropwise a solution of the HG-II cat (10 
mol%) dissolved in toluene (0.02M). A second batch of vinylboronic acid pinacol ester (1.6 
mmol) was added to the reaction mixture after 20 minutes (TLC showed complete 
consumption of vinylboronic acid pinacol ester), followed by dropwise addition of second 
batch of the HG-II cat (10 mol%) in toluene (0.02 M). The reaction mixture was heated for 
1 hour at 80 ºC after which the TLC showed complete consumption of protected diol. The 
reaction mixture was cooled to room temperature and the solvent was evaporated and 
purified via flash chromatography. 
Yield: 98% (137mg isolated as yellow colored oil from 99 mg of protected diol 4.22.1); 
FTIR (thin film): 2980, 2363, 1722, 1637, 1371, 1223, 1146, 851, 771 cm-1; 
Optical Rotation: [α]D =  +14.1 (c = 1.02, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.37–7.27 (m, 5H), 6.60 (dd, J = 18.2, 6.9 Hz, 1H), 5.47 (dd, 
J = 18.2, 1.3 Hz, 1H), 4.50 (d, J = 1.4 Hz, 2H), 3.94 (dq, J = 9.8, 6.3 Hz, 1H), 3.73 (dt, J = 












12.8, 9.6, 5.9 Hz, 1H), 1.49 (ddd, J = 12.8, 9.8, 6.3 Hz, 1H), 1.32 (s, 3H), 1.32 (s, 3H), 1.28 
(s, 12H), 1.00 (d, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 155.7, 138.4, 128.3 (2C), 127.7 (2C), 127.5, 118.7, 100.3, 
83.0 (2C), 73.1, 69.4, 66.6, 63.8, 43.6, 36.0, 35.6, 24.8 (2C), 24.76 (2C), 24.7, 24.4, 14.6; 








The Suzuki-Miyaura coupling was performed following the literature procedure reported by 
Organ and coworkers.2  To a stirred solution of boronic ester 4.24.1(1.5 mmol) dissolved in 
degassed THF (0.25 M) was added Pd-PEPSI-IPent catalyst (2 mol%). The reaction 
flask/vial was then purged with Argon (3X). Bromo-furan compound 4.19.3 (1 mmol) was 
added to the solution followed by the addition of 5M KOH (4 mmol). The reaction mixture 
was heated at 70 ºC for 7 hours after which TLC showed complete consumption of starting 
material. The reaction mixture was cooled to room temperature and extracted with EtOAc 
(3x). The combined organic layer was dried over Na2SO4 and the solvent was evaporated. 
The solvent was evaporated and purified via flash chromatography. 
Yield: 56% (9.5 mg isolated as pale yellow colored oil starting from 10 mg of bromofuran 
compound 4.19.3);  
FTIR (thin film): 2955, 1751, 1373, 1227, 1103, 702 cm-1; 
Optical Rotation: [α]D = +54.4 (c = 0.16, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.50–7.03 (m, 5H), 6.40 (d, J = 3.3 Hz, 1H), 6.22–6.19 (m, 
2H), 6.14 (d, J = 3.2 Hz, 1H), 5.17 (d, J = 7.4 Hz, 1H), 4.76 (d, J = 7.4 Hz, 1H), 4.50 (d, J = 





















6.3 Hz, 1H), 3.71 (dt, J = 9.6, 6.3 Hz, 1H), 3.61–3.50 (m, 2H), 2.43–2.32 (m, 1H), 1.78 (q, J 
= 6.4 Hz, 2H), 1.76–1.70 (m, 1H), 1.57(s, 3H), 1.55 (s, 3H), 1.54–1.49 (m, 1H), 1.33 (s, 6H), 
1.27 (t, J = 7.2 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 169.9, 154.2, 148.5, 138.4, 132.6, 128.4 (2C), 127.7 (2C), 
127.5, 118.3, 112.0, 111.2, 107.0, 100.4, 77.6, 74.4, 73.1, 70.0, 66.6, 63.9, 61.6, 41.2, 36.1, 
36.0, 26.7, 26.2, 24.6, 24.4, 15.3, 14.1; 





To a solution of phosphonium ylide (1.9 mmol) dissolved in THF (0.28 M) was added 
tBuOK (1.8 mmol) in one portion at 0 ºC. An orange coloration was observed upon the 
addition of tBuOK. A solution of 5-bromo-2-furaldehyde (4.20.3) in THF (0.57 M) was 
added immediately to this mixture at 0 ºC producing a color change from orange to yellow. 
The reaction was stirred at 0 ºC for 30 minutes after which the TLC showed complete 
consumption of the starting material. The reaction mixture was quenched with the addition 
of H2O (11 mL).  The layers were separated and extracted with Et2O (3X 20 mL) and the 
combined layer was washed with, brine and dried over Na2SO4. The solvent was evaporated 
under continuous Argon flow and purified via flash chromatography using pentane.7 
Yield: 65% (70 mg isolated as colorless oil that turned pale yellow after few days of storing 
in Et2O under Argon at –20 ºC from 100 mg of 5-bromo-2-furaldehyde); trans/cis: 6:1; 
                                                
[7] The Wittig product was found to be very unstable at room temperature (rapid color 
change from pale yellow to black was observed within 24 hours when stored at bench top 
and decomposition occurred). But the product was relatively stable when stored in ether 
under Argon at 0 ºC for few days. For this purpose, the product was used in next reaction 
immediately after purification.  
 






FTIR (thin film): 3026, 1784, 1686, 1489, 1207, 1192, 1124, 1011, 951, 779 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.32 (d, J = 3.3 Hz, 1H), 6.22 (d, J = 3.4 Hz, 1H), 6.15 (dq, J 
= 11.7, 1.8 Hz, 1H), 5.68 (dq, J = 11.7, 7.3 Hz, 1H), 1.97 (dd, J = 7.3, 1.7 Hz, 3H); 





To a solution of Weinreb amide 4.27.2 (1 mmol) dissolved in THF (0.3 M) was added a 
solution of propenylmagnesium bromide (0.5 M in THF, 2 mmol) at 0 ºC. After 30 minutes 
of stirring at 0 ºC, the reaction was quenched with NH4Cl (5 mL) at 0 ºC and stirred at 
ambient temperature till the effervescence ceased. The layers were separated and extracted 
with Et2O (3X 20 mL) and the combined layer was washed with H2O, brine and dried over 
Na2SO4. The solvent was evaporated and purified via flash chromatography. 
Yield: 95% (1.77 g isolated as colorless oil from 2 g of Weinreb amide 4.27.2); 
FTIR (neat): 2916, 1690, 1620, 1512, 1250, 1095, 818 cm-1; 
Optical Rotation: [α]D = +9.4 (c = 0.16, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.25–7.21 (m, 2H), 6.92 (dt, J = 15.7, 6.9 Hz, 1H), 6.88–6.85 
(m, 2H), 6.21 (dq, J = 15.6, 1.7 Hz, 1H), 4.45 (d, J = 11.7 Hz, 1H), 4.41 (d, J = 11.7 Hz, 
1H), 3.81 (s, 3H), 3.67 (dd, J = 9.2, 7.3 Hz, 1H), 3.42 (dd, J = 9.2, 6.0 Hz, 1H), 3.15–3.05 
(m, 1H), 1.90 (dd, J = 6.9, 1.7 Hz, 3H), 1.10 (d, J = 7.0 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 202.1, 159.1, 143.0, 130.9, 130.3, 129.2 (2C), 113.7 (2C), 
72.9, 71.8, 55.3, 44.0, 18.3, 14.1; 


















The substituted allylic alcohol was prepared following the literature procedure reported by 
Chandrasekhar and coworkers.3 To a solution of enone 4.27.3 (1 mmol) dissolved in THF 
(0.33 M) was added a solution of (R)-2-methyl-CBS-oxazaborolidine (1M in Toluene, 2 
mmol) at –40 ºC. After 10 minutes of stirring at –40 ºC, BH3•DMS (5 mmol) was added and 
the reaction was stirred at – 40 ºC for 2 additional hours. Upon completion of the reaction, 
monitored by TLC, the reaction was quenched with EtOH (4 mL) at -40 ºC and stirred at 
ambient temperature. The layers were separated and extracted with Et2O (3X 30 mL) and the 
combined layer was washed with H2O, brine and dried over Na2SO4. The solvent was 
evaporated and purified via flash chromatography. 
Yield: 77%( 931 mg isolated as colorless oil starting from 1.2 g of enone); dr: 8:1; 
FTIR (thin film): 3421, 2959, 2914, 2854, 1610, 1512, 1248, 1090, 966, 771 cm-1; 
Optical Rotation: [α]D = +26.0 (c = 0.21, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.29–7.23 (m, 2H), 6.91–6.87 (m, 2H), 5.66 (dqd, J = 15.3, 
6.5, 0.9 Hz, 1H), 5.45 (ddd, J = 15.2, 7.5, 1.6 Hz, 1H), 4.46 (s, 2H), 3.93 (t, J = 7.5 Hz, 1H), 
3.82 (s, 3H), 3.57 (dd, J = 9.2, 4.3 Hz, 1H), 3.43 (dd, J = 9.2, 7.6 Hz, 1H), 3.33 (s, 1H), 1.87 
(qd, J = 7.3, 4.3 Hz, 1H), 1.71 (dd, J = 6.4, 1.6 Hz, 3H), 0.85 (d, J = 7.0 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 159.2, 132.5, 129.9, 129.3 (2C), 127.7, 113.8 (2C), 77.7, 
74.6, 73.0, 55.3, 38.7, 17.7, 13.7; 




















To a solution of allylic alcohol 4.26.7 (1 mmol) dissolved in degassed CH2Cl2 (0.1 M) was 
added propenyl bromofuran 4.26.6 (3 mmol) followed by the HG-II catalyst (6 mol%) and 
para-benzoquinone (10 mol%). The reaction mixture was refluxed for 3 hours after which 
the TLC showed significant consumption of allylic alcohol (< 20% starting material 
remained).8  The reaction mixture was cooled to room temperature and the solvent was 
evaporated.  The crude product was purified via flash chromatography. 
Yield: 75% (57.3 mg isolated as green colored oil from 50 mg of allylic alcohol 4.26.7); 
FTIR (thin film): 3431, 2905, 2359, 1612, 1514, 1248, 820 cm-1; 
Optical Rotation: [α]D = –9.8 (c = 0.5, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.29–7.22 (m, 2H), 6.90–6.86 (m, 2H), 6.35 (dd, J = 15.8, 
1.4 Hz, 1H), 6.28 (d, J = 3.4 Hz, 1H), 6.20–6.14 (m, 2H), 4.46 (s, 2H), 4.21–4.13 (m, 1H), 
3.81 (s, 3H), 3.63 (dd, J = 9.2, 3.9 Hz, 1H), 3.55 (d, J = 3.8 Hz, 1H), 3.45 (dd, J = 9.3, 7.2 
Hz, 1H), 1.95 (ddt, J = 10.9, 7.0, 3.9 Hz, 1H), 0.97 (d, J = 7.0 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 159.3, 154.6, 130.5, 129.7, 129.4 (2C), 121.2, 118, 113.8 
(2C), 112.9, 110, 76.6, 74.2, 73.1, 55.3, 38.9, 13.9; 
HRMS cald for C18H21BrO4SiNa (M+Na)+ 403.0521; found: 403.0505, 405.0489 (TOF MS 
ES+). 
  
                                                
[8] It is important to note here that the reaction produced lesser yield if run for more that 3 





















To a flask containing alcohol 4.26.5 (1 mmol) dissolved in CH2Cl2 (0.1 M) was added 2,6-
lutidine (4 mmol). The reaction mixture was cooled to -78 ºC and TBSOTf (2 mmol) was 
added drop wise. The reaction mixture was stirred for 1 hour at -78 ºC till the complete 
consumption of starting material, monitored by TLC. The reaction was quenched with 
NH4Cl (5 mL). The layers were separated and extracted with CH2Cl2 (2X 20 mL). The 
combined organic layer was dried over Na2SO4, the solvent was evaporated and purified via 
flash chromatography. 
Yield: 88% (66.5 mg isolated as colorless oil that turned pale yellow color after few days of 
storing it under Argon atmosphere at – 20 ºC starting from 57 mg of alcohol 4.26.5); 
FTIR (thin film):  2928, 2855, 2359, 1612, 1512, 1248, 835, 775 cm-1; 
Optical Rotation: [α]D =  +2.4 (c = 0.38, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.28–7.24 (m, 2H), 6.91–6.84 (m, 2H), 6.28 (d, J = 3.3 Hz, 
1H), 6.20 (dd, J = 15.8, 1.1 Hz, 1H), 6.13 (d, J = 3.3 Hz, 1H), 6.10 (dd, J = 15.8, 6.2 Hz, 
1H), 4.46 (d, J = 11.6 Hz, 1H), 4.39 (d, J = 11.6 Hz, 1H), 4.30 (ddd, J = 6.4, 5.5, 1.2 Hz, 
1H), 3.82 (s, 3H), 3.44 (dd, J = 9.3, 6.4 Hz, 1H), 3.34 (dd, J = 9.3, 6.2 Hz, 1H), 2.05–1.96 
(m, 1H), 0.93–0.86 (m, 12H), 0.06 (s, 3H), 0.02 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 159.0, 154.8, 130.7, 130.5, 129.2 (2C), 121.0, 117.7, 113.7 
(2C), 112.9, 109.5, 74.0, 72.6, 71.9, 55.3, 40.5, 25.9 (3C), 18.2, 12.7, –4.3, –4.9; 





















The dihydroxylation of furan was achieved by following the literature procedure reported by 
Phillips and coworkers.4 To a flask containing compound 4.26.2 (1 mmol) dissolved in 
tBuOH-H2O (1:1, 0.2 M each) were added OsO4 (2 mol%), CH3SO2NH2 (2 mmol), AD-
mix-α (1.4 g/mmol) and (DHQ)2PHAL (4 mol%) at 0 ºC. The orange colored reaction 
mixture was then stirred at 0 ºC for 2 days in dark. The reaction mixture was quenched with 
solid Na2SO3 and stirred vigorously for several hours till the disappearance of the yellow 
color. The reaction mixture was filtered through celite, the aqueous layer was extracted with 
EtOAc (2 X 20 mL) and evaporated after drying over Na2SO4. The crude product was 
purified via flash chromatography. 
Yield: 69% (17 mg isolated as colorless oil starting from 23 mg of 4.26.2); ds: 20:1; 
FTIR (thin film): 3369, 2953, 2928, 2856, 2359, 1612, 1512, 1250, 1038, 835 cm-1; 
Optical Rotation: [α]D = +13.0 (c = 0.28, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.26–7.22 (m, 2H), 6.91–6.87 (m, 2H), 6.31 (dd, J = 3.3, 0.8 
Hz, 1H), 6.27 (d, J = 3.3 Hz, 1H), 4.71 (dd, J = 6.8, 3.6 Hz, 1H), 4.55 (d, J = 5.3 Hz, 1H), 
4.50 (d, J = 11.4 Hz, 1H), 4.44 (d, J = 11.4 Hz, 1H), 3.82 (s, 3H), 3.81–3.79 (m, 1H), 3.72 
(dd, J = 6.3, 2.4 Hz, 1H), 3.59 (dd, J = 9.2, 7.7 Hz, 1H), 3.32 (dd, J = 9.1, 3.2 Hz, 1H), 3.00 
(d, J = 6.8 Hz, 1H), 2.11 (tdd, J = 10.0, 4.9, 3.3 Hz, 1H), 0.96 (d, J = 7.2 Hz, 3H), 0.90 (s, 
9H), 0.13 (s, 3H), 0.05 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 159.4, 157.3 129.6 (2C), 129.1, 120.9, 113.9 (2C), 111.9, 



























To a stirred solution of boronic ester 4.24.1 (1.5 mmol) and furan 4.26.1 (1 mmol) dissolved 
in degassed THF (0.1 M) were added Pd(PPh3)4 (20 mol%) and K3PO4 (4 mmol) under 
argon atmosphere. The reaction mixture was then purged with Argon (3x) and was refluxed 
for 6 hours after which the TLC showed significant consumption of starting material (<10% 
of furan remained unreacted). The reaction mixture was cooled to room temperature and 
quenched with H2O (2 mL). The organic layer was extracted with EtOAc (3 X 20 mL) and 
purified via flash chromatography. 
Yield: 50% (65 mg isolated starting from 92 mg of furan 4.26.1); 
FTIR (thin film): 3416, 2930, 2359, 1715, 1614, 1514, 1454, 1379, 1250, 1097, 837 cm-1; 
Optical Rotation: [α]D = +20.6 (c = 0.11, CHCl3); 
1H NMR  (500 MHz, Chloroform-d) δ 7.38–7.27 (m, 5H), 7.26–7.22 (m, 2H), 6.91–6.85 (m, 
2H), 6.29 (d, J = 3.3 Hz, 1H), 6.19 (d, J = 16.2 Hz, 1H), 6.15–6.09 (m, 2H), 4.70 (t, J = 4.9 
Hz, 1H), 4.51 (d, J = 8.5 Hz, 1H), 4.50 (d, J = 2.0 Hz, 2H), 4.48–4.40 (m, 2H), 3.94 (dq, J = 
9.9, 6.5 Hz, 1H), 3.88–3.83 (m, 1H), 3.81 (s, 3H), 3.76 – 3.70 (m, 1H), 3.69–3.66 (m, 1H), 
3.61 (dd, J = 9.1, 8.0 Hz, 1H), 3.54 (td, J = 6.3, 2.9 Hz, 2H), 3.28 (dd, J = 9.1, 3.7 Hz, 1H), 
3.06 (d, J = 5.4 Hz, 1H), 2.37 (q, J = 6.8 Hz, 1H), 2.17–2.07 (m, 1H), 1.77 (q, J = 6.4 Hz, 
2H), 1.75–1.69 (m, 1H), 1.52 (ddd, J = 12.7, 9.8, 6.2 Hz, 1H), 1.32 (s, 3H), 1.31 (s, 3H), 





















13C NMR (126 MHz, CDCl3) δ 159.4, 153.5, 152.8, 138.5, 131.4, 129.5 (2C), 129.2, 128.3 
(2C), 127.7 (2C), 127.5, 118.6, 113.9 (2C), 108.7, 107.1, 100.4, 75.0, 74.8, 73.1, 73.06, 
70.6, 69.9, 68.1, 66.7, 63.9, 55.2, 41.3, 36.2, 36.0, 35.9, 25.9 (3C), 24.6, 24.4, 18.2, 15.5, 
15.0, –4.4, –4.6; 







To a stirred solution of compound 4.28.1 (1mmol) dissolved in CH2Cl2 (0.06 M) were added 
o-NBSH (15 mmol) and Et3N (2 ml/g) under argon atmosphere at room temperature 
producing an orange-colored heterogeneous reaction mixture. The reaction mixture was then 
stirred for 15 hours at room temperature after which the reaction mixture became clear and a 
dark orange coloration was observed. A second batch of o-NBSH (15 mmol) and Et3N (2 
ml/g) were added and the reaction was stirred for additional 15 hours. The reaction was 
diluted with EtOAc (10 mL), extracted with saturated aqueous NaHCO3 (7 mL) followed by 
washing with EtOAc (2 x 20 mL). The combined organic layers were dried (Na2SO4) and 
concentrated under reduced pressure. The crude product was purified via flash 
chromatography. 
Yield: 84% (33 mg isolated as yellow colored sticky liquid from 40 mg of Suzuki-Miyaura 
product); 
FTIR (thin film): 3400, 2930, 2856, 1512, 1458, 1377, 1248, 1095, 1038, 835, 775 cm-1; 
Optical Rotation: [α]D = +9.2 (c = 0.3, CHCl3); 
1H NMR  (500 MHz, Chloroform-d) δ 7.38–7.28 (m, 5H), 7.26–7.22 (m, 2H), 6.92–6.85 (m, 

















2.0 Hz, 2H), 4.47 (d, J = 4.1 Hz, 2H), 4.45 – 4.43 (m, 1H), 4.03–3.89 (m, 1H), 3.86–3.82 
(m, 1H), 3.81 (s, 3H), 3.65 (dd, J = 5.3, 2.4 Hz, 1H), 3.61 (dd, J = 9.1, 7.9 Hz, 1H), 3.58–
3.51 (m, 3H), 3.28 (dd, J = 9.1, 3.8 Hz, 1H), 3.06 (d, J = 5.1 Hz, 1H), 2.69 (ddd, J = 15.7, 
10.7, 5.2 Hz, 1H), 2.56 (ddd, J = 15.8, 10.5, 6.0 Hz, 1H), 2.16–2.01 (m, 1H), 1.97–1.86 (m, 
1H), 1.78 (q, J = 6.3 Hz, 2H), 1.65 (ddd, J = 12.6, 9.6, 6.0 Hz, 1H), 1.54 (ddd, J = 12.7, 9.9, 
6.3 Hz, 2H), 1.40 (dddd, J = 13.7, 10.5, 8.8, 5.3 Hz, 1H), 1.32 (s, 3H), 1.32 (s, 3H), 0.92 (d, 
J = 7.2 Hz, 3H), 0.89 (s, 9H), 0.88 (d, J = 6.8 Hz, 3H), 0.11 (s, 3H), 0.02 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 159.3, 156.2, 152.5, 138.5, 129.5 (2C), 129.3, 128.4 (2C), 
127.7 (2C), 127.5, 113.9 (2C), 107.8, 105.2, 100.3, 75.0, 74.7, 73.1, 73.0, 70.6, 70.3, 68.0, 
66.7, 63.9, 55.3, 37.5, 36.4, 36.2, 36.0, 30.9, 25.9 (3C), 25.5, 24.6, 24.3, 18.2, 15.0, 14.3, –
4.4, –4.7; 







The synthesis of α,β-unsaturated hydroxypyranone 4.28.3 was performed by following the 
modified literature procedure reported by O’Doherty and coworkers.5 To a solution of furan 
4.28.2 (1 mmol) dissolved in THF (1.3 M) and H2O (5.8 M) was added NaHCO3 (2 mmol) 
and NaOAc.3H2O (1 mmol). The solution was cooled to 0 ºC and NBS (1 mmol) was added. 
The reaction mixture was stirred for 1–2 hours at 0 ºC until the disappearance of the starting 
material, monitored by TLC. Upon completion, the reaction mixture was diluted9 and 
filtered over celite, evaporated and purified via flash chromatography. 
                                                
[9]. The literature reports for similar but less complex substrates mentioned quenching with 






















Yield: 82% (8 mg isolated as colorless sticky liquid starting from 10 mg of hydrogenated 
Suzuki-Miyaura product); 
FTIR (thin film): 3373, 2955, 2932, 2856, 1688, 1610, 1458, 1377, 1250, 1223, 1105, 1038, 
835, 775, 698 cm-1; 
Optical Rotation: [α]D = +27.14 (c = 0.14, CHCl3); 
1H NMR  (500 MHz, Chloroform-d) δ 7.38–7.28 (m, 5H), 7.19–7.15 (m, 2H), 6.90–6.86 (m, 
2H), 6.78 (d, J = 10.4 Hz, 1H), 6.13 (d, J = 10.5 Hz, 1H), 6.08 (s, 1H), 5.61 (s, 1H), 4.58 (t, 
J = 2.0 Hz, 1H), 4.50 (d, J = 2.2 Hz, 2H), 4.45 (d, J = 11.4 Hz, 1H), 4.40 (d, J = 11.3 Hz, 
1H), 4.01 (dd, J = 9.2, 2.4 Hz, 1H), 3.95 (dt, J = 12.6, 6.2 Hz, 1H), 3.87 (dt, J = 9.2, 2.4 Hz, 
1H), 3.81 (s, 3H), 3.60–3.50 (m, 4H), 3.40 (dd, J = 9.4, 1.6 Hz, 1H), 2.08 (dd, J = 9.9, 4.8 
Hz, 1H), 1.93 (td, J = 13.1, 4.4 Hz, 2H), 1.78 (q, J = 6.2 Hz, 2H), 1.72 (dd, J = 13.0, 4.4 Hz, 
1H), 1.69–1.60 (m, 2H), 1.56–1.49 (m, 2H), 1.32 (s, 3H), 1.32 (s, 3H), 0.99 (d, J = 7.3 Hz, 
3H), 0.88 (s, 9H), 0.86 (d, J = 6.7 Hz, 3H), 0.11 (s, 3H), 0.07 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 196.7, 159.5, 149.5, 138.5, 129.7 (2C), 128.5, 128.4 (2C), 
127.7 (2C), 127.6, 126.5, 114.0 (2C), 100.3, 92.3, 78.0, 73.3, 73.1, 73.07, 72.9, 70.7, 70.3, 
66.7, 63.8, 55.3, 37.9, 37.8, 37.6, 36.2, 36.0, 26.4, 26.0 (3C), 24.6, 24.4, 18.2, 14.3, 12.3, –
4.3, –4.6; 
HRMS cald for C43H66O10SiNa (M+Na)+ 793.4323; found 793.4359 (TOF MS ES+). 
  
                                                                                                                                                 
amount of NaHCO3 required for quenching, therefore we preferred to purify the crude 








To a solution of containing α,β-unsaturated hydroxypyranone 4.28.3 (1 mmol) dissolved in 
CH2Cl2 (0.5 M) were added pyridine (4 mmol), Ac2O (4 mmol) and DMAP (0.1 mmol) at 0 
ºC. The reaction mixture was stirred for 3 hours at 0 ºC until the disappearance of the 
starting material, monitored by TLC. Upon completion, the reaction mixture was diluted and 
quenched with H2O. The layers were separated and extracted with CH2Cl2 (3X 20 mL) and 
the combined layer was washed with H2O, brine and dried over Na2SO4. The solvent was 
evaporated and purified via flash chromatography. 
Yield: 59% (5.7 mg isolated starting from 8.6 mg of α,β-unsaturated hydroxypyranone 
4.28.3); 
FTIR (thin film): 2930, 1747, 1514, 1373, 1248, 1092, 837 cm-1; 
Optical Rotation: [α]D = –14.0 (c = 0.05, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.39–7.28 (m, 5H), 7.26–7.23 (m, 2H), 7.03 (d, J = 15.9 Hz, 
1H), 6.96 (d, J = 15.9 Hz, 1H), 6.91–6.85 (m, 2H), 5.45 (d, J = 1.6 Hz, 1H), 5.26 (dd, J = 
8.6, 1.6 Hz, 1H), 4.50 (d, J = 1.9 Hz, 2H), 4.41 (s, 2H), 4.10 (dd, J = 8.5, 2.7 Hz, 1H), 3.95 
(dq, J = 9.7, 6.3 Hz, 1H), 3.81 (s, 3H), 3.62 – 3.47 (m, 3H), 3.44 (dd, J = 9.2, 6.4 Hz, 1H), 
3.17 (dd, J = 9.2, 7.0 Hz, 1H), 2.75–2.67 (m, 1H), 2.63 (ddd, J = 17.1, 9.7, 5.6 Hz, 1H), 
2.34–2.28 (m, 1H), 2.20 (s, 3H), 2.18–1.95 (m, 2H), 1.91 (s, 3H), 1.78 (q, J = 6.3 Hz, 2H), 
1.69–1.58 (m, 2H), 1.49–1.41 (m, 1H), 1.32 (s, 3H), 1.31 (s, 3H), 0.97 (d, J = 7.1 Hz, 3H), 
0.90 (s, 9H), 0.85 (d, J = 6.7 Hz, 3H), 0.16– -0.03 (m, 6H); 
13C NMR (126 MHz, CDCl3) δ 199.7, 193.9, 170.1, 169.6, 159.1, 138.5, 136.7, 132.5, 
130.4, 129.2 (2C), 128.4 (2C), 127.7 (2C), 127.5, 113.7 (2C), 100.3, 76.2, 73.1, 72.6, 71.4, 
Ac2O, pyridine
DMAP, CH2Cl2





















71.1, 70.7, 70.4, 66.6, 63.8, 55.3, 40.1, 38.1, 37.5, 36.7, 35.9, 26.6, 25.9 (3C), 24.6, 24.3, 
20.7, 20.6, 18.1, 14.6, 12.9, –3.9, –4.9; 
HRMS cald for C47H70O12SiNa (M+Na)+: 877.4534; found (TOF MS ES+): 877.4562. 
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